

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: Protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-073639
Article Type:	Protocol
Date Submitted by the Author:	15-Mar-2023
Complete List of Authors:	Wyatt, Nicola; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology Fuller, Hannah; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences Anderson, Carl ; Wellcome Sanger Institute, Wellcome Genome Campus Kennedy, Nicholas A; Royal Devon University Healthcare NHS Foundation Trust, Department of Gastroenterology; University of Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group Raine, Tim; Cambridge University Hospitals NHS Foundation Trust Ahmad, T.; Royal Devon University Healthcare NHS Foundation Trust, Department of Gastroenterology; University of Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group Allerton, Dean; Newcastle University, Newcastle Clinical Trials Unit Bardgett, Michelle; Newcastle University, Newcastle Clinical Trials Unit Clark, Emma; Newcastle University, Newcastle Clinical Trials Unit Clewes, Dawn; Newcastle University, Newcastle Clinical Trials Unit Cotobal Martin, Cristina; Wellcome Sanger Institute, Wellcome Genome Campus Doona, Mary; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology Doyle, Jennifer; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences Hancock, Helen; Newcastle University, Newcastle Clinical Trials Unit Hart, Ailsa L.; St Mark's Hospital and Academic Institute, Department of Gastroenterology; Imperial College London, Department of Surgery and Cancer Irving, Peter; Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology; King's College London, School of Immunology & Microbial Sciences Iqbal, Sameena; Wellcome Sanger Institute, Wellcome Genome Campus Kennedy, Ciara; Newcastle University, Newcastle Clinical Trials Unit King, Andrew; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology Lawrence, Sarah; Newcastle University, Newcastle Clinical Trials Unit Lees, Charlie W.; The University of Edinburgh MRC Institute of Genetics and Molecular Medicine; Western General Hospital, Institute of Genetics

	<p>&amp; Molecular Medicine  Lees, Robert; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology  Letchford, Laura; Wellcome Sanger Institute, Wellcome Genome Campus  Liddle, Trevor; Newcastle Upon Tyne Hospitals NHS Foundation Trust  Lindsay, James ; Barts Health NHS Trust, Department of Gastroenterology; Blizard Institute of Cell and Molecular Science, Centre for Immunobiology  Maier, Rebecca; Newcastle University, Newcastle Clinical Trials Unit  Mansfield, John; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology  Marchesi, Julian R.; St Mary's Hospital, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction  McGregor, Naomi; Newcastle University, Newcastle Clinical Trials Unit  McIntyre, Rebecca ; Wellcome Sanger Institute, Wellcome Genome Campus  Ostermayer, Jasmin; Wellcome Sanger Institute, Wellcome Genome Campus  Osunnuyi, Tolulope; Wellcome Sanger Institute, Wellcome Genome Campus  Powell, Nick; St Mary's Hospital, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction; Imperial College Healthcare NHS Trust, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction  Prescott, Natalie; King's College London, Department of Medical and Molecular Genetics, Guy's Hospital  Satsangi, J; University of Oxford, Nuffield Department of Medicine  Sharma, Shriya; Newcastle University, Newcastle Clinical Trials Unit  Shrestha, Tara; Newcastle University, Newcastle Clinical Trials Unit  Speight, Ally; Newcastle University Translational and Clinical Research Institute; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology  Strickland, Michelle; Wellcome Sanger Institute, Wellcome Genome Campus  Wason, James; Newcastle University, Population Health Sciences Institute  Whelan, Kevin; King's College London, Department of Nutritional Sciences  Wood, Ruth; Newcastle University, Newcastle Clinical Trials Unit  Zhang, Xinyue; Newcastle University, Population Health Sciences Institute  Parkes, M; Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology  Stewart, Christopher; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences  Jostins-Dean, Luke; University of Oxford, Kennedy Institute of Rheumatology  Lamb, Christopher; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology</p>
Keywords:	Inflammatory bowel disease < GASTROENTEROLOGY, Gastroenterology < INTERNAL MEDICINE, MICROBIOLOGY, Patient-Centered Care, Patient Reported Outcome Measures

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Defining predictors of responsiveness to advanced therapies in**  
5  
6  
7  
8 **Crohn's disease and ulcerative colitis: Protocol for the IBD-**  
9  
10  
11 **RESPONSE and nested CD-metaRESPONSE prospective,**  
12  
13  
14  
15 **multicentre, observational cohort study in precision medicine**  
16  
17

18 Nicola J. Wyatt<sup>1,2</sup>, Hannah Fuller<sup>1</sup>, Carl A. Anderson<sup>3</sup>, Nicholas A. Kennedy<sup>4,5</sup>, Tim Raine<sup>6</sup>,  
19  
20 Tariq Ahmad<sup>4,5</sup>, Dean Allerton<sup>7</sup>, Michelle Bardgett<sup>7</sup>, Emma Clark<sup>7</sup>, Dawn Clewes<sup>7</sup>, Cristina  
21  
22 Cotobal Martin<sup>3</sup>, Mary Doona<sup>2</sup>, Jennifer A. Doyle<sup>1</sup>, Helen Hancock<sup>7</sup>, Ailsa Hart<sup>8,9</sup>, Peter M.  
23  
24 Irving<sup>10,11</sup>, Sameena Iqbal<sup>3</sup>, Ciara Kennedy<sup>7</sup>, Andrew King<sup>2</sup>, Sarah Lawrence<sup>7</sup>, Charlie W.  
25  
26 Lees<sup>12,13</sup>, Robert Lees<sup>2</sup>, Laura Letchford<sup>3</sup>, Trevor Liddle<sup>14</sup>, James O. Lindsay<sup>15,16</sup>, Rebecca H.  
27  
28 Maier<sup>7</sup>, John C. Mansfield<sup>1,2</sup>, Julian R. Marchesi<sup>17</sup>, Naomi McGregor<sup>7</sup>, Rebecca E. McIntyre<sup>3</sup>,  
29  
30 Jasmin Ostermayer<sup>3</sup>, Tolulope Osunnuyi<sup>3</sup>, Nick Powell<sup>17,18</sup>, Natalie J Prescott<sup>19</sup>, Jack  
31  
32 Satsangi<sup>20</sup>, Shriya Sharma<sup>7</sup>, Tara Shrestha<sup>7</sup>, R. Alexander Speight<sup>1,2</sup>, Michelle Strickland<sup>3</sup>,  
33  
34 James M. S. Wason<sup>21</sup>, Kevin Whelan<sup>22</sup>, Ruth Wood<sup>7</sup>, Xinyue Zhang<sup>21</sup>, Miles Parkes<sup>6</sup>,  
35  
36 Christopher J. Stewart<sup>\*1</sup>, Luke Jostins-Dean<sup>\*23</sup>, Christopher A. Lamb<sup>\*1,2</sup>  
37  
38  
39  
40  
41  
42

43 \*Denotes co-senior authorship  
44  
45  
46  
47  
48

49 **Correspondence:**

50  
51 Dr Christopher Lamb, Translational & Clinical Research Institute, Faculty of Medical Sciences,  
52  
53 Newcastle University, Newcastle upon Tyne, NE2 4HH. United Kingdom

54  
55 christopher.lamb@newcastle.ac.uk  
56  
57  
58  
59  
60

**Affiliations:**

1. Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
2. Department of Gastroenterology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
3. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, United Kingdom
4. Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, United Kingdom
5. Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, United Kingdom
6. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
7. Newcastle Clinical Trials Unit (NCTU), 1-4 Claremont Terrace, Newcastle University, Newcastle upon Tyne, NE2 4AE, United Kingdom
8. Department of Gastroenterology, St Marks Hospital and Academic Institute, Gastroenterology, London, United Kingdom
9. Department of Surgery and Cancer, Imperial College, London, United Kingdom
10. Department of Gastroenterology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
11. School of Immunology & Microbial Sciences, King's College London, London, United Kingdom
12. Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom
13. Edinburgh IBD Unit, Western General Hospital, NHS Lothian, Edinburgh, United Kingdom

- 1  
2  
3  
4 14. The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne. United  
5  
6 Kingdom
- 7  
8 15. Department of Gastroenterology, Barts Health NHS Trust, The Royal London Hospital,  
9  
10 London, United Kingdom
- 11  
12 16. Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine  
13  
14 Queen Mary University of London, London, United Kingdom
- 15  
16 17. Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction,  
17  
18 St Mary's Hospital, Imperial College London, London, United Kingdom
- 19  
20 18. Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, United  
21  
22 Kingdom
- 23  
24 19. Department of Medical and Molecular Genetics, King's College London, Guy's Hospital,  
25  
26 London, United Kingdom
- 27  
28 20. Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, United  
29  
30 Kingdom
- 31  
32 Department of Nutritional Sciences, King's College London, London, United Kingdom
- 33  
34 21. Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United  
35  
36 Kingdom
- 37  
38 22. Department of Nutritional Sciences, King's College London, United Kingdom
- 39  
40 23. Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
- 41  
42  
43  
44

45  
46  
47  
48  
49  
50 **Keywords:**

51  
52  
53 Inflammatory bowel disease, Crohn disease, gastrointestinal microbiome, multiomics,  
54  
55 precision medicine

56  
57  
58 **ORCiDs (alphabetical):**

1  
2  
3  
4 Tariq Ahmad: <https://orcid.org/0000-0002-6058-5528>  
5  
6 Dean Allerton: <https://orcid.org/0000-0003-0507-4343>  
7  
8 Carl A. Anderson: <https://orcid.org/0000-0003-1719-7009>  
9  
10 Michelle Bardgett: <https://orcid.org/0000-0003-1393-2010>  
11  
12 Emma Clark: <https://orcid.org/0000-0003-0065-1463>  
13  
14 Dawn Clewes: <https://orcid.org/0000-0001-9600-859X>  
15  
16 Cristina Cotobal-Martin: <https://orcid.org/0000-0002-5877-2228>  
17  
18 Mary Doona: <https://orcid.org/0000-0001-9533-3745>  
19  
20 Jennifer A. Doyle: <https://orcid.org/0000-0001-7042-3269>  
21  
22 Hannah Fuller: <https://orcid.org/0000-0002-7965-938X>  
23  
24 Helen Hancock: <https://orcid.org/0000-0002-1494-8551>  
25  
26 Ailsa Hart: <https://orcid.org/0000-0002-7141-6076>  
27  
28 Peter M. Irving: <https://orcid.org/0000-0003-0972-8148>  
29  
30 Sameena Iqbal: <https://orcid.org/0000-0003-0926-593X>  
31  
32 Luke Jostins-Dean: <https://orcid.org/0000-0002-2475-3969>  
33  
34 Ciara Kennedy: <https://orcid.org/0000-0003-2987-0977>  
35  
36 Nicholas A. Kennedy: <https://orcid.org/0000-0003-4368-1961>  
37  
38 Andrew King: <https://orcid.org/0000-0002-5002-4751>  
39  
40 Christopher A. Lamb: <https://orcid.org/0000-0002-7271-4956>  
41  
42 Sarah Lawrence: n/a  
43  
44 Charlie W. Lees: <https://orcid.org/0000-0002-0732-8215>  
45  
46 Robert Lees: n/a  
47  
48 Laura Letchford: n/a  
49  
50 Trevor Liddle: n/a  
51  
52 James O. Lindsay: <https://orcid.org/0000-0003-3353-9590>  
53  
54 Rebecca H. Maier: <https://orcid.org/0000-0002-7350-3288>  
55  
56 John C. Mansfield: <https://orcid.org/0000-0003-2490-7750>  
57  
58 Julian R. Marchesi: <https://orcid.org/0000-0002-7994-5239>  
59  
60 Naomi McGregor: <https://orcid.org/0000-0002-5961-124X>  
Rebecca E. McIntyre: <https://orcid.org/0000-0001-5291-1533>  
Jasmin Ostermayer: <https://orcid.org/0000-0001-6461-398X>



1  
2  
3 Tolulope Osunnuyi: <https://orcid.org/0000-0002-0482-917X>

4  
5 Miles Parkes: <https://orcid.org/0000-0002-6467-0631>

6  
7 Nick Powell: <https://orcid.org/0000-0003-3231-6950>

8  
9 Natalie J. Prescott: <https://orcid.org/0000-0002-5901-7371>

10  
11 Tim Raine: <https://orcid.org/0000-0002-5855-9873>

12  
13 Jack Satsangi: <https://orcid.org/0000-0002-6357-9684>

14  
15 Shriya Sharma: <https://orcid.org/0000-0001-5237-757X>

16  
17 Tara Shrestha: n/a

18  
19 Michelle Strickland: <https://orcid.org/0000-0001-8053-400X>

20  
21 R. Alexander Speight: <https://orcid.org/0000-0003-3184-9181>

22  
23 Christopher J. Stewart: <https://orcid.org/0000-0002-6033-338X>

24  
25 James M. S. Wason: <https://orcid.org/0000-0002-4691-126X>

26  
27 Kevin Whelan: <https://orcid.org/0000-0001-5414-2950>

28  
29 Ruth Wood: <https://orcid.org/0000-0002-8296-1774>

30  
31 Nicola J. Wyatt: <https://orcid.org/0000-0001-5050-327X>

32  
33 Xinyue Zhang: <https://orcid.org/0000-0002-5321-4235>

34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

### INTRODUCTION

Characterised by chronic inflammation of the gastrointestinal tract, symptoms of inflammatory bowel disease (IBD), including diarrhoea, abdominal pain and fatigue, can significantly impact patient quality of life. Therapeutic developments in the last 20 years have revolutionised treatment. Despite this, clinical trial and real-world data show primary non-response rates up to 40%. A significant challenge is an inability to predict which class of treatment will benefit individual patients.

Current understanding of IBD pathogenesis implicates complex interactions between host genetics and the gut microbiome. Most cohorts studying the gut microbiota to date have been underpowered, examined single treatments, and produced heterogeneous results. Lack of cross-treatment comparisons and well-powered independent replication cohorts hampers the ability to infer real-world utility of predictive signatures.

IBD-RESPONSE will use multi-omic data to create a predictive tool for treatment response. Future patient benefit may include development of biomarker-based treatment stratification or manipulation of intestinal microbial targets. IBD-RESPONSE and downstream studies have the potential to improve quality of life, reduce patient risk, and reduce expenditure on ineffective treatments.

### METHODS AND ANALYSIS

This prospective, multicentre, observational study will identify and validate a predictive model for response to advanced IBD therapies, incorporating gut microbiome, metabolome, single-cell transcriptomics, human genome and clinical data. 1,325 participants commencing

1  
2  
3 advanced therapies will be recruited from ~40 UK sites. Data will be collected at baseline,  
4  
5 week 14 and week 54. The primary outcome is week 14 clinical response. Secondary  
6  
7  
8 outcomes include clinical remission, loss of response in week 14 responders, corticosteroid-  
9  
10 free response/remission, time to treatment escalation, and change in patient-reported quality  
11  
12 of life and fatigue.  
13

## 14 15 16 **ETHICS AND DISSEMINATION**

17  
18 Ethical approval has been obtained and recruitment is ongoing. Following study completion,  
19  
20 results will be submitted for publication in peer-reviewed journals and presented at scientific  
21  
22 meetings. Publications will be summarised at [www.ibd-response.co.uk](http://www.ibd-response.co.uk).  
23  
24

## 25 26 **TRIAL REGISTRATION NUMBER**

27  
28  
29 ISRCTN96296121 (pre-results)  
30  
31

## 32 33 **Article Summary**

### 34 35 36 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 37  
38  
39 • IBD-RESPONSE is the largest precision medicine study of its kind to date, designed to  
40  
41 develop a predictive tool for treatment response – or failure to respond – to IBD treatment,  
42  
43 promoting *a priori* selection of the right drug, for the right patient, at the right time.  
44  
45
- 46  
47 • IBD-RESPONSE will establish one of the largest biorepositories of longitudinal stool,  
48  
49 blood, matched tissue and organoids with detailed linked phenotypic, diet, genetic and  
50  
51 treatment outcome data in patients with IBD.  
52  
53
- 54  
55 • This study will use a standardised yet pragmatic methodology for sample collection,  
56  
57 processing and storage, allowing multicentre participation, improving generalisation and  
58  
59 transferability of findings to real-world clinical practice.  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Remote 'at home' patient data and stool collection will allow >40 IBD centres to contribute to recruitment, increasing power in this multi-omics study when compared to other studies in the field that generally recruit from one or a small number of centres.
  - Whilst recruiting sites are limited to the UK only, identified cross-validation cohorts from the UK and Canada will increase generalisability of our findings.

For peer review only

## INTRODUCTION

Crohn's disease (CD) and ulcerative colitis (UC) are the principal forms of inflammatory bowel disease (IBD).(1) Characterised by symptoms including diarrhoea, rectal bleeding, abdominal pain and extra-intestinal features such as fatigue, IBD can have a substantial negative impact on patient quality of life.(2) Approximately 20% of CD patients and 10% of UC patients are unable to work due to their condition.(3) The global prevalence of IBD is rising. In the United Kingdom (UK), 1 in 125 people are currently affected, with prevalence expected to reach 1 in 100 by 2028.(4, 5)

The biologics era has revolutionised IBD treatment in the last twenty years. Patients and clinicians have more advanced therapies to choose from than ever before. Several biologic classes are now licensed in the UK, targeting tumour necrosis factor alpha (TNF $\alpha$ ) (including infliximab and adalimumab), interleukin (IL)-12/23 (ustekinumab) cytokine pathways, or the gut-homing  $\alpha 4\beta 7$  integrin (vedolizumab). In addition, recently licensed small molecule therapies for UC include the Janus kinase inhibitors (JAKi) tofacitinib, filgotinib and upadacitinib, and the sphingosine-1-phosphate receptor (S1PR) modulator ozanimod. With several additional therapies in advanced stages of development or having completed phase 3 randomised clinical trials, the number of treatments available to patients is likely to increase.(6)

Current understanding of biological mechanisms driving the pathogenesis and natural history of IBD, implicates complex interactions between host genetics and the gut microbiome (bacteria, viruses, fungi, archaea and phage).(7) Whilst large clinical cohorts for human genetic discovery have led to major advances in understanding disease pathogenesis,(8) cohorts for the study of gut microbiota have mostly been under-powered. Nonetheless,

1  
2  
3 existing research intriguingly suggests utility of microbiome signatures in predicting response  
4 to therapy. In a small prospective study of 85 patients starting vedolizumab therapy, greater  
5  
6 alpha-diversity and higher abundance of *Roseburia inulinivorans* and a Burkholderiales  
7  
8 species at baseline were associated with therapeutic-induced remission in CD.(9)  
9  
10 Incorporation of microbial taxonomy data alongside clinical data in a predictive model  
11  
12 produced an area under the receiver operating characteristic curve (AUC) of 0.776 (compared  
13  
14 to an AUC of 0.619 using clinical data only). A larger study of 232 patients receiving  
15  
16 ustekinumab implicated *Bacteroides* and *Faecalibacterium* as predictors of treatment  
17  
18 response.(10) Here, a predictive model of response to ustekinumab using clinical metadata  
19  
20 produced an AUC of 0.616, rising to 0.844 when combined with baseline bacterial profile data.  
21  
22  
23  
24  
25  
26  
27

28 In a study of 185 (77 UC, 108 CD) patients commencing anti-cytokine (anti-TNF $\alpha$  or  
29  
30 anti-IL12/23) or anti-integrin (vedolizumab) therapy, metabolomic and proteomic analysis of  
31  
32 blood in addition to taxonomic and functional profiling of stool samples was conducted.(11)  
33  
34 Among patients receiving anti-cytokine therapy, 120 enzymes were differentially abundant in  
35  
36 baseline samples of remitters versus non-remitters. Single-species dominance (>50% of  
37  
38 enzyme copies in >50% of samples explained by a single species) was observed for 8/120  
39  
40 enzymes. *Eggerthella lenta* was dominant for 5/8 enzymes, 3 of which are involved in  
41  
42 secondary bile acid biosynthesis. Metabolomic analysis of baseline blood samples revealed  
43  
44 significant enrichment of serum secondary bile acids in patients achieving week 14 clinical  
45  
46 remission. Analysis of paired baseline stool samples revealed a significant positive correlation  
47  
48 with the abundance of 7 $\alpha$ / $\beta$ -dehydroxylation enzymes (responsible for primary to secondary  
49  
50 bile acid conversion), the presence of which was associated with a preferential response to  
51  
52 anti-cytokine therapy. This was replicated in a small validation cohort of 46 patients initiating  
53  
54 anti-TNF $\alpha$  (infliximab) therapy.  
55  
56  
57  
58  
59  
60

Beyond IBD, further proof of concept that the gut microbiome is of prognostic importance in the context of systemically administered immune-targeted therapies is found with immune checkpoint inhibitor treatment in cancer, where experimental animal data demonstrated the beneficial impact of microbial modulation on treatment outcome.(12-14)

Whilst these previous studies were important first steps to utilising gut microbial signatures in stratified treatment algorithms, they were mostly underpowered, examined single treatments, used different sequencing technologies, and produced heterogeneous non-overlapping results. The lack of cross-treatment comparisons and well-powered independent replication cohorts hampers the ability to infer real-world utility of these predictive signatures, and to move from observations of association to causation in IBD.(15)

## **METHODS AND ANALYSIS**

### **Study rationale**

A significant challenge to effective, personalised use of biologic or small molecule therapies (collectively termed 'advanced therapies') in IBD is an inability to predict which class of treatment is most likely to benefit an individual patient. Despite increasing therapeutic options, clinical trial and real-world efficacy data show primary non-response rates of up to 40% across all therapeutic classes and in those with initial symptomatic benefit, up to 40% lose response by 1 year.(1, 16-18) Consequently, complications of chronic, active inflammation including strictures, fistulae and malignancy, continue to affect a substantial number of patients and have a negative impact on patient quality of life.(2) Up to 30% of CD patients require surgical intervention within 10 years of diagnosis, and around 15% of UC patients will ultimately require a colectomy.(19) Off-target side effects may also occur, including infection and malignancy.(1) With average treatment costs of £6,156/year for CD

1  
2  
3 and £3,084/year for UC, future treatment algorithms must avoid the potential morbidity and  
4  
5 additional cost associated with expensive treatments that do not benefit individual  
6  
7 patients.(20) The absolute importance of precision medicine research to identify biomarkers  
8  
9 for treatment stratification and develop prognostic algorithms was highlighted by two recent  
10  
11 national research prioritisation exercises incorporating responses from almost 3,000 patients,  
12  
13 their families and friends.(1, 21) Validated prognostic models for treatment stratification do not  
14  
15 exist and understanding of mechanisms controlling treatment non-response is limited.  
16  
17  
18  
19

### 20 21 **Scientific objectives of IBD-RESPONSE**

22  
23 The primary scientific objective of IBD-RESPONSE is to identify and validate a  
24  
25 predictive model for clinical response or failure to respond to advanced therapies in IBD after  
26  
27 14 weeks of therapy (the primary clinical outcome, see below). Modelling will incorporate gut  
28  
29 microbiome, human genome, blood and intestinal single cell transcriptome data, and detailed  
30  
31 clinical data. Through data derived from the nested CD-metaRESPONSE cohort, predictive  
32  
33 modelling will also include detailed dietary information and blood and faecal metabolome data.  
34  
35 The co-primary scientific objective of IBD-RESPONSE is to determine the relationship  
36  
37 between clinical response and remission at week 14 and baseline gut microbiome.  
38  
39  
40  
41  
42

43  
44 Secondary scientific objectives of IBD-RESPONSE are to determine if there is a  
45  
46 relationship between the microbiome at baseline or changes in the microbiome following  
47  
48 advanced therapy with any of the secondary clinical outcomes (*Box 1*). Further exploratory  
49  
50 scientific objectives of IBD-RESPONSE are listed in *Box 2*.  
51  
52

- 53 • Clinical remission at week 14.
  - 54 • Clinical response at week 54.
  - 55 • Clinical remission at week 54.
  - 56
  - 57
  - 58
  - 59
  - 60



- Loss of response at week 54 in week 14 responders.
- Durable corticosteroid-free response or remission at week 54 defined as receiving no corticosteroids between week 14 and week 54 assessments inclusive and not meeting criteria for loss of response.
- Time to treatment escalation from baseline, defined as:
  - Advanced therapy switch due to lack of efficacy/those with loss of response (does not include biosimilar switch or switch from IV to SC route).
  - Dose intensification of drug due to lack of efficacy (does not include intensification based on therapeutic drug monitoring without flare in responders).
  - Resectional intestinal surgery (does not include examination under anaesthesia procedures in patients with perianal CD).
  - Induction or dose escalation of corticosteroids.
- Time to treatment escalation as defined above, but disregarding dose intensification.
- Time to treatment escalation as defined above, among week 14 responders.
- Time to discontinuation of index drug (persistence).
- Incidence of and time to potential side effects of treatment during follow up.
- Continuation of drug at week 14 and/or week 54 in those not meeting criteria for response and/or remission.
- Change from baseline SF subscore at week 14 and/or 54 (both CD and UC).
- Change from baseline RB subscore at week 14 and/or 54 (UC only).
- Change from baseline AP subscore at week 14 and/or 54 (CD only).
- Development of anti-drug antibodies by week 14 or 54.

- Change in CRP from baseline at week 14 or 54 (50% reduction or absolute value  $\leq 5\text{mg/L}$  deemed as clinically significant).
- Change in faecal calprotectin from baseline at week 14 or 54 (50% reduction or absolute value  $\leq 100\mu\text{g/g}$  deemed as clinically significant).
- Endoscopic remission during follow up (Mayo endoscopic subscore  $\leq 1$  for UC or SES-CD  $\leq 2$  for CD).
- Change in quality of life, physical activity dietary intake, joint pain and fatigue as measured by study questionnaires.

#### Box 1. IBD-RESPONSE secondary clinical outcome measures

Box 1 abbreviations: abdominal pain (AP), Crohn's disease (CD), c-reactive protein (CRP), intravenous (IV), rectal bleeding (RB), subcutaneous (SC), stool frequency (SF), simple endoscopic score for Crohn's disease (SES-CD), ulcerative colitis (UC)

- Test the association of microbial metabolites (metabolome) in stool or plasma, human genetics and/or single cell transcriptome data from blood or intestinal tissue with the above primary and secondary objectives.
- Determine the influence of diet on the gut microbiome and treatment response in IBD, and the factors associated with dietary intake in IBD.
- Explore host human genetic-gut microbiome-metabolome interactions in IBD pathogenesis and causal pathways to treatment response.
- Ascertain the utility of archived endoscopy collected FFPE biopsies at predicting/imputing the gut microbiome and for inclusion in the predictive model.

- Establish a longitudinal tissue, organoid and stool biobank from this well characterised clinical cohort.

#### Box 2. IBD-RESPONSE exploratory scientific objectives

Box 2 abbreviations: inflammatory bowel disease (IBD), formalin fixed paraffin embedded (FFPE)

### Study design

The design of IBD-RESPONSE and the nested CD-metaRESPONSE studies are summarised in *Figure 1*. This prospective, observational, multi-centre, cohort study will recruit participants with IBD (CD, UC, IBD-unclassified (IBD-U)) who are due to commence either biologic, JAKi or S1PR modulator therapy for symptomatic, clinically active (moderate to severe) luminal disease. Participants do not have to be naïve to advanced therapies and may be recruited when switching within or between class of advance therapy. Participants may be taking or planned to start concurrent thiopurines or methotrexate as combination therapy. Participation in the study will not change standard clinical care received. Detailed longitudinal clinical data will be collected alongside stool, blood and (where possible) biopsy samples, patient reported outcome measures, and dietary intake. Planned recruitment of 1,325 participants will consist of 762 patients with CD and 563 patients with UC (or IBD-U).

[Figure 1]

Data will be collected at baseline (prior to starting treatment), week 14 (following completion of induction therapy) and week 54. Participants will collect stool samples at each study timepoint. If a participant attends hospital within the baseline and/or week 14 study window, two blood samples (per timepoint) will be collected. Where a participant undergoes

1  
2  
3 endoscopy as part of routine clinical care during the study period, up to 12 research biopsies  
4  
5 will be collected.  
6  
7

8  
9 Of the 762 CD participants, 300 will be consented to take part in a sub-cohort (CD-  
10 metaRESPONSE). Clinical data collection will occur at the same time points as in the main  
11 cohort. Additional study components will include completion of a 4-day food diary  
12 questionnaire, capturing all food and drink consumed at the baseline and week 14 timepoints.  
13  
14 This is in addition to the food frequency questionnaire completed by all participants. CD-  
15 metaRESPONSE participants will also be required to provide two additional stool tubes (one  
16 at baseline and one at week 14) for faecal metabolome analysis.  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 All participants recruited to IBD-RESPONSE will be invited to co-recruit to IBD  
27 BioResource (if not already participating). IBD BioResource is a national platform and  
28 recallable biorepository linked to the National Institute for Health and Care Research (NIHR)  
29 BioResource that is designed to expedite IBD research, currently with >36,000  
30 participants.(22). Co-recruiting participants to IBD-RESPONSE and the IBD BioResource  
31 platform, will generate a rich dataset and provide a long term means of archiving data from  
32 IBD-RESPONSE to facilitate ongoing research and maximise downstream patient benefit. To  
33 minimise participant burden, the contact for recruitment to IBD BioResource can occur any  
34 time in the 12 months following consent to IBD-RESPONSE. If a participant ultimately decides  
35 not to participate in the IBD BioResource they will not be withdrawn from IBD-RESPONSE.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 If a participant discontinues treatment prior to week 14 or week 54 follow up, the next  
51 timepoint assessment will be brought forward and completed as a treatment discontinuation  
52 assessment. Where a participant does not respond to the first prescribed advanced therapy  
53 and a second (or third) advanced therapy is subsequently prescribed, this discontinuation  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 assessment will act as the baseline sample and data collection assessment for the successive  
4  
5 advanced therapy. Follow up samples and data collection will occur at week 14 and week 54  
6  
7 following commencement of each successive agent. The participant may remain in the study  
8  
9 up to 54 weeks after commencement of a particular agent or until the end of the study period.  
10  
11 We anticipate that up to 40% of patients will not respond to the initial prescribed therapy or  
12  
13 will lose response by 1 year and will move on to a second (or third) advanced therapy. We  
14  
15 therefore anticipate that recruitment of 1,325 participants may capture approximately 1,760  
16  
17 new treatment initiation episodes.  
18  
19  
20  
21  
22

### 23 **Study setting**

24  
25 This multi-centre cohort study will be conducted at >40 study centres, based within  
26  
27 National Health Service (NHS) Trusts across the UK. All sites must be able to accommodate  
28  
29 the needs of the IBD-RESPONSE cohort including clinical engagement, research nurse  
30  
31 support and facilities for assessments.  
32  
33  
34  
35

### 36 **Eligibility criteria**

37  
38 Individuals will be deemed eligible to enrol in the study if they fulfil all inclusion criteria  
39  
40 and meet none of the exclusion criteria (*Box 3*).  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INCLUSION CRITERIA

Individuals must fulfil all the following criteria to be enrolled in the study.

- Aged 16 years and over.
- Diagnosis of IBD: CD, UC or IBD-U.\*
- Already participating or willing to be approached for participation in IBD BioResource.
- Willing and able to provide informed consent.
- Willing to undertake study procedures including:
  - Completion of study questionnaires
  - Collection of home stool specimens
- Provision of blood and (where applicable) biopsy specimens.
- Symptoms of active luminal IBD (see definition of 'Clinically active disease', *Table 1*).
- At least one biochemical, endoscopic or radiological marker of active disease within 12 weeks of study consent (see *Box 4* and *Box 5*)
- Intention of clinical team to commence one of the following advanced therapies for active luminal IBD within 6 weeks of consent:<sup>Δ</sup>
  - Infliximab
  - Adalimumab
  - Vedolizumab
  - Ustekinumab
  - Tofacitinib
  - Filgotinib
  - Upadacitinib
  - Ozanimod

\*Individuals with IBD-U will be managed as per the UC relevant protocol.

<sup>Δ</sup>Participants may be advanced therapy-naïve or -exposed. Any new biologic or small molecule drug that becomes licensed for the treatment of IBD during the planned study period will be permitted to allow study inclusion. Drugs used through Early Access to Medicines Schemes, compassionate use or expanded access schemes for unlicensed therapies are also permitted. Patients starting immunosuppressant monotherapy with a thiopurine or methotrexate are not eligible to take part. However, use of these treatments as part of combination therapy with an advanced therapy is not an exclusion to enrolment.

## EXCLUSION CRITERIA

Individuals meeting any of the following criteria will not be eligible to participate in the study.

- Receiving oral corticosteroids for any indication where the dose is unlikely to be weaned by week 14.<sup>^</sup>
- Planned bowel resection surgery within 14 weeks of commencing therapy.
- Advanced therapy being commenced as rescue for ASUC.
- Advanced therapy being commenced as part of a CTIMP.
- Presence of an ileal pouch anal anastomosis.
- Presence of a stoma.
- Perianal CD in the absence of active luminal inflammation.
- Antibiotics or short-term ( $\leq 4$  weeks) use of probiotics within the preceding 2 weeks.<sup>†</sup>
- FMT within the preceding 12 weeks or planned FMT within 14 weeks of commencing advanced therapy for IBD.<sup>‡</sup>

<sup>^</sup>Examples may include long term steroids for IBD where weaning by 14 weeks may not be possible irrespective of response to advanced therapy, or concurrent diagnosis where long term steroids are used e.g. polymyalgia rheumatica.

<sup>†</sup>Use of long-term (>4 weeks), stable doses of probiotics does not exclude individual participation but should be noted in the eCRF.

<sup>‡</sup>Use of antibiotics or prior FMT outside the exclusion period is permitted. Antibiotic use in the preceding 1 year and ever having received FMT will be noted in the eCRF.

### Box 3. Eligibility criteria for IBD-RESPONSE

Box 3 abbreviations: Acute severe ulcerative colitis (ASUC), Clinical Trial of an Investigational Medicinal Product (CTIMP), Crohn's disease (CD), electronic case report form (eCRF), faecal microbial transplantation (FMT), inflammatory bowel disease (IBD), inflammatory bowel disease-unclassified (IBD-U), ulcerative colitis (UC).

Participants must have at least one biochemical, endoscopic or radiological (CD only) marker of clinically active luminal disease within 12 weeks of study consent (see *Box 4* (CD) and *Box 5* (UC)). Endoscopic assessment of disease activity will be judged locally and may

1  
2  
3 be assessed prospectively or retrospectively. Whilst pregnancy may influence advance  
4  
5  
6 therapy selection, pregnancy is not an exclusion criterion.  
7  
8

9 CD patients must also have at least one of the following documented within 12 weeks prior  
10 to consent:  
11

- 12 • Faecal calprotectin  $\geq 250$   $\mu\text{g/g}$ .
- 13 • CRP  $\geq 6$  mg/L.
- 14 • Any endoscopic evidence of active CD, defined as ulceration (with at least one ulcer  
15  $\geq 5\text{mm}$ ) judged locally from available clinical data (as an approximation equivalent to  
16 SES-CD of  $\geq 4$  for ileal disease or  $\geq 6$  for ileocolonic or colonic disease.
- 17 • Active inflammatory disease on imaging (MRI/CT/ultrasound) judged locally from  
18 available clinical data.  
19  
20  
21  
22  
23  
24  
25  
26  
27

28  
29 **Box 4. IBD-RESPONSE additional inclusion criteria: CD**

30  
31 Box 4 abbreviations: Crohn's disease (CD), C-reactive protein (CRP), Computed tomography (CT), Magnetic resonance  
32 imaging (MRI), Simple Endoscopic Score for Crohn's Disease (SES-CD)  
33  
34  
35

36  
37  
38 UC/IBD-U patients must also have at least one of the following documented within 12 weeks  
39 prior to consent:  
40

- 41 • Faecal calprotectin  $\geq 250$   $\mu\text{g/g}$ .
- 42 • CRP  $\geq 6$  mg/L.
- 43 • Any endoscopic evidence of at least moderately active ulcerative colitis (of any  
44 extent including proctitis), defined as features of MCS endoscopic sub-score  $\geq 2$   
45 (marked erythema, lack of vascular pattern, friability, erosions, spontaneous  
46 bleeding or ulceration).  
47  
48  
49  
50  
51  
52  
53  
54

55 **Box 5. IBD-RESPONSE additional inclusion criteria: UC and IBD-U**  
56  
57  
58  
59  
60



Box 5 abbreviations: C-reactive protein (CRP), inflammatory bowel disease-unclassified (IBD-U), Mayo Clinic Score (MCS), ulcerative colitis (UC)

## Clinical outcome measures

Key definitions related to clinical outcome measures can be found in *Table 1*.

Clinically active disease	<ul style="list-style-type: none"> <li>• CD: Unweighted PRO-2 (CD) of average daily SF subscore <math>\geq 4</math> and/or average daily AP subscore <math>\geq 2</math>.</li> <li>• UC: Total PRO-2 (UC) <math>\geq 3</math> with RB subscore <math>\geq 1</math>.</li> </ul> <p>PRO-2 data will be entered by patients over 4 days (minimum 2 days PRO-2 data is permissible for PRO-2 calculation).</p>
Clinical remission	<p>Patient remains on drug and meets the following criteria:</p> <ul style="list-style-type: none"> <li>• CD: Unweighted PRO-2 (CD) average daily SF subscore <math>\leq 2.8</math> and average daily AP subscore <math>\leq 1</math> (and neither worse than inclusion scores at baseline).</li> <li>• UC: PRO-2 (UC) SF subscore <math>\leq 1</math> with a decrease of <math>\geq 1</math> point(s) in SF subscore from baseline, plus RB subscore = 0.</li> </ul> <p><b>AND</b> an absence of any of the following at time of assessment:</p> <ul style="list-style-type: none"> <li>• Resectional bowel surgery at any time after baseline until time of current assessment.</li> <li>• Current use of oral corticosteroids/failure to wean oral corticosteroids prescribed at baseline.</li> </ul>
Clinical response	<p>Meeting criteria for clinical remission <b>OR</b>:</p> <ul style="list-style-type: none"> <li>• CD: unweighted PRO-2 (CD) <math>\geq 30\%</math> reduction in average daily SF subscore and/or <math>\geq 30\%</math> decrease in average daily AP subscore (and neither worse than inclusion scores at baseline).</li> <li>• UC: total PRO-2 (UC) decrease <math>\geq 3</math> from baseline.</li> </ul>

	<p><b>AND</b> an absence of any of the following at time of assessment:</p> <ul style="list-style-type: none"> <li>• Resectional bowel surgery at any time after baseline until time of current assessment.</li> <li>• Current use of oral corticosteroids/failure to wean oral corticosteroids prescribed at baseline.</li> </ul>
Week 14 non-response	<ul style="list-style-type: none"> <li>• Not meeting clinical response criteria AND not having stopped drug for any reason other than lack of efficacy.</li> </ul>
Week 54 loss of response	<ul style="list-style-type: none"> <li>• Not meeting clinical response criteria at week 54 having met clinical response criteria at week 14 (AND not having stopped drug for any reason other than inefficacy between week 14 and 54 assessments).</li> </ul>
<p><b>Table 1. IBD-RESPONSE key clinical definitions</b></p> <p>Table 1 abbreviations: abdominal pain (AP), Crohn's disease (CD), patient reported outcome (PRO)-2, rectal bleeding (RB), stool frequency (SF), ulcerative colitis (UC).</p>	

### Primary clinical outcome measures

Clinical response at week 14 after commencing therapy.

### Secondary clinical outcome measures

Secondary clinical outcome measures are listed in *Box 1*.

### Sample size calculations

The sample size (n=1,325 cases overall, including n=300 cases for CD-metaRESPONSE sub-cohort) was chosen to ensure sufficient power to answer the co-primary scientific objective (to detect associations between microbiome measures and clinical response or remission) and key exploratory scientific objectives (to detect associations between metabolites and clinical response or remission, and to detect associations between

1  
2  
3 genetics and microbiome measures). Sample size calculations for predictive models require  
4  
5 extensive assumptions about the number and effect size of associations and the correlation  
6  
7 structure of the data. We noted predictive models built with microbiome and/or metabolite  
8  
9 measures with high in-sample predictive accuracy (including AUC=0.78 with n=84 from  
10  
11 Ananthakrishnan et al.(9), AUC=0.91 with n=76 from Ding et al.(23), and AUC=0.84 with  
12  
13 n=232 from the CERTIFI study(10)), implying that n=300 individuals (from CD-  
14  
15 metaRESPONSE) and n=1,325 individuals (from IBD-RESPONSE), should be sufficient for  
16  
17 high predictive in-sample accuracy.  
18  
19  
20  
21  
22

### 23 Sample size for analysis of primary objective

24  
25  
26 We took plausible effect sizes for the primary scientific objective analysis from the  
27  
28 effect of *Bacteroides* levels in stool on ustekinumab response (d=0.66, from the from the  
29  
30 CERTIFI study(10)) and the effect of anti-drug immunogenicity on remission after anti-TNF $\alpha$   
31  
32 treatment (d=0.30, from the PANTS study(16)). We calculated power for a simple two-sample  
33  
34 t-test (using the R package pwr), assuming the expected non-response rate at 14 weeks  
35  
36 (23.8%) and non-remission rate at 54 weeks (63.1%) from the PANTS study. We assumed a  
37  
38 conservative Bonferroni-corrected significance threshold of 1e-5 (correcting for 5000  
39  
40 microbiome measures). The sample size of n=1,325 gives a power of close to 100% for the  
41  
42 larger *Bacteroides* effect size for both week 14 response and week 54 remission, and 57%  
43  
44 and 80% for the smaller anti-drug immunogenicity effect size for week 14 response  
45  
46 and week 54 remission, respectively.  
47  
48  
49  
50  
51  
52

### 53 Sample size for analysis of secondary and exploratory scientific objectives

54  
55  
56 We took plausible effect sizes for the exploratory metabolite analysis from the effects  
57  
58 of three selected stool lipid and bile acid metabolites on anti-TNF $\alpha$  response from Ding et  
59  
60

1  
2  
3 al.(23): faecal triglyceride (d=1.00), and two bile acid metabolites; BA1 (d=0.89) and BA3  
4  
5 (d=0.70). We assumed a conservative Bonferroni-corrected significance threshold of  $5e-5$   
6  
7 (correcting for 1000 metabolites). For n=300, this gives a power of 99.7%, 91% and 74%  
8  
9 for faecal triglyceride, BA1 and BA3 respectively for week 14 response, and 100%, 99.8% and  
10  
11 91% for week 54 remission.  
12  
13

14  
15  
16 We do not anticipate that this study on its own will be well powered to detect new  
17  
18 associations between genotype and microbiome measures in IBD. It is known from studies of  
19  
20 healthy individuals that genetic variants that explain more than 3% of variation ( $R^2=0.03$ ) in  
21  
22 microbial abundance are rare.(24) Assuming a conservative significance threshold of  $< 1e-11$   
23  
24 (correcting for  $1e6$  independent genotypes and 5000 microbiome measures), n=1,325  
25  
26 samples would only have 33% power to detect associations with  $R^2=0.03$  (calculated  
27  
28 using genpwr(25)). We will therefore combine our samples with a further  
29  
30 genotype/microbiome study of IBD (PREdiCCt) to increase sample size to n=2,325. This will  
31  
32 provide us 80% power to detect genetic associations with  $R^2>0.025$ . In the case where such  
33  
34 genotype/microbiome measure associations exist, and are associated with a causal  
35  
36 biomarker for week 54 remission, a Mendelian Randomization analysis would have >80%  
37  
38 power to demonstrate causality of this biomarker when the causal effect odds ratios is larger  
39  
40 than 2 (calculated using mRnd(26)).  
41  
42  
43  
44  
45  
46

### 47 **Study procedures and measures**

48  
49  
50 Participants  $\geq 16$  years old may be identified from a variety of settings such as  
51  
52 outpatient clinics (face-to-face or virtual), flare assessments, IBD clinical nurse specialist  
53  
54 helplines/email contact, endoscopy examinations, infusion suites, multidisciplinary team  
55  
56 meetings and virtual biologics clinics (*Figure 1*). Consent will be taken electronically using a  
57  
58  
59  
60

1  
2  
3 REDCap (Research Electronic Data Capture) online database. Full informed e-consent will be  
4  
5 supported by an appropriately delegated member of the study team, using a laptop, tablet or  
6  
7 mobile device in the patient's own home, or using a hospital tablet, laptop, computer or patient  
8  
9 mobile device during a scheduled visit to hospital as part of routine clinical care. Paper copies  
10  
11 of the consent form will be made available for those patients unable to access e-consent. If a  
12  
13 later decision is made not to commence an advanced therapy for IBD, the participant will not  
14  
15 be eligible to continue in the study and must be withdrawn. Data collected up to the point of  
16  
17 withdrawal may be used for the study. Any samples collected will be used for research within  
18  
19 IBD-RESPONSE or stored for future research.  
20  
21  
22  
23  
24

25 All research activity will be completed by the participant either remotely or during  
26  
27 hospital visits scheduled to deliver routine clinical care (see *Figure 2*). Participants will be  
28  
29 asked to complete data collection after consent and before starting treatment (baseline), and  
30  
31 at week 14 and week 54 following commencement of advanced therapy in line with routine  
32  
33 dosing schedule visits. This will include patient questionnaires, stool samples and, where  
34  
35 applicable, blood and biopsy specimens. Participants will be asked to complete questionnaires  
36  
37 with data entered directly into the study specific REDCap database. Paper questionnaires will  
38  
39 be made available for those participants without access or who express a preference to  
40  
41 complete in paper format. Participants will be asked to complete questionnaires related to  
42  
43 disease activity, health, physical activity, quality of life and diet at the three assessment  
44  
45 timepoints (see *Box 6*).  
46  
47  
48  
49  
50  
51

## 52 **Participant samples**

53  
54  
55 All sample collection and processing will be standardised, with full requirements  
56  
57 detailed in a study Sample Collection Manual.  
58  
59  
60

1  
2  
3  
4 Stool samples will be collected by participants at home using stool collection kits and  
5  
6 returned using a prepaid Royal Mail Safebox™. All participants will collect two stool samples  
7  
8 per study assessment timepoint (DNA Genotek OMNIgene®•GUT tube and universal  
9  
10 polystyrene tube). Participants recruited to the CD-metaRESPONSE sub-cohort will be  
11  
12 required to collect a third stool sample at baseline and week 14 (DNA Genotek  
13  
14 OMNImet®•GUT tube). DNA extraction and metagenomic shotgun sequencing will be  
15  
16 performed on buffered samples. Calprotectin will be measured in unbuffered stool. Remaining  
17  
18 fresh stool and nucleic acids will be cryopreserved for use in future research.  
19  
20  
21  
22

23 Participants who attend a clinical appointment prior to commencing advanced therapy  
24  
25 or within the week 14 visit window (week 10-20; week 12-16 preferred) will be asked to provide  
26  
27 two blood samples (lithium heparin (LiH) tube and ethylenediaminetetra-acetic acid (EDTA)  
28  
29 tube). Blood samples will be utilised for single cell analysis, plasma extraction and  
30  
31 cryopreservation. Any remaining blood samples or derivatives will be stored at Newcastle  
32  
33 Biobank for use in future research. Participants will not be asked to attend hospital specifically  
34  
35 for blood sample collection. If participants are not scheduled to attend hospital face-to-face  
36  
37 within either study assessment window, blood samples will not be taken.  
38  
39  
40  
41  
42

43 If a participant has a lower gastrointestinal endoscopy as part of planned care during  
44  
45 study participation, up to 12 research biopsies (one set of six biopsies to be collected from the  
46  
47 colon in all participants and a further set of six biopsies from the ileum in CD participants) will  
48  
49 be taken. Where a participant meets the study eligibility criteria and a disease assessment  
50  
51 endoscopy is planned prior to starting therapy, consent should be received ahead of their  
52  
53 planned endoscopy to enable the collection of research biopsies. Biopsy samples will be  
54  
55 utilised for single cell sequencing and organoid generation. 16S rRNA gene sequencing of  
56  
57  
58  
59  
60

both FFPE and fresh tissue will also be undertaken. Any remaining biopsy samples will be stored for use in future research.

[Figure 2]

#### COMPLETED BY ALL PARTICIPANTS AT BASELINE, WEEK 14 AND WEEK 54

##### **PRO-2 (CD or UC version depending on diagnosis)**

PRO-2 is a validated questionnaire measuring patient reported outcomes including stool frequency, abdominal pain and rectal bleeding.(27, 28).

##### **Bristol Stool Form Scale (BSFS)**

The BSFS is a 7-point scale that helps describe stool shape and consistency and assess bowel patterns and habits.(29)

##### **IBD-Control**

The IBD-Control questionnaire comprises 13 items plus a visual analogue scale (VAS) ranging from 0–100.(30) The questionnaire measures patient related outcome of their disease state during the past 2 weeks.

##### **PROMIS-Fatigue 8a Short Form**

The Patient Reported Outcomes Measurement Information System (PROMIS), are validated questionnaires that help evaluate patients' quality of life.(31)

##### **EQ-5D-5L**

The EQ-5D-5L is a quality-of-life questionnaire and is a widely used generic PROM incorporating five domains: 1) mobility, 2) self-care, 3) usual activities, 4) pain/discomfort, 5) anxiety/depression.(32, 33) Scores for each domain are combined to describe the patient's state of health.

##### **International Physical Activity Questionnaire (IPAQ)**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

IPAQ is a commonly used self-reported questionnaire to estimate physical activity and sedentary behaviours for adults across a range of socio-economic settings.(34) The IPAQ measures the type of physical activities people do as part of their everyday lives.(34)

#### **IBD-RESPONSE Joint Pain and Stiffness Score (JPSS)**

The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a patient reported questionnaire which quantifies clinical disease activity in Ankylosing Spondylitis (AS) and combines five disease activity variables (four 10-point Likert scale patient symptom responses and a CRP measurement), to produce a single score.(35-37) We believe joint pain to be an under-recognised symptom in active inflammatory bowel disease which may change in response to therapy as inflammation resolves/fails to resolve and so we have modified the ASDAS to assess joint pain, swelling and stiffness in all IBD-RESPONSE patients irrespective of whether they have a rheumatological diagnosis. We have called this modified score the IBD-RESPONSE Joint Pain and Stiffness Score (JPSS).

#### **Food frequency questionnaire (FFQ)**

The FFQ will be completed by participants directly into the study specific REDCap database and can also be completed on paper. The FFQ requests information on 175 food items, their typical portion size and frequency of consumption and has been extensively validated for measuring nutrient intakes in adults.(38) Data are converted to nutrient intake using the Composition of Foods Integrated Dataset (COFIDs), as well as diet quality indices and other food components (e.g. polyphenols) and food categorisation (e.g. ultra-processed foods). The FFQ data will initially be analysed at the Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen and other collaborating institutions at the Department of Nutritional Sciences, King's College London.

**COMPLETED BY CD-METARESPONSE PARTICIPANTS AT BASELINE AND WEEK 14 ONLY**

#### **4-day food diaries**

The 4-day food diary measures current food intake. It will comprehensively and prospectively measure all intake allowing calculation of energy and nutrient intake, dietary



indices (e.g. diet diversity and Mediterranean diet), intake of ultra-processed foods, prebiotic and emulsifier intake.

Box 6. Summary of patient questionnaires completed throughout study period

## Statistical analysis

The analysis approach for our primary objective will be to test for the association between features of the patient microbiome at baseline and primary clinical response to treatment at 14 weeks. Features will include alpha diversity, abundance of bacterial taxa (including species, genus and phyla) as well as the abundance of genes within various microbial pathways (for example using KEGG pathways, MetaCyc metabolic pathways and gene families). Association testing will be carried out using negative binomial regression, controlling for total sequence depth and pre-defined technical and clinical confounders, and significance will be determined using Benjamini-Hochberg multiple testing correction to ensure a false discovery rate of less than 5%. Individuals who are lost to follow-up or withdraw from the study before 14 weeks will be removed from the analysis, though we will also carry out a robustness analysis where we include individuals lost to follow-up as non-responders to ensure the results are robust to this choice.

For the predictive modelling aim, we will use a random forest classifier to predict primary response to treatment at 14 weeks using microbiome, host genetic and clinical features at baseline. Model parameters will be tuned and accuracy assessed using nested cross-validation. This full model will be compared to a clinical-variables-only model, with improvement measured by area under the received operator curve, as well as positive and

1  
2  
3 negative predictive power. A further model will be fitted using the same approach including  
4  
5 metabolomic and dietary data on the CD-metaRESPONSE subset.  
6  
7

8  
9       Secondary and exploratory objective analyses will use the same general analysis  
10  
11 approach as described above. For time-dependent events, such as treatment escalation due  
12  
13 to loss of response, a Cox proportional hazards regression will be used to assess the impact  
14  
15 of microbiome features on time to event, with patients censored at 54 weeks, last recorded (if  
16  
17 lost to follow-up) or date of withdrawal (if withdrawn). The dietary data will be analysed to test  
18  
19 the association between primary response and measures of specific nutrients (such as dietary  
20  
21 fibre) and dietary indices will be used to assess adherence to certain recommended diets  
22  
23 (such as achievement of food-based dietary guidelines or a “Mediterranean diet”). Host  
24  
25 genotype data will be used to test for associations between primary response and generate  
26  
27 polygenic risk scores of susceptibility to Crohn’s disease and ulcerative colitis, as well as pre-  
28  
29 specified variants associated with response to therapy (including HLA-DQA1\*05). In all these  
30  
31 individual analyses, Benjamini-Hochberg will be applied used to control the false discovery  
32  
33 rate at 5%.  
34  
35  
36  
37  
38  
39

40       Statistical analysis will be carried out in R.  
41

## 42 43 **Replication**

44  
45       Scaling up microbiome discoveries and providing validation of results is needed to  
46  
47 benefit patients. Whilst IBD-RESPONSE is the largest project of its kind to date, it is a UK-  
48  
49 only programme. Translating findings to maximise patient benefit requires international  
50  
51 collaboration. Standardised data collection and data integration from different countries and  
52  
53 ethnic groups is key to establishing predictors of treatment response that are generalisable  
54  
55 and replicable.  
56  
57  
58  
59  
60

1  
2  
3  
4 We will validate our predictive model using an appropriate, already assembled  
5  
6 microbiome validation cohort. To generate this replication cohort, we will use banked stool  
7  
8 DNA from the Prognostic effect of Environmental factors in Crohn's and Colitis Study  
9  
10 (PREdiCCt; [www.predicct.co.uk](http://www.predicct.co.uk)), led by Professor Charlie Lees. PREdiCCt is a prospective  
11  
12 observational study of IBD participants in clinical remission, designed to identify whether  
13  
14 baseline factors (including genetics, dietary habits and gut microbiota) predict subsequent  
15  
16 disease flare. We will perform metagenomic sequencing of 1,000 stool samples from patients  
17  
18 who experienced a disease flare during the PREdiCCt study. We expect approximately 40%  
19  
20 of PREdiCCt patients to experience a disease flare requiring commencement of biologics. As  
21  
22 these patients all have baseline (clinical remission) stool microbiome samples in storage, they  
23  
24 provide a well matched and cost-efficient set of samples for replicating IBD-RESPONSE  
25  
26 results.  
27  
28  
29  
30  
31

32  
33 We will also carry out a collaborative cross-replication analysis of results from IBD-  
34  
35 RESPONSE and the Montreal, Canada iGenoMed-MTT cohort, led by Professor John Rioux  
36  
37 to evaluate how well microbiome associations and predictive algorithms replicate across  
38  
39 continents. This will involve analysis of stored stool samples from 105 Canadian IBD patients  
40  
41 collected prior to commencing advanced therapies (following the sequencing and analysis  
42  
43 protocols established in IBD-RESPONSE) with treatment outcome data. It will provide a rapid  
44  
45 "first-look" analysis to discover and assess microbiome predictors of biological response in an  
46  
47 international cohort with extensive metadata, ahead of larger studies coming online over a  
48  
49 longer timeframe within IBD-RESPONSE and allow later cross-replication/meta-analysis.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Potential future benefit to patients

IBD-RESPONSE will provide timely and important information regarding associations between the gut microbiome and responsiveness to treatment in IBD. It will likely highlight potential mechanisms through which the microbiota may drive inflammation. We hope that findings from IBD-RESPONSE will lead to new personalised avenues for IBD treatment through discovery and validation of predictive tools that may be incorporated directly into clinical practice or further tested in stratified clinical trials. This could lead to the development of experimental techniques to modify gut microbes; for example, donor selection for faecal microbial transplantation, identification of single or multiple strains of microbes, or use of antimicrobials, phage or microbial metabolites that may be used to induce a more 'treatment responsive' microbiome.

### Patient and public involvement statement

IBD-RESPONSE was informed by two national patient research prioritisation exercises in IBD care led by members of our team and involving feedback from 3,000 people living with IBD, their family and friends.(1, 21). These identify aspects of precision medicine, microbiome and diet in IBD as of high importance. The initial IBD-RESPONSE grant proposal to the Medical Research Council (MRC) was reviewed by the NIHR Research Design Service North East and North Cumbria Patient and Public Involvement Panel and was presented and discussed at the 2020 Crohn's & Colitis UK Patient and Public Involvement in Research Day. IBD-RESPONSE has been supported by two patient representatives in the Study Oversight Committee (SOC) since inception. The study team have engaged with lay members of the SOC to ensure all patient facing documents including the participant information sheet (PIS), consent forms, stool collection guidance for patients and study questionnaires have

1  
2  
3 undergone review. Patients will also be involved in dissemination activities relating to outputs  
4  
5  
6 from this research.  
7

## 8 9 **ETHICS AND DISSEMINATION**

10  
11 Ethical approval for the study was obtained from the Wales Research Ethics Committee 5  
12  
13 (reference 21/WA/0228). Recruitment to IBD-RESPONSE began in February 2022 and is  
14  
15 currently ongoing at sites around the UK.  
16  
17

18  
19 In line with the Newcastle University and The Newcastle upon Tyne Hospitals NHS  
20  
21 Foundation Trust research data policy, datasets will be kept for at least five years after the  
22  
23 date they were last accessed. Metadata linked to genomic and metagenomic datasets will  
24  
25 include anonymised clinical information. Examples include diagnosis (UC/CD/IBD-U), disease  
26  
27 location, disease behaviour, complications, extra-intestinal manifestations, co-morbidities,  
28  
29 family history, smoking history, surgical interventions, and outcomes from prior drug therapies.  
30  
31  
32

33  
34 Raw data files in the original format (e.g. fastq) and the accompanying anonymised  
35  
36 phenotypic data will be uploaded to a public repository e.g. the NCBI database of Genotypes  
37  
38 and Phenotypes (dbGaP) at <https://www.ncbi.nlm.nih.gov/gap/>.  
39  
40

41  
42 As part of CD-metaRESPONSE, microbial sequence and faecal/serum metabolomic  
43  
44 data will be integrated with single-cell RNA sequencing, human genomics and clinical outcome  
45  
46 data; the whole dataset will be made available to other investigators and will be archived long  
47  
48 term within the IBD BioResource to facilitate downstream research.  
49  
50

51  
52 The CI, SMG, Sponsor, Funders and research team members are committed to ensure  
53  
54 that the research findings are shared. Findings will be written up and submitted to a peer-  
55  
56 reviewed scientific journal. Findings will be presented by the study team at national and  
57  
58 international conferences for example the British Society of Gastroenterology (BSG) annual  
59  
60

1  
2  
3 meeting, the European Crohn's and Colitis (ECCO) meeting and Digestive Diseases Week  
4 (DDW). The study team will prepare a lay summary of the study findings for dissemination to  
5  
6 the study participants and members of the national patient group, Crohn's & Colitis UK.  
7  
8 Following study completion, results will be submitted for publication in peer-reviewed journals  
9  
10 and presented at national and international scientific meetings.  
11  
12  
13  
14  
15

## 16 **REGISTRATION DETAILS**

17  
18 Trial registration number: ISRCTN96296121 (pre-results).  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Lamb CA, Kennedy NA, Raine T, Hendy P, Smith PJ, Limdi J, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019.
2. Floyd DN, Langham S, Severac HC, Levesque BG. The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review. *Dig Dis Sci*. 2015;60(2):299-312.
3. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Risk factors of work disability in patients with inflammatory bowel disease--a Dutch nationwide web-based survey: work disability in inflammatory bowel disease. *J Crohns Colitis*. 2014;8(7):590-7.
4. Jones GR, Lyons M, Plevris N, Jenkinson PW, Bisset C, Burgess C, et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. *Gut*. 2019;68(11):1953-60.
5. Hamilton B, Green H, Heerasing N, Hendy P, Moore L, Chanchlani N, et al. Incidence and prevalence of inflammatory bowel disease in Devon, UK. *Frontline Gastroenterology*. 2021;12(6):461.
6. Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. *BioDrugs*. 2021;35(5):473-503.
7. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature*. 2012;491(7422):119-24.
8. Luo Y, de Lange KM, Jostins L, Moutsianas L, Randall J, Kennedy NA, et al. Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. *Nat Genet*. 2017;49(2):186-92.
9. Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, et al. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. *Cell Host Microbe*. 2017;21(5):603-10 e3.
10. Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, et al. Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients. *MBio*. 2018;9(2).
11. Lee JWJ, Plichta D, Hogstrom L, Borren NZ, Lau H, Gregory SM, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. *Cell Host & Microbe*. 2021;29(8):1294-304.e4.
12. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science*. 2018;359(6371):91-7.
13. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science*. 2018;359(6371):104-8.
14. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*. 2018;359(6371):97-103.
15. Plichta DR, Graham DB, Subramanian S, Xavier RJ. Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships. *Cell*. 2019;178(5):1041-56.

16. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. *Lancet Gastroenterol Hepatol*. 2019;4(5):341-53.
17. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, et al. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. *Am J Gastroenterol*. 2018;113(9):1345.
18. Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, et al. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. *Clin Gastroenterol Hepatol*. 2016;14(2):242-50 e1-2.
19. Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. *Clinical Gastroenterology and Hepatology*. 2021;19(10):2031-45.e11.
20. Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. *Frontline Gastroenterol*. 2015;6(3):169-74.
21. Hart AL, Lomer M, Verjee A, Kemp K, Faiz O, Daly A, et al. What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance. *J Crohns Colitis*. 2017;11(2):204-11.
22. Parkes M, Investigators IBDB. IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn's and Colitis. *Gut*. 2019;68(9):1537-40.
23. Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, et al. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease. *J Crohns Colitis*. 2020;14(8):1090-102.
24. Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV, et al. The effect of host genetics on the gut microbiome. *Nat Genet*. 2016;48(11):1407-12.
25. Moore CM, Jacobson SA, Fingerlin TE. Power and Sample Size Calculations for Genetic Association Studies in the Presence of Genetic Model Misspecification. *Hum Hered*. 2019;84(6):256-71.
26. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol*. 2013;42(5):1497-501.
27. Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. *Aliment Pharmacol Ther*. 2015;42(10):1200-10.
28. Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. *Aliment Pharmacol Ther*. 2015;41(1):77-86.
29. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. *Scand J Gastroenterol*. 1997;32(9):920-4.
30. Bodger K, Ormerod C, Shackcloth D, Harrison M, Collaborative IBDC. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. *Gut*. 2014;63(7):1092-102.
31. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. *Med Care*. 2007;45(5 Suppl 1):S3-S11.



- 1  
2  
3 32. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary  
4 testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res.* 2011;20(10):1727-36.  
5  
6 33. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement  
7 properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country  
8 study. *Qual Life Res.* 2013;22(7):1717-27.  
9  
10 34. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International  
11 physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc.*  
12 2003;35(8):1381-95.  
13  
14 35. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-  
15 endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis.*  
16 2009;68(1):18-24.  
17  
18 36. Machado PM, Landewe R, Heijde DV, Assessment of SpondyloArthritis international S.  
19 Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease  
20 activity states. *Ann Rheum Dis.* 2018;77(10):1539-40.  
21  
22 37. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly  
23 discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. *Ann*  
24 *Rheum Dis.* 2009;68(12):1811-8.  
25  
26 38. Hollis JL, Craig LCA, Whybrow S, Clark H, Kyle JAM, McNeill G. Assessing the relative validity of  
27 the Scottish Collaborative Group FFQ for measuring dietary intake in adults. *Public Health Nutrition.*  
28 2017;20(3):449-55.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## WORD COUNT

4,363 words

## AUTHOR STATEMENT

All authors contributed to clinical protocol and/or laboratory standard operating procedures.

The grants to fund IBD-RESPONSE and CD-metaRESPONSE were conceptualised and written by CAL, LJ-D, CJS, MP, CA, NAK, TR, TA, AH, HH, CWL, JCM, JRM, NPo, NPr, JS, RAS. Clinical study design and analytical plans were further developed by these authors plus MB, EC, DC, MD, AK, CK, PMI, JOL, RL, SL, TL, RM, SS, TS, JW, KW, NJW, RW and XZ with critical review from all authors. Laboratory standard operating procedures were developed by CAL, CJS, HF, REM, LJ-D, CK, NAK, CA, MB, EC, DC, JAD, MD, SI, JOL, CCM, JRM, TO, MP, MS, NP, NJP, TR, MS, SS and NJW. Manuscript drafting was led by NJW and CAL with subsequent critical review and revision by all authors.

## FUNDING

The IBD-RESPONSE cohort is supported by a grant from the Medical Research Council (funder reference MR/T032162/1) and the CD-metaRESPONSE cohort by, the Leona M. and Harry B. Helmsley Charitable Trust (funder reference 2002-04255). Single cell RNA sequencing in IBD-RESPONSE and CD-metaRESPONSE is supported by a grant from the Leona M. and Harry B. Helmsley Charitable Trust (funder reference 2304-05972). Cross-replication analysis utilising the Canada iGenoMed-MTT cohort us supported by a grant from Crohn's and Colitis UK (funder reference M2022-4 Lamb). CJS is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number 221745/Z/20/Z) and the 2021 Lister Institute Prize Fellow Award. NJW is supported by the NIHR Academic Clinical Fellowship (ACF) programme. LJD is supported by a Sir Henry Dale

1  
2  
3 Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number  
4 208750/Z/17/Z) and the Kennedy Trust for Rheumatology Research. JMSW is funded by a  
5  
6 NIHR Research Professorship (NIHR301614). XZ is funded by a NIHR Pre-doctoral  
7  
8 Fellowship (NIHR302014).  
9  
10  
11

## 12 13 **ACKNOWLEDGEMENTS**

14  
15  
16 We are grateful for support from the Newcastle Clinical Trials Unit, the National Phenome  
17  
18 Centre, Imperial College London and the NIHR Biomedical Research Centres from Newcastle,  
19  
20 Imperial and Cambridge. The views expressed are those of the authors and not necessarily  
21  
22 those of our funders, the NIHR or the Department of Health and Social Care.  
23  
24  
25

## 26 27 **COMPETING INTERESTS STATEMENT**

28  
29 Tariq Ahmad reports personal grants from F. Hoffmann-La Roche AG, Biogen Inc, AbbVie,  
30  
31 Janssen, Celltrion, Galapagos NV, Immunodiagnostik, and Takeda, outside the submitted  
32  
33 work; personal fees for educational development/delivery from from Pfizer, payment or  
34  
35 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
36  
37 events from Pfizer, Takeda, and F. Hoffman-La Roche AG; support for attending meetings  
38  
39 from Celltrion, Tillotts, and Pfizer. Carl A. Anderson reports grants from the Wellcome Sanger  
40  
41 Institute Quinquennial Review 2021-2026, Crohn's and Colitis Foundation (USA), the Medical  
42  
43 Research Council, Open Targets UK, and Helmsley Charitable Trust; consulting fees from  
44  
45 BridgeBio Ltd, Genomics PLC, and Brigham & Women's Hospital Boston; payment or  
46  
47 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
48  
49 events from GlaxoSmithKline; support for attending meetings and/or travel membership from  
50  
51 the Wellcome Sanger Institute Quinquennial Review 2021-2026; (Chair) of the Board of  
52  
53 Trustees for the Sanger Prize; other interests as Director of Anderson Genomics Consultancy  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Ltd. Michelle Bardgett reports partial personal salary funding from the Medical Research  
4 Council. Ailsa Hart reports personal consulting fees from AbbVie, BMS, Celltrion, Falk,  
5 Galapagos, Janssen, Pfizer, Takeda, and Roche; payment or honoraria for lectures,  
6 presentations, speakers bureaus, manuscript writing or educational events from BMS,  
7 Celltrion, Falk, Galapagos, Janssen, Pfizer, Takeda, Roche, and AbbVie; support for attending  
8 meetings and/or travel from BMS, Celltrion, Falk, Galapagos, Janssen, Pfizer, Takeda, Roche,  
9 and AbbVie. Peter M. Irving reports reports personal grants from Celltrion, Galapagos, and  
10 Pfizer, outside the submitted work; personal consulting fees from AbbVie, Takeda, BMS,  
11 Janssen, Arena, Pfizer, Galapagos, Lilly, Boehringer-Ingelheim, and Celgene; payment or  
12 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
13 events from AbbVie, Takeda, Janssen, Lilly, BMS, Pfizer, and Galapagos; support for  
14 attending meetings and/or travel from AbbVie and Tillotts. Luke Jostins-Dean reports grants  
15 from the Wellcome Trust, the Royal Society, the Kennedy Trust for Rheumatology Research,  
16 the Leona M. and Harry B. Helmsley Charitable Trust, and the Medical Research Council;  
17 grants from Novartis Pharmaceutical, outside the submitted work; consulting fees from  
18 Nightingale Health and Genomics PLC. Ciara Kennedy reports partial salary funding from the  
19 Medical Research Council. Nicholas A. Kennedy reports grants from AbbVie, Biogen,  
20 Celltrion, Galapagos, and Immunodiagnostik; consulting fees from AbbVie, Bristol-Meyer  
21 Squibb, and Dr Falk; payment or honoraria for lectures, presentations, speakers bureaus,  
22 manuscript writing or educational events from AbbVie, Dr Falk, Tillotts, Galapagos, and  
23 Takeda; support for attending meetings and/or travel from Tillotts; participation (Chair) on the  
24 Board of the British Society of Gastroenterology IBD Clinical Research Group. Christopher A.  
25 Lamb reports grants from Janssen, Takeda, AbbVie, AstraZeneca, Eli Lilly, Orion, Pfizer,  
26 Roche, Sanofi Aventis, UCB, Biogen, and Genentech Inc; payment or honoraria for lectures,  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 presentations, speakers bureaus, manuscript writing or educational events from Ferring,  
4  
5 Takeda, Janssen, and Dr Falk; participation (Secretary) on the British Society of  
6  
7 Gastroenterology IBD Section; participation on the Steering Committee of IBD UK. Charlie  
8  
9 W. Lees reports grants from UKRI Future Leaders Fellowship; personal consulting fees from  
10  
11 AbbVie, Pfizer, Janssen, Takeda, Galapagos, Fresenius Kabi, Novartis/Sandoz, BMS, and  
12  
13 Celltrion; payment or honoraria for lectures, presentations, speakers bureaus, manuscript  
14  
15 writing or educational events from AbbVie, Pfizer, Janssen, Takeda, Galapagos, Fresenius  
16  
17 Kabi, Novartis/Sandoz, BMS, Ferring, Dr Falk, and Celltrion. James O. Lindsay reports grants  
18  
19 from AbbVie, and Gilead; personal consulting fees from Allergan, AbbVie, Bristol Myers Squibb,  
20  
21 Celgene, Cornerstones US, Galapagos, Gilead, GSK, Lilly, MSD UK, Shire UK, Shire  
22  
23 International, Ferring UK, Ferring International, Celltrion, Takeda, Pfizer, and Janssen;  
24  
25 payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or  
26  
27 educational events from AbbVie, Bristol Myers Squibb, Cornerstones US, Galapagos, Ferring  
28  
29 UK, Ferring International, Celltrion, Takeda, Pfizer, and Janssen; support to attend meetings  
30  
31 and/or travel from AbbVie, and Janssen. Rebecca H. Maier reports that she is an independent  
32  
33 membership on the Trial Steering Committee for the National Institute for Health and Care  
34  
35 Research funded ALLEGRO trial. Julian R. Marchesi reports personal consulting fees from  
36  
37 EnteroBiotix Limited and Cultech Limited; patent held (without financial gain) on *C. Difficile*  
38  
39 therapy (WO2019197836A1), participation (Chair) on the IDMC Board. Naomi McGregor  
40  
41 reports partial (10%) salary funding from the Medical Research Council. Rebecca E. McIntyre  
42  
43 reports personal salary funding from the Wellcome Sanger Institute. Jasmin Ostermayer  
44  
45 reports stock held in Novartis AG. Miles Parkes reports grants from Pfizer and Gilead;  
46  
47 personal consulting fees from Galapagos; payment or honoraria for lectures, presentations,  
48  
49 speakers bureaus, manuscript writing or educational events from Janssen. Nick Powell  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 reports grants from Bristol-Myers Squibb, Takeda, and Pfizer; consulting fees from AbbVie,  
4  
5 Allergan, Astra-Zeneca, Bristol-Myers Squibb, Celgene, Celltrion, Galapagos, GSK, Takeda,  
6  
7 and Vifor; payment or honoraria for lectures, presentations, speakers bureaus, manuscript  
8  
9 writing or educational events from AbbVie, Bristol-Myers Squibb, Ferring, Galapagos,  
10  
11 Janssen, Roche, Pfizer, Takeda, and Tillotts; support for attending meetings and/or travel from  
12  
13 AbbVie, Allergan, Celltrion, Janssen, and Takeda; participation on a data safety monitoring  
14  
15 board or advisory board for AbbVie, Allergan, Astra-Zeneca, Bristol-Myers Squibb, Celgene,  
16  
17 Celltrion, Galapagos, GSK, Takeda, and Vifor. Tim Raine reports personal grants from  
18  
19 AbbVie; personal consulting fees from AbbVie, Arena, Aslan, AstraZeneca, Boehringer-  
20  
21 Ingelheim, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen,  
22  
23 Mylan, MSD, Novartis, Pfizer, Roche, Sandoz, Takeda, UCB, and XAP therapeutics;  
24  
25 participation on the board of UCB, membership (Chair) of the ECCO Guidelines Committee,  
26  
27 membership of the UEG Scientific Committee. Jack Satsangi reports grants from Crohn's and  
28  
29 Colitis UK, Helmsley Trust, ECCO, the European Commission, CCFA, and Action Medical  
30  
31 Research; payment or honoraria for lectures, presentations, speakers bureaus, manuscript  
32  
33 writing or educational events from Roche; participation on a Data Safety Monitoring Board or  
34  
35 Advisory Board for the MODULATE trial and the TRIBUTE trial; leadership or fiduciary role  
36  
37 as the Director of the Royal College of Physicians IBD Registry, and Governing Body Fellow  
38  
39 at Green Templeton College. R. Alexander Speight reports personal consulting fees from  
40  
41 GSK; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing  
42  
43 or educational events from Falk, and AbbVie; payment of conference fees to attend the British  
44  
45 Society of Gastroenterology Annual Conference 2022 from Celltrion; participation on a Data  
46  
47 Safety Monitoring Board or Advisory Board for the IBD-RESPONSE study (unpaid), and  
48  
49 Abbvie; participation on the British Society of Gastroenterology IBD Section Committee.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Christopher J. Stewart reports personal consultancy fees from Astarte Medical; payment or  
4 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
5 events from Nestle Nutrition Institute. James M. S. Wason reports grants from Intercept;  
6 consulting fees from Worg and UCB; payment or honoraria for lectures, presentations,  
7 speakers bureaus, manuscript writing or educational events from Janssen; participation on a  
8 Data Safety Monitoring Board or Advisory Board for Roche. Kevin Whelan reports grants from  
9 the Leona M. and Harry B. Helmsley Charitable Trust, Crohn's and Colitis UK, Almond Board  
10 of California, Danone, International Dried Fruit and Nut Council, Medical Research Council,  
11 National Institute for Health and care Research; royalty or license payments for Volatile  
12 organic compounds in the diagnosis and management of irritable bowel syndrome, and Wiley  
13 BDA Advances in Nutrition & Dietetics book series; personal consulting fees from Danone;  
14 payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or  
15 educational events from Janssen; support for attending meetings and/or travel from Yakult;  
16 participation on a Data Safety Monitoring Board or Advisory Board for the MODULATE trial  
17 (unpaid). The remaining authors disclose no conflicts of interest.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## FIGURE LEGENDS

**Figure 1. Study overview schematic** (created with BioRender.com). 1,325 participants with IBD planned to commence an advanced therapy will be recruited, including a nested sub-cohort of 300 CD patients (CD-metaRESPONSE). All participants will collect two stool sample tubes at each study assessment timepoint (baseline, week 14 and week 54). CD-metaRESPONSE participants will be required to collect a third stool sample tube at baseline and week 14. If a participant attends hospital for a face-to-face appointment within the baseline and/or week 14 study assessment window, blood samples will be collected. If a participant attends hospital for a lower gastrointestinal endoscopy at any time during the study period (pre- or post- treatment), biopsy samples will be collected. Participants will complete several questionnaires at each assessment time point. For CD-metaRESPONSE participants, additional detailed analyses will be undertaken of metabolic profiles (metabolome) in stool and matched blood plus in-depth dietary assessment (additional elements highlighted in blue boxes). Data generated will be used to perform predictive modelling. Any remaining participant samples will form a large biorepository for use in future research.

Figure 1 abbreviations: anti-tumour necrosis factor alpha (anti-TNF $\alpha$ ), anti-interleukin (anti-IL), Bristol stool form scale (BSFS), Crohn's disease (CD), formalin-fixed paraffin embedded (FFPE), inflammatory bowel disease (IBD), International Physical Activity Questionnaire (IPAQ), janus kinase inhibitor (JAKi), Joint Pain and Stiffness Score (JPSS), Patient Reported Outcome-2 (PRO-2), Patient Reported Outcomes Measurement Information System (PROMIS), sphingosine-1-phosphate receptor (S1PR), ulcerative colitis (UC).

**Figure 2. Flowchart providing overview of study events.**



1  
2  
3 Figure 2 abbreviations: Crohn's disease (CD), inflammatory bowel disease (IBD), Janus  
4 kinase inhibitor (JAKi), Mayo Clinic Score (MCS), multidisciplinary team (MDT), Patient  
5  
6 Reported Outcome-2 (PRO-2), simple endoscopic score for Crohn's disease (SES-CD),  
7  
8 sphingosine-1-phosphate receptor (S1PR), Research Electronic Data Capture (REDCap),  
9  
10 ulcerative colitis (UC).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Study overview schematic (created with BioRender.com). 1,325 participants with IBD planned to commence an advanced therapy will be recruited, including a nested sub-cohort of 300 CD patients (CD-metaRESPONSE). All participants will collect two stool sample tubes at each study assessment timepoint (baseline, week 14 and week 54). CD-metaRESPONSE participants will be required to collect a third stool sample tube at baseline and week 14. If a participant attends hospital for a face-to-face appointment within the baseline and/or week 14 study assessment window, blood samples will be collected. If a participant attends hospital for a lower gastrointestinal endoscopy at any time during the study period (pre- or post-treatment), biopsy samples will be collected. Participants will complete several questionnaires at each assessment time point. For CD-metaRESPONSE participants, additional detailed analyses will be undertaken of metabolic profiles (metabolome) in stool and matched blood plus in-depth dietary assessment (additional elements highlighted in blue boxes). Data generated will be used to perform predictive modelling. Any remaining participant samples will form a large biorepository for use in future research.

Figure 1 abbreviations: anti-tumour necrosis factor alpha (anti-TNF $\alpha$ ), anti-interleukin (anti-IL), Bristol stool form scale (BSFS), Crohn's disease (CD), formalin-fixed paraffin embedded (FFPE), inflammatory bowel disease (IBD), International Physical Activity Questionnaire (IPAQ), janus kinase inhibitor (JAKi), Joint Pain and Stiffness Score (JPSS), Patient Reported Outcome-2 (PRO-2), Patient Reported Outcomes Measurement Information System (PROMIS), sphingosine-1-phosphate receptor (S1PR), ulcerative colitis (UC).

400x228mm (300 x 300 DPI)

**Where:** Face-to-face clinics, telephone consultations, endoscopy lists, infusion suites, MDT meetings, virtual biologics clinics, IBD nurse helpline  
**Who:** ≥16 years old; symptomatic, active luminal IBD; no minimum disease duration  
**Advanced therapy being commenced:** Licensed biologic, JAKi or S1PR modulator (infliximab, adalimumab, vedolizumab, ustekinumab, tofacitinib, filgotinib, upadacitinib, ozanimod) or early access/compassionate use therapy (e.g. risankizumab)  
**Screening tips:**  
 4 UC symptoms: increased stool frequency relative to baseline AND at least one episode of recent rectal bleeding within e.g. last 3-5 days  
 5 CD symptoms of active flare: presence of liquid or very soft stools AND/OR presence of abdominal pain  
 6 Active disease confirmed by clinical test in 12 weeks prior to consent: faecal calprotectin, CRP, endoscopy or imaging (CD only)  
 7 Participants do not need to be naïve to advanced therapies e.g. can previously have received a biologic  
 8 Participants switching between advanced therapies do not need a minimum washout period  
 9 Participants can be receiving or about to start concomitant thiopurine or methotrexate alongside planned advanced therapy  
 10 Participants can be receiving or starting steroids at baseline provided likely to have fully weaned by week 14

## Eligibility confirmed

## Study information and informed consent given

17 Participant Information Sheet (PIS) provided (paper or electronic format)  
 18 Potential participant questions answered by local study team  
 19 REDCap access given to participant to complete informed study consent

## Consent verified

23 Stool sample collection kit given to/posted to participant once valid consent obtained and verified by local study team

## Baseline assessment

**Ideal: Week 0**  
 Target: Up to 6 weeks prior to commencing advanced therapy  
 Permitted: Assessment >6 weeks prior to commencing advanced therapy is permitted, e.g. if delayed due to infusion unit capacity

**All participants to complete after consent and before starting advanced therapy:**  
 30 Participant questionnaires completed on REDCap  
 31 Stool sample tubes (n=2) collected and returned using prepaid Royal Mail Safebox™  
 32 If attending hospital for a face-to-face clinical encounter within assessment window, two tubes (total  
 33 20mls) blood collected  
**CD-metaRESPONSE sub-cohort (in addition to above requirements):**  
 34 Third stool sample tube collected (provided in home stool sample collection kit)  
 35 Third stool sample tube collected (provided in home stool sample collection kit)  
 36 Prospective 4-day food diary completed

Participants unable/unwilling to complete PRO-2 questionnaire, those not meeting PRO-2 threshold for clinically active disease, missing stool samples or who do not start treatment will be withdrawn from the study

## Eligibility re-confirmed

40 Baseline 4 day PRO-2 (minimum 2 days data) assessed to confirm inclusion criteria for clinically active disease met

## Biologic, JAKi or S1PR modulator commenced

WEEK 0

## Week 14 assessment

**Ideal: Week 14**  
 Target: Week 12 - 16  
 Permitted: Week 10 - 20

50 per baseline assessment (including additional requirements for CD-metaRESPONSE)

## Week 54 assessment

**Ideal: Week 54**  
 Permitted: Week 48 - 60

**All participants:**  
 56 Participant questionnaires completed on REDCap  
 57 Stool sample tubes (n=2) collected and returned using prepaid Royal Mail Safebox™

If a participant stops treatment, the next planned study assessment should be brought forward and completed as a treatment discontinuation assessment. Where an alternative advanced therapy is then commenced, this discontinuation assessment will serve as the baseline assessment for the next therapy. Further assessments should then be completed at week 14 and 54 after commencing a new advanced therapy as per the study protocol

# BMJ Open

## Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: Protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-073639.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Sep-2023
Complete List of Authors:	Wyatt, Nicola; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology Watson, Hannah; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences Anderson, Carl ; Wellcome Sanger Institute, Wellcome Genome Campus Kennedy, Nicholas A; Royal Devon University Healthcare NHS Foundation Trust, Department of Gastroenterology; University of Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group Raine, Tim; Cambridge University Hospitals NHS Foundation Trust Ahmad, T.; Royal Devon University Healthcare NHS Foundation Trust, Department of Gastroenterology; University of Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group Allerton, Dean; Newcastle University, Newcastle Clinical Trials Unit Bardgett, Michelle; Newcastle University, Newcastle Clinical Trials Unit Clark, Emma; Newcastle University, Newcastle Clinical Trials Unit Clewes, Dawn; Newcastle University, Newcastle Clinical Trials Unit Cotobal Martin, Cristina; Wellcome Sanger Institute, Wellcome Genome Campus Doona, Mary; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology Doyle, Jennifer; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences Hancock, Helen; Newcastle University, Newcastle Clinical Trials Unit Hart, Ailsa L.; St Mark's Hospital and Academic Institute, Department of Gastroenterology; Imperial College London, Department of Surgery and Cancer Irving, Peter; Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology; King's College London, School of Immunology & Microbial Sciences Iqbal, Sameena; Wellcome Sanger Institute, Wellcome Genome Campus Kennedy, Ciara; Newcastle University, Newcastle Clinical Trials Unit King, Andrew; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology Lawrence, Sarah; Newcastle University, Newcastle Clinical Trials Unit Lees, Charlie W.; The University of Edinburgh MRC Institute of Genetics and Molecular Medicine; Western General Hospital, Institute of Genetics

	<p>&amp; Molecular Medicine  Lees, Robert; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology  Letchford, Laura; Wellcome Sanger Institute, Wellcome Genome Campus  Liddle, Trevor; Newcastle Upon Tyne Hospitals NHS Foundation Trust  Lindsay, James ; Barts Health NHS Trust, Department of Gastroenterology; Blizard Institute of Cell and Molecular Science, Centre for Immunobiology  Maier, Rebecca; Newcastle University, Newcastle Clinical Trials Unit  Mansfield, John; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology  Marchesi, Julian R.; St Mary's Hospital, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction  McGregor, Naomi; Newcastle University, Newcastle Clinical Trials Unit  McIntyre, Rebecca ; Wellcome Sanger Institute, Wellcome Genome Campus  Ostermayer, Jasmin; Wellcome Sanger Institute, Wellcome Genome Campus  Osunnuyi, Tolulope; Wellcome Sanger Institute, Wellcome Genome Campus  Powell, Nick; St Mary's Hospital, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction; Imperial College Healthcare NHS Trust, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction  Prescott, Natalie; King's College London, Department of Medical and Molecular Genetics, Guy's Hospital  Satsangi, J; University of Oxford, Nuffield Department of Medicine  Sharma, Shriya; Newcastle University, Newcastle Clinical Trials Unit  Shrestha, Tara; Newcastle University, Newcastle Clinical Trials Unit  Speight, Ally; Newcastle University Translational and Clinical Research Institute; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology  Strickland, Michelle; Wellcome Sanger Institute, Wellcome Genome Campus  Wason, James; Newcastle University, Population Health Sciences Institute  Whelan, Kevin; King's College London, Department of Nutritional Sciences  Wood, Ruth; Newcastle University, Newcastle Clinical Trials Unit  Zhang, Xinyue; Newcastle University, Population Health Sciences Institute  Parkes, M; Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology  Stewart, Christopher; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences  Jostins-Dean, Luke; University of Oxford, Kennedy Institute of Rheumatology  Lamb, Christopher; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology</p>
<p>&lt;b&gt;Primary Subject Heading&lt;/b&gt;:</p>	<p>Gastroenterology and hepatology</p>
<p>Secondary Subject Heading:</p>	<p>Pharmacology and therapeutics, Patient-centred medicine, Immunology (including allergy), Genetics and genomics, Diagnostics</p>
<p>Keywords:</p>	<p>Inflammatory bowel disease &lt; GASTROENTEROLOGY, Gastroenterology &lt; INTERNAL MEDICINE, MICROBIOLOGY, Patient-Centered Care, Patient Reported Outcome Measures</p>



SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Defining predictors of responsiveness to advanced therapies in**  
5  
6  
7  
8 **Crohn's disease and ulcerative colitis: Protocol for the IBD-**  
9  
10  
11 **RESPONSE and nested CD-metaRESPONSE prospective,**  
12  
13  
14  
15 **multicentre, observational cohort study in precision medicine**  
16  
17

18 Nicola J. Wyatt<sup>1,2</sup>, Hannah Fuller<sup>1</sup>, Carl A. Anderson<sup>3</sup>, Nicholas A. Kennedy<sup>4,5</sup>, Tim Raine<sup>6</sup>,  
19  
20 Tariq Ahmad<sup>4,5</sup>, Dean Allerton<sup>7</sup>, Michelle Bardgett<sup>7</sup>, Emma Clark<sup>7</sup>, Dawn Clewes<sup>7</sup>, Cristina  
21  
22 Cotobal Martin<sup>3</sup>, Mary Doona<sup>2</sup>, Jennifer A. Doyle<sup>1</sup>, Helen Hancock<sup>7</sup>, Ailsa Hart<sup>8,9</sup>, Peter M.  
23  
24 Irving<sup>10,11</sup>, Sameena Iqbal<sup>3</sup>, Ciara Kennedy<sup>7</sup>, Andrew King<sup>2</sup>, Sarah Lawrence<sup>7</sup>, Charlie W.  
25  
26 Lees<sup>12,13</sup>, Robert Lees<sup>2</sup>, Laura Letchford<sup>3</sup>, Trevor Liddle<sup>14</sup>, James O. Lindsay<sup>15,16</sup>, Rebecca H.  
27  
28 Maier<sup>7</sup>, John C. Mansfield<sup>1,2</sup>, Julian R. Marchesi<sup>17</sup>, Naomi McGregor<sup>7</sup>, Rebecca E. McIntyre<sup>3</sup>,  
29  
30 Jasmin Ostermayer<sup>3</sup>, Tolulope Osunnuyi<sup>3</sup>, Nick Powell<sup>17,18</sup>, Natalie J Prescott<sup>19</sup>, Jack  
31  
32 Satsangi<sup>20</sup>, Shriya Sharma<sup>7</sup>, Tara Shrestha<sup>7</sup>, Ally Speight<sup>1,2</sup>, Michelle Strickland<sup>3</sup>, James M.  
33  
34 S. Wason<sup>21</sup>, Kevin Whelan<sup>22</sup>, Ruth Wood<sup>7</sup>, Xinyue Zhang<sup>21</sup>, Miles Parkes<sup>6</sup>, Christopher J.  
35  
36 Stewart<sup>\*1</sup>, Luke Jostins-Dean<sup>\*23</sup>, Christopher A. Lamb<sup>\*1,2</sup>  
37  
38  
39  
40  
41  
42

43 \*Denotes co-senior authorship  
44  
45  
46  
47  
48

49 **Correspondence:**  
50

51 Dr Christopher Lamb, Translational & Clinical Research Institute, Faculty of Medical Sciences,  
52  
53 Newcastle University, Newcastle upon Tyne, NE2 4HH. United Kingdom  
54

55  
56 christopher.lamb@newcastle.ac.uk  
57  
58  
59  
60

**Affiliations:**

1. Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
2. Department of Gastroenterology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
3. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, United Kingdom
4. Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, United Kingdom
5. Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, United Kingdom
6. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
7. Newcastle Clinical Trials Unit (NCTU), 1-4 Claremont Terrace, Newcastle University, Newcastle upon Tyne, NE2 4AE, United Kingdom
8. Department of Gastroenterology, St Marks Hospital and Academic Institute, Gastroenterology, London, United Kingdom
9. Department of Surgery and Cancer, Imperial College, London, United Kingdom
10. Department of Gastroenterology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
11. School of Immunology & Microbial Sciences, King's College London, London, United Kingdom
12. Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom
13. Edinburgh IBD Unit, Western General Hospital, NHS Lothian, Edinburgh, United Kingdom



- 1  
2  
3  
4 14. The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne. United  
5  
6 Kingdom  
7  
8  
9 15. Department of Gastroenterology, Barts Health NHS Trust, The Royal London Hospital,  
10  
11 London, United Kingdom  
12  
13 16. Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine  
14  
15 Queen Mary University of London, London, United Kingdom  
16  
17  
18 17. Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction,  
19  
20 St Mary's Hospital, Imperial College London, London, United Kingdom  
21  
22  
23 18. Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, United  
24  
25 Kingdom  
26  
27  
28 19. Department of Medical and Molecular Genetics, King's College London, Guy's Hospital,  
29  
30 London, United Kingdom  
31  
32  
33 20. Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, United  
34  
35 Kingdom  
36  
37 Department of Nutritional Sciences, King's College London, London, United Kingdom  
38  
39  
40 21. Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United  
41  
42 Kingdom  
43  
44  
45 22. Department of Nutritional Sciences, King's College London, United Kingdom  
46  
47  
48 23. Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom  
49

50 **Keywords:**

51  
52  
53 Inflammatory bowel disease, Crohn disease, gastrointestinal microbiome, multiomics,  
54  
55 precision medicine  
56  
57

58 **ORCiDs (alphabetical):**  
59  
60

1  
2  
3  
4 Tariq Ahmad: <https://orcid.org/0000-0002-6058-5528>  
5  
6 Dean Allerton: <https://orcid.org/0000-0003-0507-4343>  
7  
8 Carl A. Anderson: <https://orcid.org/0000-0003-1719-7009>  
9  
10 Michelle Bardgett: <https://orcid.org/0000-0003-1393-2010>  
11  
12 Emma Clark: <https://orcid.org/0000-0003-0065-1463>  
13  
14 Dawn Clewes: <https://orcid.org/0000-0001-9600-859X>  
15  
16 Cristina Cotobal-Martin: <https://orcid.org/0000-0002-5877-2228>  
17  
18 Mary Doona: <https://orcid.org/0000-0001-9533-3745>  
19  
20 Jennifer A. Doyle: <https://orcid.org/0000-0001-7042-3269>  
21  
22 Hannah Fuller: <https://orcid.org/0000-0002-7965-938X>  
23  
24 Helen Hancock: <https://orcid.org/0000-0002-1494-8551>  
25  
26 Ailsa Hart: <https://orcid.org/0000-0002-7141-6076>  
27  
28 Peter M. Irving: <https://orcid.org/0000-0003-0972-8148>  
29  
30 Sameena Iqbal: <https://orcid.org/0000-0003-0926-593X>  
31  
32 Luke Jostins-Dean: <https://orcid.org/0000-0002-2475-3969>  
33  
34 Ciara Kennedy: <https://orcid.org/0000-0003-2987-0977>  
35  
36 Nicholas A. Kennedy: <https://orcid.org/0000-0003-4368-1961>  
37  
38 Andrew King: <https://orcid.org/0000-0002-5002-4751>  
39  
40 Christopher A. Lamb: <https://orcid.org/0000-0002-7271-4956>  
41  
42 Sarah Lawrence: n/a  
43  
44 Charlie W. Lees: <https://orcid.org/0000-0002-0732-8215>  
45  
46 Robert Lees: <https://orcid.org/0009-0003-7439-1681>  
47  
48 Laura Letchford: n/a  
49  
50 Trevor Liddle: n/a  
51  
52 James O. Lindsay: <https://orcid.org/0000-0003-3353-9590>  
53  
54 Rebecca H. Maier: <https://orcid.org/0000-0002-7350-3288>  
55  
56 John C. Mansfield: <https://orcid.org/0000-0003-2490-7750>  
57  
58 Julian R. Marchesi: <https://orcid.org/0000-0002-7994-5239>  
59  
60 Naomi McGregor: <https://orcid.org/0000-0002-5961-124X>  
Rebecca E. McIntyre: <https://orcid.org/0000-0001-5291-1533>  
Jasmin Ostermayer: <https://orcid.org/0000-0001-6461-398X>

1  
2  
3 Tolulope Osunnuyi: <https://orcid.org/0000-0002-0482-917X>

4  
5 Miles Parkes: <https://orcid.org/0000-0002-6467-0631>

6  
7 Nick Powell: <https://orcid.org/0000-0003-3231-6950>

8  
9 Natalie J. Prescott: <https://orcid.org/0000-0002-5901-7371>

10  
11 Tim Raine: <https://orcid.org/0000-0002-5855-9873>

12  
13 Jack Satsangi: <https://orcid.org/0000-0002-6357-9684>

14  
15 Shriya Sharma: <https://orcid.org/0000-0001-5237-757X>

16  
17 Tara Shrestha: n/a

18  
19 Michelle Strickland: <https://orcid.org/0000-0001-8053-400X>

20  
21 Ally Speight: <https://orcid.org/0000-0003-3184-9181>

22  
23 Christopher J. Stewart: <https://orcid.org/0000-0002-6033-338X>

24  
25 James M. S. Wason: <https://orcid.org/0000-0002-4691-126X>

26  
27 Kevin Whelan: <https://orcid.org/0000-0001-5414-2950>

28  
29 Ruth Wood: <https://orcid.org/0000-0002-8296-1774>

30  
31 Nicola J. Wyatt: <https://orcid.org/0000-0001-5050-327X>

32  
33 Xinyue Zhang: <https://orcid.org/0000-0002-5321-4235>

## Abstract

### INTRODUCTION

Characterised by chronic inflammation of the gastrointestinal tract, inflammatory bowel disease (IBD) symptoms including diarrhoea, abdominal pain and fatigue can significantly impact patient quality of life. Therapeutic developments in the last 20 years have revolutionised treatment. Despite these developments, clinical trials and real-world data show primary non-response rates up to 40%. A significant challenge is an inability to predict which treatment will benefit individual patients.

Current understanding of IBD pathogenesis implicates complex interactions between host genetics and the gut microbiome. Most cohorts studying the gut microbiota to date have been underpowered, examined single treatments, and produced heterogeneous results. Lack of cross-treatment comparisons and well-powered independent replication cohorts hampers the ability to infer real-world utility of predictive signatures.

IBD-RESPONSE will use multi-omic data to create a predictive tool for treatment response. Future patient benefit may include development of biomarker-based treatment stratification or manipulation of intestinal microbial targets. IBD-RESPONSE and downstream studies have the potential to improve quality of life, reduce patient risk, and reduce expenditure on ineffective treatments.

### METHODS AND ANALYSIS

This prospective, multicentre, observational study will identify and validate a predictive model for response to advanced IBD therapies, incorporating gut microbiome, metabolome, single-cell transcriptome, human genome and clinical data. 1,325 participants commencing

1  
2  
3 advanced therapies will be recruited from ~40 UK sites. Data will be collected at baseline,  
4  
5 week 14 and week 54. The primary outcome is week 14 clinical response. Secondary  
6  
7  
8 outcomes include clinical remission, loss of response in week 14 responders, corticosteroid-  
9  
10 free response/remission, time to treatment escalation, and change in patient-reported  
11  
12 outcome measures.  
13  
14

## 15 16 **ETHICS AND DISSEMINATION**

17  
18 Ethical approval was obtained from the Wales Research Ethics Committee 5  
19  
20 (ref:21/WA/0228). Recruitment is ongoing. Following study completion, results will be  
21  
22 submitted for publication in peer-reviewed journals and presented at scientific meetings.  
23  
24 Publications will be summarised at [www.ibd-response.co.uk](http://www.ibd-response.co.uk).  
25  
26  
27  
28

## 29 **TRIAL REGISTRATION NUMBER**

30  
31  
32 ISRCTN96296121(pre-results)  
33  
34

## 35 **Article Summary**

### 36 37 38 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 39  
40  
41  
42 • IBD-RESPONSE is the largest precision medicine study of its kind to date, designed to  
43  
44 develop a predictive tool for treatment response – or failure to respond – to IBD treatment,  
45  
46 promoting *a priori* selection of the right drug, for the right patient, at the right time.  
47  
48
- 49  
50  
51 • IBD-RESPONSE will establish one of the largest biorepositories of longitudinal stool,  
52  
53 blood, matched tissue and organoids with detailed linked phenotypic, diet, genetic and  
54  
55 treatment outcome data in patients with IBD.  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- This study will use a standardised yet pragmatic methodology for sample collection, processing and storage, allowing multicentre participation, improving generalisation and transferability of findings to real-world clinical practice.
  - Remote 'at home' patient data and stool collection will allow >40 IBD centres to contribute to recruitment, increasing power in this multi-omics study when compared to other studies in the field that generally recruit from one or a small number of centres.
  - Whilst recruiting sites are limited to the UK only, identified cross-validation cohorts from the UK and Canada will increase generalisability of our findings.

## INTRODUCTION

Crohn's disease (CD) and ulcerative colitis (UC) are the principal forms of inflammatory bowel disease (IBD).(1) Characterised by symptoms including diarrhoea, rectal bleeding, abdominal pain and extra-intestinal features such as fatigue, IBD can have a substantial negative impact on patient quality of life.(2) Approximately 20% of CD patients and 10% of UC patients are unable to work due to their condition.(3) The global prevalence of IBD is rising. In the United Kingdom (UK), 1 in 125 people are affected, with prevalence expected to reach 1 in 100 by 2028.(4, 5) Outside of Western Europe and North America, the incidence is rising rapidly in many regions including South America, Latin America, Asia and Africa.(6, 7)

The biologics era has revolutionised IBD treatment in the last twenty years. Patients and clinicians have more advanced therapies to choose from than ever before. Several biologic classes are now licensed in the UK, targeting tumour necrosis factor alpha (TNF $\alpha$ ) (including infliximab and adalimumab), interleukin (IL)-12/23 cytokine pathways (ustekinumab), or the gut-homing  $\alpha 4\beta 7$  integrin (vedolizumab). In addition, recently licensed small molecule therapies for UC include the Janus kinase inhibitors (JAKi) tofacitinib, filgotinib and upadacitinib, and the sphingosine-1-phosphate receptor (S1PR) modulator ozanimod. With several additional therapies in advanced stages of development or having completed phase 3 randomised clinical trials, the number of treatments available to patients is likely to increase.(8)

Current understanding of biological mechanisms driving the pathogenesis and natural history of IBD, implicates complex interactions between host genetics and the gut microbiome (bacteria, viruses, fungi, archaea and phage).(9) Whilst large clinical cohorts for human genetic discovery have led to major advances in understanding disease pathogenesis,(10)

1  
2  
3 cohorts for the study of gut microbiota have mostly been under-powered. Nonetheless,  
4  
5 existing research intriguingly suggests utility of microbiome signatures in predicting response  
6  
7 to therapy. In a small prospective study of 85 patients starting vedolizumab therapy, greater  
8  
9 alpha-diversity and higher abundance of *Roseburia inulinivorans* and a Burkholderiales  
10  
11 species at baseline were associated with therapeutic-induced remission in CD.(11)  
12  
13 Incorporation of microbial taxonomy data alongside clinical data in a predictive model  
14  
15 produced an area under the receiver operating characteristic curve (AUC) of 0.776 (compared  
16  
17 to an AUC of 0.619 using clinical data only). A larger study of 232 patients receiving  
18  
19 ustekinumab implicated *Bacteroides* and *Faecalibacterium* as predictors of treatment  
20  
21 response.(12) Here, a predictive model of response to ustekinumab using clinical metadata  
22  
23 produced an AUC of 0.616, rising to 0.844 when combined with baseline bacterial profile data.  
24  
25  
26  
27  
28  
29

30 Beyond IBD, further proof of concept that the gut microbiome is of prognostic  
31  
32 importance in the context of systemically administered immune-targeted therapies is found  
33  
34 with immune checkpoint inhibitor treatment in cancer, where experimental animal data  
35  
36 demonstrated the beneficial impact of microbial modulation on treatment outcome.(13-15)  
37  
38  
39

40 Metabolites derived from the gut microbiome are important intermediaries in the host-  
41  
42 microbiome dialogue.(16) Specific classes of metabolites, such as bile acids (BA), short-chain  
43  
44 fatty acids (SCFA) and tryptophan metabolites, may play a role in modulating disease activity  
45  
46 and treatment responsiveness in IBD.(17) In a study of 185 (77 UC, 108 CD) patients  
47  
48 commencing anti-cytokine (anti-TNF $\alpha$  or anti-IL12/23) or anti-integrin (vedolizumab) therapy,  
49  
50 metabolomic and proteomic analysis of blood in addition to taxonomic and functional profiling  
51  
52 of stool samples was conducted.(18) Among patients receiving anti-cytokine therapy, 120  
53  
54 enzymes were differentially abundant in baseline samples of remitters versus non-remitters.  
55  
56 Single-species dominance (>50% of enzyme copies in >50% of samples explained by a single  
57  
58  
59  
60



1  
2  
3 species) was observed for 8/120 enzymes. *Eggerthella lenta* was dominant for 5 of these 8  
4  
5 enzymes, 3 of which are involved in secondary BA biosynthesis. Metabolomic analysis of  
6  
7 baseline blood samples revealed significant enrichment of serum secondary BAs in patients  
8  
9 achieving week 14 clinical remission. Paired baseline stool samples revealed a significant  
10  
11 positive correlation with the abundance of 7 $\alpha$ / $\beta$ -dehydroxylation enzymes (responsible for  
12  
13 primary to secondary BA conversion), presence of which was associated with a preferential  
14  
15 response to anti-cytokine therapy. This was replicated by the authors in a small validation  
16  
17 cohort of 46 patients initiating anti-TNF $\alpha$  (infliximab) therapy. In a small study of 29 patients  
18  
19 with moderate-severe UC receiving vedolizumab treatment, untargeted metabolomic analysis  
20  
21 of stool showed significantly higher levels of SCFAs including butyrate in those achieving week  
22  
23 14 remission (defined as total Mayo score  $\leq$ 2, all subscores  $\leq$ 1) versus non-remitters.(19)  
24  
25 Combining metabolite data (SCFA levels for butyrate and isobutyric acid) with microbial profile  
26  
27 data predicted anti-integrin response with an AUC of 0.961.  
28  
29  
30  
31  
32  
33  
34

35 Whilst these previous studies are important first steps to utilising gut microbial  
36  
37 signatures in stratified treatment algorithms, they were mostly underpowered, examined single  
38  
39 treatments, used different sequencing technologies, and produced heterogeneous non-  
40  
41 overlapping results. The lack of cross-treatment comparisons and well-powered independent  
42  
43 replication cohorts hampers the ability to infer real-world utility of these predictive signatures,  
44  
45 and to move from observations of association to causation in IBD.(20)  
46  
47  
48  
49

## 50 METHODS AND ANALYSIS

### 51 Study rationale

52  
53 A significant challenge to effective, personalised use of biologic or small molecule  
54  
55 therapies (collectively termed 'advanced therapies') in IBD is an inability to predict which class  
56  
57  
58  
59  
60

1  
2  
3 of treatment is most likely to benefit an individual patient (see *Figure 1*). Despite increasing  
4  
5 therapeutic options, clinical trial and real-world efficacy data show primary non-response rates  
6  
7 of up to 40% across all therapeutic classes and in those with initial symptomatic benefit, up to  
8  
9 40% lose response by 1 year.(1, 21-23) Consequently, complications of chronic, active  
10  
11 inflammation including strictures, fistulae and malignancy, continue to affect a substantial  
12  
13 number of patients and have a negative impact on patient quality of life.(2) Up to 30% of CD  
14  
15 patients require surgical intervention within 10 years of diagnosis, and around 15% of UC  
16  
17 patients will ultimately require a colectomy.(24) Off-target side effects may also occur,  
18  
19 including infection and malignancy.(1) With average treatment costs of £6,156/year for CD  
20  
21 and £3,084/year for UC, future treatment algorithms must avoid the potential morbidity and  
22  
23 additional cost associated with expensive treatments that do not benefit individual  
24  
25 patients.(25)  
26  
27  
28  
29  
30  
31

32  
33 The absolute importance of precision medicine research to identify biomarkers for  
34  
35 treatment stratification and develop prognostic algorithms was highlighted by two recent  
36  
37 national research prioritisation exercises incorporating responses from almost 3,000 patients,  
38  
39 their families and friends.(1, 26) Validated prognostic models for treatment stratification do not  
40  
41 exist and understanding of mechanisms controlling treatment non-response is limited.  
42  
43 Through a multi-omic, precision medicine approach, the IBD-RESPONSE study seeks to  
44  
45 improve selection of the right drug, for the right patient, at the right time. Other translational  
46  
47 outputs of IBD-RESPONSE could bring into focus potential non-pharmacological approaches  
48  
49 to treating IBD that do not necessarily involve large health economic expenditure. This could  
50  
51 include manipulating the gut microbiome via the microbiota, through refinement of faecal  
52  
53 microbial transplant protocols, use of pre- and probiotics, and dietary interventions.  
54  
55  
56  
57  
58  
59  
60

## Scientific objectives of IBD-RESPONSE

The primary scientific objective of IBD-RESPONSE is to identify and validate a predictive model for clinical response or failure to respond to advanced therapies in IBD after 14 weeks of therapy (the primary clinical outcome, see below). Modelling will incorporate gut microbiome, human genome, blood and intestinal single cell transcriptome data, and detailed clinical data. Through data derived from a nested sub-cohort (CD-metaRESPONSE), predictive modelling will also include detailed dietary information and blood and faecal metabolome data. The co-primary scientific objective of IBD-RESPONSE is to determine the relationship between clinical response and remission at week 14 and baseline gut microbiome.

Secondary scientific objectives of IBD-RESPONSE are to determine if there is a relationship between the microbiome at baseline or changes in the microbiome following advanced therapy with any of the secondary clinical outcomes (*Box 1*). Further exploratory scientific objectives of IBD-RESPONSE are listed in *Box 2*.

- Clinical remission at week 14.
- Clinical response at week 54.
- Clinical remission at week 54.
- Loss of response at week 54 in week 14 responders.
- Durable corticosteroid-free response or remission at week 54 defined as receiving no corticosteroids between week 14 and week 54 assessments inclusive and not meeting criteria for loss of response.
- Time to treatment escalation from baseline, defined as:
  - Advanced therapy switch due to lack of efficacy/those with loss of response (does not include biosimilar switch or switch from IV to SC route).

- Dose intensification of drug due to lack of efficacy (does not include intensification based on therapeutic drug monitoring without flare in responders).
- Resectional intestinal surgery (does not include examination under anaesthesia procedures in patients with perianal CD).
- Induction or dose escalation of corticosteroids.
- Time to treatment escalation as defined above, but disregarding dose intensification.
- Time to treatment escalation as defined above, among week 14 responders.
- Time to discontinuation of index drug (persistence).
- Incidence of and time to potential side effects of treatment during follow up.
- Continuation of drug at week 14 and/or week 54 in those not meeting criteria for response and/or remission.
- Change from baseline SF subscore at week 14 and/or 54 (both CD and UC).
- Change from baseline RB subscore at week 14 and/or 54 (UC only).
- Change from baseline AP subscore at week 14 and/or 54 (CD only).
- Development of anti-drug antibodies by week 14 or 54.
- Change in CRP from baseline at week 14 or 54 (50% reduction or absolute value  $\leq 5\text{mg/L}$  deemed as clinically significant).
- Change in faecal calprotectin from baseline at week 14 or 54 (50% reduction or absolute value  $\leq 100\mu\text{g/g}$  deemed as clinically significant).
- Endoscopic remission during follow up (Mayo endoscopic subscore  $\leq 1$  for UC or SES-CD  $\leq 2$  for CD).

- Change in quality of life, physical activity dietary intake, joint pain and fatigue as measured by study questionnaires.

#### Box 1. IBD-RESPONSE secondary clinical outcome measures

Box 1 abbreviations: abdominal pain (AP), Crohn's disease (CD), c-reactive protein (CRP), intravenous (IV), rectal bleeding (RB), subcutaneous (SC), stool frequency (SF), simple endoscopic score for Crohn's disease (SES-CD), ulcerative colitis (UC)

- Test the association of microbial metabolites (metabolome) in stool or plasma, human genetics and/or single cell transcriptome data from blood or intestinal tissue with the above primary and secondary objectives.
- Determine the influence of diet on the gut microbiome and treatment response in IBD, and the factors associated with dietary intake in IBD.
- Explore host human genetic-gut microbiome-metabolome interactions in IBD pathogenesis and causal pathways to treatment response.
- Ascertain the utility of archived endoscopy collected FFPE biopsies at predicting/imputing the gut microbiome and for inclusion in the predictive model.
- Establish a longitudinal tissue, organoid and stool biobank from this well characterised clinical cohort.

#### Box 2. IBD-RESPONSE exploratory scientific objectives

Box 2 abbreviations: inflammatory bowel disease (IBD), formalin fixed paraffin embedded (FFPE)

## Study design

The design of IBD-RESPONSE and the nested CD-metaRESPONSE studies are summarised in *Figure 2*. This prospective, observational, multi-centre, cohort study will recruit participants with IBD (CD, UC, IBD-unclassified (IBD-U)) who are due to commence either biologic, JAKi or S1PR modulator therapy for symptomatic, clinically active (moderate to severe) luminal disease. Participants do not have to be naïve to advanced therapies and may be recruited when switching within or between class of advance therapy. Participants may be taking or planned to start concurrent thiopurines or methotrexate as combination therapy. Participation in the study will not change standard clinical care received. Detailed longitudinal clinical data will be collected alongside stool, blood and (where possible) biopsy samples, patient reported outcome measures, and dietary intake. Planned recruitment of 1,325 participants will consist of 762 patients with CD and 563 patients with UC (or IBD-U).

Data will be collected at baseline (prior to starting treatment), week 14 (following completion of induction therapy) and week 54. Participants will collect stool samples at each study timepoint. If a participant attends hospital within the baseline and/or week 14 study window, two blood samples (per timepoint) will be collected. Where a participant undergoes endoscopy as part of routine clinical care during the study period, up to 12 research biopsies will be collected.

Of 762 CD participants, 300 will be consented to take part in the nested CD-metaRESPONSE sub-cohort. Inclusion criteria are identical to the main cohort. Clinical data collection will occur at the same time points as in the main cohort. Additional study components will include completion of a 4-day food diary questionnaire, capturing all food and drink consumed at the baseline and week 14 timepoints. This is in addition to the food

1  
2  
3 frequency questionnaire completed by all participants. CD-metaRESPONSE participants will  
4  
5 also be required to provide two additional stool tubes (one at baseline and one at week 14)  
6  
7 for faecal metabolome analysis. Participants will be recruited to CD-metaRESPONSE from a  
8  
9 limited number of the participating sites. These sites will initially preferentially recruit eligible  
10  
11 participants with CD to CD-metaRESPONSE. Once the recruitment target of 300 participants  
12  
13 is achieved, all new participants identified with a diagnosis of CD will be recruited to the main  
14  
15 cohort.  
16  
17  
18  
19

20  
21 All participants recruited to IBD-RESPONSE will be invited to co-recruit to IBD  
22  
23 BioResource (if not already participating). IBD BioResource is a national platform and  
24  
25 recallable biorepository linked to the National Institute for Health and Care Research (NIHR)  
26  
27 BioResource that is designed to expedite IBD research, currently with >36,000  
28  
29 participants.<sup>(27)</sup> Co-recruiting participants to IBD-RESPONSE and the IBD BioResource  
30  
31 platform, will generate a rich dataset and provide a long term means of archiving data from  
32  
33 IBD-RESPONSE to facilitate ongoing research and maximise downstream patient benefit. To  
34  
35 minimise participant burden, the contact for recruitment to IBD BioResource can occur any  
36  
37 time in the 12 months following consent to IBD-RESPONSE. If a participant ultimately decides  
38  
39 not to participate in the IBD BioResource they will not be withdrawn from IBD-RESPONSE.  
40  
41  
42  
43  
44

45  
46 If a participant discontinues treatment prior to week 14 or week 54 follow up, the next  
47  
48 timepoint assessment will be brought forward and completed as a treatment discontinuation  
49  
50 assessment. Where a participant does not respond to the first prescribed advanced therapy  
51  
52 and a second (or third) advanced therapy is subsequently prescribed, this discontinuation  
53  
54 assessment will act as the baseline sample and data collection assessment for the successive  
55  
56 advanced therapy. Follow up samples and data collection will occur at week 14 and week 54  
57  
58 following commencement of each successive agent. The participant may remain in the study  
59  
60

1  
2  
3 up to 54 weeks after commencement of a particular agent or until the end of the study period.

4  
5 We anticipate that up to 40% of patients will not respond to the initial prescribed therapy or  
6  
7  
8 will lose response by 1 year and will move on to a second (or third) advanced therapy. We  
9  
10 therefore anticipate that recruitment of 1,325 participants may capture approximately 1,760  
11  
12 new treatment initiation episodes.  
13  
14

### 15 16 **Study setting**

17  
18 This multi-centre cohort study will be conducted at >40 study centres, based within  
19  
20 National Health Service (NHS) Trusts across the UK. All sites must be able to accommodate  
21  
22 the needs of the IBD-RESPONSE cohort including clinical engagement, research nurse  
23  
24 support and facilities for assessments.  
25  
26  
27

### 28 29 **Eligibility criteria**

30  
31 Individuals will be deemed eligible to enrol in the study if they fulfil all inclusion criteria  
32  
33 and meet none of the exclusion criteria (*Box 3*).  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## INCLUSION CRITERIA

Individuals must fulfil all the following criteria to be enrolled in the study.

- Aged 16 years and over.
- Diagnosis of IBD: CD, UC or IBD-U.\*
- Already participating or willing to be approached for participation in IBD BioResource.
- Willing and able to provide informed consent.
- Willing to undertake study procedures including:
  - Completion of study questionnaires
  - Collection of home stool specimens
- Provision of blood and (where applicable) biopsy specimens.
- Symptoms of active luminal IBD (see definition of 'Clinically active disease', *Table 1*).
- At least one biochemical, endoscopic or radiological marker of active disease within 16 weeks of study consent (see *Box 4* and *Box 5*)
- Intention of clinical team to commence one of the following advanced therapies for active luminal IBD within 6 weeks of consent:<sup>Δ</sup>
  - Infliximab
  - Adalimumab
  - Vedolizumab
  - Ustekinumab
  - Tofacitinib
  - Filgotinib
  - Upadacitinib
  - Ozanimod

\*Individuals with IBD-U will be managed as per the UC relevant protocol.

<sup>Δ</sup>Participants may be advanced therapy-naïve or -exposed. Any new biologic or small molecule drug that becomes licensed for the treatment of IBD during the planned study period will be permitted to allow study inclusion. Drugs used through Early Access to Medicines Schemes, compassionate use or expanded access schemes for unlicensed therapies are also permitted. Patients starting immunosuppressant monotherapy with a thiopurine or methotrexate are not eligible to take part. However, use of these treatments as part of combination therapy with an advanced therapy is not an exclusion to enrolment.

## EXCLUSION CRITERIA

Individuals meeting any of the following criteria will not be eligible to participate in the study.

- Receiving oral corticosteroids for any indication where the dose is unlikely to be weaned by week 14.<sup>^</sup>
- Planned bowel resection surgery within 14 weeks of commencing therapy.
- Advanced therapy being commenced as rescue for ASUC.
- Advanced therapy being commenced as part of a CTIMP.
- Presence of an ileal pouch anal anastomosis.
- Presence of a stoma.
- Perianal CD in the absence of active luminal inflammation.
- Antibiotics or short-term ( $\leq 4$  weeks) use of probiotics within the preceding 2 weeks.<sup>†</sup>
- FMT within the preceding 12 weeks or planned FMT within 14 weeks of commencing advanced therapy for IBD.<sup>‡</sup>

<sup>^</sup>Examples may include long term steroids for IBD where weaning by 14 weeks may not be possible irrespective of response to advanced therapy, or concurrent diagnosis where long term steroids are used e.g. polymyalgia rheumatica.

<sup>†</sup>Use of long-term (>4 weeks), stable doses of probiotics does not exclude individual participation but should be noted in the eCRF.

<sup>‡</sup>Use of antibiotics or prior FMT outside the exclusion period is permitted. Antibiotic use in the preceding 1 year and ever having received FMT will be noted in the eCRF.

### Box 3. Eligibility criteria for IBD-RESPONSE

Box 3 abbreviations: Acute severe ulcerative colitis (ASUC), Clinical Trial of an Investigational Medicinal Product (CTIMP), Crohn's disease (CD), electronic case report form (eCRF), faecal microbial transplantation (FMT), inflammatory bowel disease (IBD), inflammatory bowel disease-unclassified (IBD-U), ulcerative colitis (UC).

Participants must have at least one biochemical, endoscopic or radiological (CD only) marker of clinically active luminal disease within 16 weeks of study consent (see *Box 4* (CD) and *Box 5* (UC)). Endoscopic assessment of disease activity will be judged locally and may

1  
2  
3 be assessed prospectively or retrospectively. Whilst pregnancy may influence advance  
4  
5  
6 therapy selection, pregnancy is not an exclusion criterion.  
7  
8

9 CD patients must also have at least one of the following documented within 16 weeks prior  
10 to consent:  
11

- 12 • Faecal calprotectin  $\geq 250$   $\mu\text{g/g}$ .
- 13 • CRP  $\geq 6$  mg/L.
- 14 • Any endoscopic evidence of active CD, defined as ulceration (with at least one ulcer  
15  $\geq 5\text{mm}$ ) judged locally from available clinical data (as an approximation equivalent to  
16 SES-CD of  $\geq 4$  for ileal disease or  $\geq 6$  for ileocolonic or colonic disease.
- 17 • Active inflammatory disease on imaging (MRI/CT/ultrasound) judged locally from  
18 available clinical data.  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 **Box 4. IBD-RESPONSE and CD-metaRESPONSE additional inclusion criteria: CD**

29  
30  
31 Box 4 abbreviations: Crohn's disease (CD), C-reactive protein (CRP), Computed tomography (CT), Magnetic resonance  
32 imaging (MRI), Simple Endoscopic Score for Crohn's Disease (SES-CD)  
33  
34  
35

36  
37  
38 UC/IBD-U patients must also have at least one of the following documented within 16 weeks  
39 prior to consent:  
40  
41

- 42 • Faecal calprotectin  $\geq 250$   $\mu\text{g/g}$ .
- 43 • CRP  $\geq 6$  mg/L.
- 44 • Any endoscopic evidence of at least moderately active ulcerative colitis (of any  
45 extent including proctitis), defined as features of MCS endoscopic sub-score  $\geq 2$   
46 (marked erythema, lack of vascular pattern, friability, erosions, spontaneous  
47 bleeding or ulceration).  
48  
49  
50  
51  
52  
53  
54

55 **Box 5. IBD-RESPONSE additional inclusion criteria: UC and IBD-U**  
56  
57  
58  
59  
60

Box 5 abbreviations: C-reactive protein (CRP), inflammatory bowel disease-unclassified (IBD-U), Mayo Clinic Score (MCS), ulcerative colitis (UC)

## Clinical outcome measures

Key definitions related to clinical outcome measures can be found in *Table 1*.

Clinically active disease	<ul style="list-style-type: none"> <li>• CD: Unweighted PRO-2 (CD) of average daily SF subscore <math>\geq 4</math> and/or average daily AP subscore <math>\geq 2</math>.</li> <li>• UC: Total PRO-2 (UC) <math>\geq 3</math> with RB subscore <math>\geq 1</math>.</li> </ul> <p>PRO-2 data will be entered by patients over 4 days (minimum 2 days PRO-2 data is permissible for PRO-2 calculation).</p>
Clinical remission	<p>Patient remains on drug and meets the following criteria:</p> <ul style="list-style-type: none"> <li>• CD: Unweighted PRO-2 (CD) average daily SF subscore <math>\leq 2.8</math> and average daily AP subscore <math>\leq 1</math> (and neither worse than inclusion scores at baseline).</li> <li>• UC: PRO-2 (UC) SF subscore <math>\leq 1</math> with a decrease of <math>\geq 1</math> point(s) in SF subscore from baseline, plus RB subscore = 0.</li> </ul> <p><b>AND</b> an absence of any of the following at time of assessment:</p> <ul style="list-style-type: none"> <li>• Resectional bowel surgery at any time after baseline until time of current assessment.</li> <li>• Current use of oral corticosteroids/failure to wean oral corticosteroids prescribed at baseline.</li> </ul>
Clinical response	<p>Meeting criteria for clinical remission <b>OR</b>:</p> <ul style="list-style-type: none"> <li>• CD: unweighted PRO-2 (CD) <math>\geq 30\%</math> reduction in average daily SF subscore and/or <math>\geq 30\%</math> decrease in average daily AP subscore (and neither worse than inclusion scores at baseline).</li> <li>• UC: total PRO-2 (UC) decrease <math>\geq 3</math> from baseline.</li> </ul>

	<p><b>AND</b> an absence of any of the following at time of assessment:</p> <ul style="list-style-type: none"> <li>• Resectional bowel surgery at any time after baseline until time of current assessment.</li> <li>• Current use of oral corticosteroids/failure to wean oral corticosteroids prescribed at baseline.</li> </ul>
Week 14 non-response	<ul style="list-style-type: none"> <li>• Not meeting clinical response criteria AND not having stopped drug for any reason other than lack of efficacy.</li> </ul>
Week 54 loss of response	<ul style="list-style-type: none"> <li>• Not meeting clinical response criteria at week 54 having met clinical response criteria at week 14 (AND not having stopped drug for any reason other than inefficacy between week 14 and 54 assessments).</li> </ul>
<p><b>Table 1. IBD-RESPONSE key clinical definitions</b></p> <p>Table 1 abbreviations: abdominal pain (AP), Crohn's disease (CD), patient reported outcome (PRO)-2, rectal bleeding (RB), stool frequency (SF), ulcerative colitis (UC).</p>	

### Primary clinical outcome measures

Clinical response at week 14 after commencing therapy.

### Secondary clinical outcome measures

Secondary clinical outcome measures are listed in *Box 1*.

### Sample size calculations

The sample size (n=1,325 cases overall, including n=300 cases for CD-metaRESPONSE sub-cohort) was chosen to ensure sufficient power to answer the co-primary scientific objective (to detect associations between microbiome measures and clinical response or remission) and key exploratory scientific objectives (to detect associations between metabolites and clinical response or remission, and to detect associations between genetics and microbiome measures). Sample size calculations for predictive models require

1  
2  
3 extensive assumptions about the number and effect size of associations and the correlation  
4 structure of the data. We noted predictive models built with microbiome and/or metabolite  
5  
6 measures with high in-sample predictive accuracy (including AUC=0.78 with n=84 from  
7  
8 Ananthakrishnan et al.(11), AUC=0.91 with n=76 from Ding et al.(28), and AUC=0.84 with  
9  
10 n=232 from the CERTIFI study(12)), implying that n=300 individuals (from CD-  
11  
12 metaRESPONSE) and n=1,325 individuals (from IBD-RESPONSE), should be sufficient for  
13  
14 high predictive in-sample accuracy.  
15  
16  
17  
18  
19

### 20 Sample size for analysis of primary objective

21  
22 We took plausible effect sizes for the primary scientific objective analysis from the  
23 effect of *Bacteroides* levels in stool on ustekinumab response (d=0.66, from the CERTIFI  
24 study(12)) and the effect of anti-drug immunogenicity on remission after anti-TNF $\alpha$  treatment  
25 (d=0.30, from the PANTS study(21)). We calculated power for a simple two-sample t-test  
26 (using the R package pwr), assuming the expected non-response rate at 14 weeks (23.8%)  
27 and non-remission rate at 54 weeks (63.1%) from the PANTS study. We assumed a  
28 conservative Bonferroni-corrected significance threshold of 1e-5 (correcting for 5000  
29 microbiome measures). We calculated the minimum sample size required to achieve 80%  
30 power for the two effect sizes and two outcomes (*Supplementary Figure 1*), showing that  
31 relatively low sample sizes are required to have high power to detect the larger plausible effect  
32 size (n=282 for remission and n=361 for response), but that larger sample sizes are required  
33 to have high power to detect the smaller plausible effect size (n=1,331 for remission and  
34 n=1,705 for response). The sample size of n=1,325 chosen for our study gives a power of  
35 close to 100% for the larger *Bacteroides* effect size for both week 14 response and week 54  
36 remission, and 57% and 80% for the smaller anti-drug immunogenicity effect size for week 14  
37 response and week 54 remission, respectively.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Sample size for analysis of secondary and exploratory scientific objectives

We took plausible effect sizes for the exploratory metabolite analysis from the effects of three selected stool lipid and bile acid metabolites on anti-TNF $\alpha$  response from Ding et al.(28): faecal triglyceride (d=1.00), and two bile acid metabolites; BA1 (d=0.89) and BA3 (d=0.70). We assumed a conservative Bonferroni-corrected significance threshold of 5e-5 (correcting for 1000 metabolites). For n=300, this gives a power of 99.7%, 91% and 74% for faecal triglyceride, BA1 and BA3 respectively for week 14 response, and 100%, 99.8% and 91% for week 54 remission.

We do not anticipate that this study on its own will be well powered to detect new associations between genotype and microbiome measures in IBD. It is known from studies of healthy individuals that genetic variants that explain more than 3% of variation ( $R^2=0.03$ ) in microbial abundance are rare.(29) Assuming a conservative significance threshold of  $< 1e-11$  (correcting for  $1e6$  independent genotypes and 5000 microbiome measures), n=1,325 samples would only have 33% power to detect associations with  $R^2=0.03$  (calculated using genpwr(30)). We will therefore combine our samples with a further genotype/microbiome study of IBD (PREdiCCt) to increase sample size to n=2,325. This will provide us 80% power to detect genetic associations with  $R^2>0.025$ . In the case where such genotype/microbiome measure associations exist, and are associated with a causal biomarker for week 54 remission, a Mendelian Randomization analysis would have >80% power to demonstrate causality of this biomarker when the causal effect odds ratios is larger than 2 (calculated using mRnd(31)).

## Study procedures and measures

Participants  $\geq 16$  years old may be identified from a variety of settings such as outpatient clinics (face-to-face or virtual), flare assessments, IBD clinical nurse specialist helplines/email contact, endoscopy examinations, infusion suites, multidisciplinary team meetings and virtual biologics clinics (*Figure 2*). Consent will be taken electronically using a REDCap (Research Electronic Data Capture) online database. Full informed e-consent will be supported by an appropriately delegated member of the study team, using a laptop, tablet or mobile device in the patient's own home, or using a hospital tablet, laptop, computer or patient mobile device during a scheduled visit to hospital as part of routine clinical care. Paper copies of the consent form will be made available for those patients unable to access e-consent. If a later decision is made not to commence an advanced therapy for IBD, the participant will not be eligible to continue in the study and must be withdrawn. Data collected up to the point of withdrawal may be used for the study. Any samples collected will be used for research within IBD-RESPONSE or stored for future research.

All research activity will be completed by the participant either remotely or during hospital visits scheduled to deliver routine clinical care (see *Figure 3*). Participants will be asked to complete data collection after consent and before starting treatment (baseline), and at week 14 and week 54 following commencement of advanced therapy in line with routine dosing schedule visits. This will include patient questionnaires, stool samples and, where applicable, blood and biopsy specimens. Participants will be asked to complete questionnaires with data entered directly into the study specific REDCap database. Paper questionnaires will be made available for those participants without access or who express a preference to complete in paper format. Participants will be asked to complete questionnaires related to



1  
2  
3 disease activity, health, physical activity, quality of life and diet at the three assessment  
4  
5  
6 timepoints (see *Box 6*).  
7

## 8 9 **Participant samples**

10  
11 All sample collection and processing will be standardised, with full requirements  
12  
13 detailed in a study Sample Collection Manual.  
14  
15

16  
17 Stool samples will be collected by participants at home using stool collection kits and  
18  
19 returned using a prepaid Royal Mail Safebox™. All participants will collect two stool samples  
20  
21 per study assessment timepoint (DNA Genotek OMNIgene®•GUT tube and universal  
22  
23 polystyrene tube). Participants recruited to the CD-metaRESPONSE sub-cohort will be  
24  
25 required to collect a third stool sample at baseline and week 14 (DNA Genotek  
26  
27 OMNImet®•GUT tube). DNA extraction and metagenomic shotgun sequencing will be  
28  
29 performed on buffered samples. Calprotectin will be measured in unbuffered stool. Remaining  
30  
31 fresh stool and nucleic acids will be cryopreserved for use in future research.  
32  
33  
34  
35

36  
37 Participants who attend a clinical appointment prior to commencing advanced therapy  
38  
39 or within the week 14 visit window (week 10-20; week 12-16 preferred) will be asked to provide  
40  
41 two blood samples (lithium heparin (LiH) tube and ethylenediaminetetra-acetic acid (EDTA)  
42  
43 tube). Blood samples will be utilised for single cell analysis, plasma extraction and  
44  
45 cryopreservation. Any remaining blood samples or derivatives will be stored at Newcastle  
46  
47 Biobank for use in future research. Participants will not be asked to attend hospital specifically  
48  
49 for blood sample collection. If participants are not scheduled to attend hospital face-to-face  
50  
51 within either study assessment window, blood samples will not be taken.  
52  
53  
54  
55

56  
57 If a participant has a lower gastrointestinal endoscopy as part of planned care during  
58  
59 study participation, up to 12 research biopsies (one set of six biopsies to be collected from the  
60

colon in all participants and a further set of six biopsies from the ileum in CD participants) will be taken. Where a participant meets the study eligibility criteria and a disease assessment endoscopy is planned prior to starting therapy, consent should be received ahead of their planned endoscopy to enable the collection of research biopsies. Biopsy samples will be utilised for single cell sequencing and organoid generation. 16S rRNA gene sequencing of both FFPE and fresh tissue will also be undertaken. Any remaining biopsy samples will be stored for use in future research.

[Figure 3]

#### COMPLETED BY ALL PARTICIPANTS AT BASELINE, WEEK 14 AND WEEK 54

##### **PRO-2 (CD or UC version depending on diagnosis)**

PRO-2 is a validated questionnaire measuring patient reported outcomes including stool frequency, abdominal pain and rectal bleeding.(32, 33)

##### **Bristol Stool Form Scale (BSFS)**

The BSFS is a 7-point scale that helps describe stool shape and consistency and assess bowel patterns and habits.(34)

##### **IBD-Control**

The IBD-Control questionnaire comprises 13 items plus a visual analogue scale (VAS) ranging from 0–100.(35) The questionnaire measures patient related outcome of their disease state during the past 2 weeks.

##### **PROMIS-Fatigue 8a Short Form**

The Patient Reported Outcomes Measurement Information System (PROMIS), are validated questionnaires that help evaluate patients' quality of life.(36)

##### **EQ-5D-5L**

The EQ-5D-5L is a quality-of-life questionnaire and is a widely used generic PROM incorporating five domains: 1) mobility, 2) self-care, 3) usual activities, 4) pain/discomfort,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

5) anxiety/depression.(37, 38) Scores for each domain are combined to describe the patient's state of health.

### **International Physical Activity Questionnaire (IPAQ)**

IPAQ is a commonly used self-reported questionnaire to estimate physical activity and sedentary behaviours for adults across a range of socio-economic settings.(39) The IPAQ measures the type of physical activities people do as part of their everyday lives.(39)

### **IBD-RESPONSE Joint Pain and Stiffness Score (JPSS)**

The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a patient reported questionnaire which quantifies clinical disease activity in Ankylosing Spondylitis (AS) and combines five disease activity variables (four 10-point Likert scale patient symptom responses and a CRP measurement), to produce a single score.(40-42) We believe joint pain to be an under-recognised symptom in active inflammatory bowel disease which may change in response to therapy as inflammation resolves/fails to resolve and so we have modified the ASDAS to assess joint pain, swelling and stiffness in all IBD-RESPONSE patients irrespective of whether they have a rheumatological diagnosis. We have called this modified score the IBD-RESPONSE Joint Pain and Stiffness Score (JPSS).

### **Food frequency questionnaire (FFQ)**

The FFQ will be completed by participants directly into the study specific REDCap database and can also be completed on paper. The FFQ requests information on 175 food items, their typical portion size and frequency of consumption and has been extensively validated for measuring nutrient intakes in adults.(43) Data are converted to nutrient intake using the Composition of Foods Integrated Dataset (COFIDs), as well as diet quality indices and other food components (e.g. polyphenols) and food categorisation (e.g. ultra-processed foods). The FFQ data will initially be analysed at the Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen and other collaborating institutions at the Department of Nutritional Sciences, King's College London.

1  
2  
3  
4 **COMPLETED BY CD-METARESPONSE PARTICIPANTS AT BASELINE AND WEEK 14**  
5 **ONLY**  
6  
7

8 **4-day food diaries**  
9

10 The 4-day food diary measures current food intake. It will comprehensively and  
11 prospectively measure all intake allowing calculation of energy and nutrient intake, dietary  
12 indices (e.g. diet diversity and Mediterranean diet), intake of ultra-processed foods, prebiotic  
13 and emulsifier intake.  
14  
15  
16  
17

18  
19 Box 6. Summary of patient questionnaires completed throughout study period  
20  
21  
22  
23  
24

25 **Statistical analysis**  
26

27  
28 The analysis approach for our primary objective will be to test for the association  
29 between features of the patient microbiome at baseline and primary clinical response to  
30 treatment at 14 weeks. Features will include alpha diversity, abundance of bacterial taxa  
31 (including species, genus and phyla) as well as the abundance of genes within various  
32 microbial pathways (for example using KEGG pathways, MetaCyc metabolic pathways and  
33 gene families). Association testing will be carried out using negative binomial regression,  
34 controlling for total sequence depth and pre-defined technical and clinical confounders, and  
35 significance will be determined using Benjamini-Hochberg multiple testing correction to ensure  
36 a false discovery rate of less than 5%.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 For the predictive modelling aim, we will use a random forest classifier to predict  
50 primary response to treatment at 14 weeks using microbiome, host genetic and clinical  
51 features at baseline. Model parameters will be tuned and accuracy assessed using nested  
52 cross-validation. This full model will be compared to a clinical-variables-only model, with  
53 improvement measured by area under the received operator curve, as well as positive and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 negative predictive power. A further model will be fitted using the same approach including  
4  
5 metabolomic and dietary data on the CD-metaRESPONSE subset. Our primary predictive  
6  
7 measure will be reported for a random forest classifier, but a further sensitivity analysis will be  
8  
9 carried out by fitting alternative prediction models to test whether this has a strong effect on  
10  
11 the predictive accuracy, using both simpler models (including logistic regression with a LASSO  
12  
13 penalty) and other more advanced methods (such as neural networks and support vector  
14  
15 machines), The results of the predictive models will be reported in future publications  
16  
17 according to the TRIPOD guidelines.(44)  
18  
19  
20  
21  
22

23 Secondary and exploratory objective analyses will use the same general analysis  
24  
25 approach as described above. For time-dependent events, such as treatment escalation due  
26  
27 to loss of response, a Cox proportional hazards regression will be used to assess the impact  
28  
29 of microbiome features on time to event, with patients censored at 54 weeks, last recorded (if  
30  
31 lost to follow-up) or date of withdrawal (if withdrawn). The dietary data will be analysed to test  
32  
33 the association between primary response and measures of specific nutrients (such as dietary  
34  
35 fibre) and dietary indices will be used to assess adherence to certain recommended diets  
36  
37 (such as achievement of food-based dietary guidelines or a “Mediterranean diet”). Host  
38  
39 genotype data will be used to test for associations between primary response and generate  
40  
41 polygenic risk scores of susceptibility to Crohn’s disease and ulcerative colitis, as well as pre-  
42  
43 specified variants associated with response to therapy (including HLA-DQA1\*05). In all these  
44  
45 individual analyses, Benjamini-Hochberg will be applied used to control the false discovery  
46  
47 rate at 5%.  
48  
49  
50  
51  
52  
53  
54

55 Loss to follow-up and missing data will be handled during the analyses in different  
56  
57 ways depending on the specific question being addressed. For the primary analysis at 14  
58  
59 weeks, individuals who are lost to follow-up or withdraw from the study before 14 weeks will  
60

1  
2  
3  
4 be removed from the analysis, though we will also carry out a robustness analysis where we  
5  
6 include individuals lost to follow-up as non-responders to ensure the results are robust to this  
7  
8 choice. Secondary and exploratory analyses at specific time-points will be treated in the same  
9  
10 fashion. For time-dependent events, analysed using survival models, individuals who are lost  
11  
12 to follow-up or withdraw will be treated as censored at this time point (the point of withdrawal  
13  
14 for withdrawn participants, and the last point of contact for patients lost to follow-up), though  
15  
16 we will also carry out sensitivity analyses where these are instead treated as adverse  
17  
18 outcomes where appropriate (e.g. treating withdrawals as adverse events). For missing data,  
19  
20 standard quality control criteria for microbiome, metabolome and genetic data will be used to  
21  
22 remove variables with excessive missing data (as well as other markers of poor data quality).  
23  
24 Where data is missing for microbiome or other experimental assays for specific individuals  
25  
26 after QC, only participants with non-missing data for this variable will be analysed. When  
27  
28 constructing and validating predictive models, individuals with missing data for the predictive  
29  
30 variables being tested, or that have withdrawn or been lost to follow-up before the assessment  
31  
32 time, will be excluded from model building and testing. Statistical analysis will be carried out  
33  
34 in R.  
35  
36  
37  
38  
39  
40  
41

## 42 **Replication**

43  
44  
45       Scaling up microbiome discoveries and providing validation of results is needed to  
46  
47 benefit patients. Whilst IBD-RESPONSE is the largest project of its kind to date, it is a UK-  
48  
49 only programme. Translating findings to maximise patient benefit requires international  
50  
51 collaboration. Standardised data collection and data integration from different countries and  
52  
53 ethnic groups is key to establishing predictors of treatment response that are generalisable  
54  
55 and replicable.  
56  
57  
58  
59  
60

1  
2  
3  
4 We will validate our predictive model using an appropriate, already assembled  
5  
6 microbiome validation cohort. To generate this replication cohort, we will use banked stool  
7  
8 DNA from the Prognostic effect of Environmental factors in Crohn's and Colitis Study  
9  
10 (PREdiCCt; [www.predicct.co.uk](http://www.predicct.co.uk)), led by Professor Charlie Lees. PREdiCCt is a prospective  
11  
12 observational study of IBD participants in clinical remission, designed to identify whether  
13  
14 baseline factors (including genetics, dietary habits and gut microbiota) predict subsequent  
15  
16 disease flare. We will perform metagenomic sequencing of 1,000 stool samples from patients  
17  
18 who experienced a disease flare during the PREdiCCt study. We expect approximately 40%  
19  
20 of PREdiCCt patients to experience a disease flare requiring commencement of biologics. As  
21  
22 these patients all have baseline (clinical remission) stool microbiome samples in storage, they  
23  
24 provide a well matched and cost-efficient set of samples for replicating IBD-RESPONSE  
25  
26 results.  
27  
28  
29  
30  
31

32  
33 We will also carry out a collaborative cross-replication analysis of results from IBD-  
34  
35 RESPONSE and the Montreal, Canada iGenoMed-MTT cohort, led by Professor John Rioux  
36  
37 to evaluate how well microbiome associations and predictive algorithms replicate across  
38  
39 continents. This will involve analysis of stored stool samples from 105 Canadian IBD patients  
40  
41 collected prior to commencing advanced therapies (following the sequencing and analysis  
42  
43 protocols established in IBD-RESPONSE) with treatment outcome data. It will provide a rapid  
44  
45 "first-look" analysis to discover and assess microbiome predictors of biological response in an  
46  
47 international cohort with extensive metadata, ahead of larger studies coming online over a  
48  
49 longer timeframe within IBD-RESPONSE and allow later cross-replication/meta-analysis.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Potential future benefit to patients

IBD-RESPONSE will provide timely and important information regarding associations between the gut microbiome and responsiveness to treatment in IBD. It will likely highlight potential mechanisms through which the microbiota may drive inflammation. We hope that findings from IBD-RESPONSE will lead to new personalised avenues for IBD treatment through discovery and validation of predictive tools that may be incorporated directly into clinical practice or further tested in stratified clinical trials. This could lead to the development of experimental techniques to modify gut microbes; for example, donor selection for faecal microbial transplantation, identification of single or multiple strains of microbes, or use of antimicrobials, phage or microbial metabolites that may be used to induce a more 'treatment responsive' microbiome.

### Patient and public involvement statement

IBD-RESPONSE was informed by two national patient research prioritisation exercises in IBD care led by members of our team and involving feedback from 3,000 people living with IBD, their family and friends.(1, 26) These identify aspects of precision medicine, microbiome and diet in IBD as of high importance. The initial IBD-RESPONSE grant proposal to the Medical Research Council (MRC) was reviewed by the NIHR Research Design Service North East and North Cumbria Patient and Public Involvement Panel and was presented and discussed at the 2020 Crohn's & Colitis UK Patient and Public Involvement in Research Day. IBD-RESPONSE has been supported by two patient representatives in the Study Oversight Committee (SOC) since inception. The study team have engaged with lay members of the SOC to ensure all patient facing documents including the participant information sheet (PIS), consent forms, stool collection guidance for patients and study questionnaires have



1  
2  
3 undergone review. Patients will also be involved in dissemination activities relating to outputs  
4  
5  
6 from this research.  
7

## 8 9 **ETHICS AND DISSEMINATION**

10  
11 Ethical approval for the study was obtained from the Wales Research Ethics Committee 5  
12  
13 (reference 21/WA/0228). Recruitment to IBD-RESPONSE began in February 2022 and is  
14  
15 currently ongoing at sites around the UK.  
16  
17

18  
19 In line with the Newcastle University and The Newcastle upon Tyne Hospitals NHS  
20  
21 Foundation Trust research data policy, datasets will be kept for at least five years after the  
22  
23 date they were last accessed. Metadata linked to genomic and metagenomic datasets will  
24  
25 include anonymised clinical information. Examples include diagnosis (UC/CD/IBD-U), disease  
26  
27 location, disease behaviour, complications, extra-intestinal manifestations, co-morbidities,  
28  
29 family history, smoking history, surgical interventions, and outcomes from prior drug therapies.  
30  
31  
32

33  
34 Raw data files in the original format (e.g. fastq) and the accompanying anonymised  
35  
36 phenotypic data will be uploaded to a public repository e.g. the NCBI database of Genotypes  
37  
38 and Phenotypes (dbGaP) at <https://www.ncbi.nlm.nih.gov/gap/>.  
39  
40

41  
42 As part of CD-metaRESPONSE, microbial sequence and faecal/serum metabolomic  
43  
44 data will be integrated with single-cell RNA sequencing, human genomics and clinical outcome  
45  
46 data; the whole dataset will be made available to other investigators and will be archived long  
47  
48 term within the IBD BioResource to facilitate downstream research.  
49  
50

51  
52 The CI, SMG, Sponsor, Funders and research team members are committed to ensure  
53  
54 that the research findings are shared. Findings will be written up and submitted to a peer-  
55  
56 reviewed scientific journal. Findings will be presented by the study team at national and  
57  
58 international conferences for example the British Society of Gastroenterology (BSG) annual  
59  
60

1  
2  
3 meeting, the European Crohn's and Colitis (ECCO) meeting and Digestive Diseases Week  
4 (DDW). The study team will prepare a lay summary of the study findings for dissemination to  
5  
6 the study participants and members of the national patient group, Crohn's & Colitis UK.  
7  
8 Following study completion, results will be submitted for publication in peer-reviewed journals  
9  
10 and presented at national and international scientific meetings.  
11  
12  
13  
14  
15

## 16 **REGISTRATION DETAILS**

17  
18  
19 Trial registration number: ISRCTN96296121 (pre-results).  
20  
21

## 22 **FUNDING**

23  
24 The IBD-RESPONSE cohort is supported by a grant from the Medical Research Council  
25 (funder reference MR/T032162/1) and the CD-metaRESPONSE cohort by The Leona M. and  
26  
27 Harry B. Helmsley Charitable Trust (funder reference 2002-04255). Single cell RNA  
28  
29 sequencing in IBD-RESPONSE and CD-metaRESPONSE is supported by a grant from the  
30  
31 Helmsley Charitable Trust (funder reference 2304-05972). Cross-replication analysis utilising  
32  
33 the Canada iGenoMed-MTT cohort is supported by a grant from Crohn's and Colitis UK  
34  
35 (funder reference M2022-4 Lamb). CJS is supported by a Sir Henry Dale Fellowship jointly  
36  
37 funded by the Wellcome Trust and the Royal Society (Grant Number 221745/Z/20/Z) and the  
38  
39 2021 Lister Institute Prize Fellow Award. NJW is supported by the NIHR Academic Clinical  
40  
41 Fellowship (ACF) programme. LJD is supported by a Sir Henry Dale Fellowship jointly funded  
42  
43 by the Wellcome Trust and the Royal Society (Grant Number 208750/Z/17/Z) and the Kennedy  
44  
45 Trust for Rheumatology Research. JMSW is funded by a NIHR Research Professorship  
46  
47 (NIHR301614). XZ is funded by a NIHR Pre-doctoral Fellowship (NIHR302014).  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ACKNOWLEDGEMENTS

We are grateful for support from the Newcastle Clinical Trials Unit, the National Phenome Centre, Imperial College London and the NIHR Biomedical Research Centres from Newcastle, Imperial and Cambridge. The views expressed are those of the authors and not necessarily those of our funders, the NIHR or the Department of Health and Social Care.

## CONTRIBUTORSHIP STATEMENT

All authors contributed to clinical protocol and/or laboratory standard operating procedures. The grants to fund IBD-RESPONSE and CD-metaRESPONSE were conceptualised and written by CAL, LJ-D, CJS, MP, CA, NAK, TR, TA, AH, HH, CWL, JCM, JRM, NPo, NPr, AS, JS. Clinical study design and analytical plans were further developed by these authors plus MB, EC, DC, MD, AK, CK, PMI, JOL, RL, SL, TL, RM, SS, TS, JW, KW, NJW, RW and XZ with critical review from all authors. Laboratory standard operating procedures were developed by CAL, CJS, HF, REM, LJ-D, CK, NAK, CA, MB, EC, DC, JAD, MD, SI, JOL, CCM, JRM, TO, MP, MS, NP, NJP, TR, MS, SS and NJW. Manuscript drafting was led by NJW and CAL with subsequent critical review and revision by all authors.

## COMPETING INTERESTS

Tariq Ahmad reports personal grants from F. Hoffmann-La Roche AG, Biogen Inc, AbbVie, Janssen, Celltrion, Galapagos NV, Immunodiagnostik, and Takeda, outside the submitted work; personal fees for educational development/delivery from from Pfizer, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer, Takeda, and F. Hoffman-La Roche AG; support for attending meetings from Celltrion, Tillotts, and Pfizer. Carl A. Anderson reports grants from the Wellcome Sanger Institute Quinquennial Review 2021-2026, Crohn's and Colitis Foundation (USA), the Medical

1  
2  
3  
4 Research Council, Open Targets UK, and the Helmsley Charitable Trust; consulting fees from  
5  
6 BridgeBio Ltd, Genomics PLC, and Brigham & Women's Hospital Boston; payment or  
7  
8 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
9  
10 events from GlaxoSmithKline; support for attending meetings and/or travel membership from  
11  
12 the Wellcome Sanger Institute Quinquennial Review 2021-2026; (Chair) of the Board of  
13  
14 Trustees for the Sanger Prize; other interests as Director of Anderson Genomics Consultancy  
15  
16 Ltd. Michelle Bardgett reports partial personal salary funding from the Medical Research  
17  
18 Council. Ailsa Hart reports personal consulting fees from AbbVie, BMS, Celltrion, Falk,  
19  
20 Galapagos, Janssen, Pfizer, Takeda, and Roche; payment or honoraria for lectures,  
21  
22 presentations, speakers bureaus, manuscript writing or educational events from BMS,  
23  
24 Galapagos, Janssen, Pfizer, Takeda, and Roche; payment or honoraria for lectures,  
25  
26 presentations, speakers bureaus, manuscript writing or educational events from BMS,  
27  
28 Celltrion, Falk, Galapagos, Janssen, Pfizer, Takeda, Roche, and AbbVie; support for attending  
29  
30 meetings and/or travel from BMS, Celltrion, Falk, Galapagos, Janssen, Pfizer, Takeda, Roche,  
31  
32 and AbbVie. Peter M. Irving reports reports personal grants from Celltrion, Galapagos, and  
33  
34 Pfizer, outside the submitted work; personal consulting fees from AbbVie, Takeda, BMS,  
35  
36 Janssen, Arena, Pfizer, Galapagos, Lilly, Boehringer-Ingelheim, and Celgene; payment or  
37  
38 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
39  
40 events from AbbVie, Takeda, Janssen, Lilly, BMS, Pfizer, and Galapagos; support for  
41  
42 attending meetings and/or travel from AbbVie and Tillotts. Luke Jostins-Dean reports grants  
43  
44 from the Wellcome Trust, the Royal Society, the Kennedy Trust for Rheumatology Research,  
45  
46 the Helmsley Charitable Trust, and the Medical Research Council; grants from Novartis  
47  
48 Pharmaceutical, outside the submitted work; consulting fees from Nightingale Health and  
49  
50 Genomics PLC. Ciara Kennedy reports partial salary funding from the Medical Research  
51  
52 Council. Nicholas A. Kennedy reports grants from AbbVie, Biogen, Celltrion, Galapagos, and  
53  
54 Immunodiagnostik; consulting fees from AbbVie, Bristol-Meyer Squibb, and Dr Falk; payment  
55  
56  
57  
58  
59  
60

1  
2  
3 or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
4 events from AbbVie, Dr Falk, Tillotts, Galapagos, and Takeda; support for attending meetings  
5 and/or travel from Tillotts; participation (Chair) on the Board of the British Society of  
6 Gastroenterology IBD Clinical Research Group. Christopher A. Lamb reports grants from  
7 Janssen, Takeda, AbbVie, AstraZeneca, Eli Lilly, Orion, Pfizer, Roche, Sanofi Aventis, UCB,  
8 Biogen, and Genentech Inc; payment or honoraria for lectures, presentations, speakers  
9 bureaus, manuscript writing or educational events from Ferring, Takeda, Janssen, and Dr  
10 Falk; participation (Secretary) on the British Society of Gastroenterology IBD Section;  
11 participation on the Steering Committee of IBD UK. Charlie W. Lees reports grants from UKRI  
12 Future Leaders Fellowship; personal consulting fees from AbbVie, Pfizer, Janssen, Takeda,  
13 Galapagos, Fresenius Kabi, Novartis/Sandoz, BMS, and Celltrion; payment or honoraria for  
14 lectures, presentations, speakers bureaus, manuscript writing or educational events from  
15 AbbVie, Pfizer, Janssen, Takeda, Galapagos, Fresenius Kabi, Novartis/Sandoz, BMS, Ferring,  
16 Dr Falk, and Celltrion. James O. Lindsay reports grants from AbbVie, and Gilead; personal  
17 consulting fees from Allergan, AbbVie, Bristol Myers Squibb, Celgene, Cornerstones US,  
18 Galapagos, Gilead, GSK, Lilly, MSD UK, Shire UK, Shire International, Ferring UK, Ferring  
19 International, Celltrion, Takeda, Pfizer, and Janssen; payment or honoraria for lectures,  
20 presentations, speakers bureaus, manuscript writing or educational events from AbbVie,  
21 Bristol Myers Squibb, Cornerstones US, Galapagos, Ferring UK, Ferring International,  
22 Celltrion, Takeda, Pfizer, and Janssen; support to attend meetings and/or travel from AbbVie,  
23 and Janssen. Rebecca H. Maier reports that she is an independent membership on the Trial  
24 Steering Committee for the National Institute for Health and Care Research funded ALLEGRO  
25 trial. Julian R. Marchesi reports personal consulting fees from EnteroBiotix Limited and  
26 Cultech Limited; patent held (without financial gain) on *C. Difficile* therapy  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (WO2019197836A1), participation (Chair) on the IDMC Board. Naomi McGregor reports  
4 partial (10%) salary funding from the Medical Research Council. Rebecca E. McIntyre reports  
5 personal salary funding from the Wellcome Sanger Institute. Jasmin Ostermayer reports stock  
6 held in Novartis AG. Miles Parkes reports grants from Pfizer and Gilead; personal consulting  
7 fees from Galapagos; payment or honoraria for lectures, presentations, speakers bureaus,  
8 manuscript writing or educational events from Janssen. Nick Powell reports grants from  
9 Bristol-Myers Squibb, Takeda, and Pfizer; consulting fees from AbbVie, Allergan, Astra-  
10 Zeneca, Bristol-Myers Squibb, Celgene, Celltrion, Galapagos, GSK, Takeda, and Vifor;  
11 payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or  
12 educational events from AbbVie, Bristol-Myers Squibb, Ferring, Galapagos, Janssen, Roche,  
13 Pfizer, Takeda, and Tillotts; support for attending meetings and/or travel from AbbVie,  
14 Allergan, Celltrion, Janssen, and Takeda; participation on a data safety monitoring board or  
15 advisory board for AbbVie, Allergan, Astra-Zeneca, Bristol-Myers Squibb, Celgene, Celltrion,  
16 Galapagos, GSK, Takeda, and Vifor. Tim Raine reports personal grants from AbbVie;  
17 personal consulting fees from AbbVie, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim,  
18 BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan,  
19 MSD, Novartis, Pfizer, Roche, Sandoz, Takeda, UCB, and XAP therapeutics; participation on  
20 the board of UCB, membership (Chair) of the ECCO Guidelines Committee, membership of  
21 the UEG Scientific Committee. Jack Satsangi reports grants from Crohn's and Colitis UK, the  
22 Helmsley Charitable Trust, ECCO, the European Commission, CCFA, and Action Medical  
23 Research; payment or honoraria for lectures, presentations, speakers bureaus, manuscript  
24 writing or educational events from Roche; participation on a Data Safety Monitoring Board or  
25 Advisory Board for the MODULATE trial and the TRIBUTE trial; leadership or fiduciary role  
26 as the Director of the Royal College of Physicians IBD Registry, and Governing Body Fellow  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 at Green Templeton College. Ally Speight reports personal consulting fees from GSK;  
4 payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or  
5 educational events from Falk, and AbbVie; payment of conference fees to attend the British  
6 Society of Gastroenterology Annual Conference 2022 from Celltrion; participation on a Data  
7 Safety Monitoring Board or Advisory Board for the IBD-RESPONSE study (unpaid), and  
8 Abbvie; participation on the British Society of Gastroenterology IBD Section Committee.  
9  
10 Christopher J. Stewart reports personal consultancy fees from Astarte Medical; payment or  
11 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
12 events from Nestle Nutrition Institute. James M. S. Wason reports grants from Intercept;  
13 consulting fees from Worg and UCB; payment or honoraria for lectures, presentations,  
14 speakers bureaus, manuscript writing or educational events from Janssen; participation on a  
15 Data Safety Monitoring Board or Advisory Board for Roche. Kevin Whelan reports grants from  
16 the Helmsley Charitable Trust, Crohn's and Colitis UK, Almond Board of California, Danone,  
17 International Dried Fruit and Nut Council, Medical Research Council, National Institute for  
18 Health and care Research; royalty or license payments for Volatile organic compounds in the  
19 diagnosis and management of irritable bowel syndrome, and Wiley BDA Advances in Nutrition  
20 & Dietetics book series; personal consulting fees from Danone; payment or honoraria for  
21 lectures, presentations, speakers bureaus, manuscript writing or educational events from  
22 Janssen; support for attending meetings and/or travel from Yakult; participation on a Data  
23 Safety Monitoring Board or Advisory Board for the MODULATE trial (unpaid). The remaining  
24 authors disclose no conflicts of interest.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*. 2019;68(Suppl 3):s1-s106.
2. Floyd DN, Langham S, Severac HC, Levesque BG. The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review. *Dig Dis Sci*. 2015;60(2):299-312.
3. van der Valk ME, Mangan MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Risk factors of work disability in patients with inflammatory bowel disease--a Dutch nationwide web-based survey: work disability in inflammatory bowel disease. *J Crohns Colitis*. 2014;8(7):590-7.
4. Jones GR, Lyons M, Plevris N, Jenkinson PW, Bisset C, Burgess C, et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. *Gut*. 2019;68(11):1953-60.
5. Hamilton B, Green H, Heerasing N, Hendy P, Moore L, Chanchlani N, et al. Incidence and prevalence of inflammatory bowel disease in Devon, UK. *Frontline Gastroenterology*. 2021;12(6):461.
6. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol*. 2020;5(1):17-30.
7. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet*. 2017;390(10114):2769-78.
8. Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. *BioDrugs*. 2021;35(5):473-503.
9. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature*. 2012;491(7422):119-24.
10. Luo Y, de Lange KM, Jostins L, Moutsianas L, Randall J, Kennedy NA, et al. Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. *Nat Genet*. 2017;49(2):186-92.
11. Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, et al. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. *Cell Host Microbe*. 2017;21(5):603-10 e3.
12. Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, et al. Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients. *MBio*. 2018;9(2).
13. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science*. 2018;359(6371):91-7.
14. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science*. 2018;359(6371):104-8.
15. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*. 2018;359(6371):97-103.



16. Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. *Nature Reviews Gastroenterology & Hepatology*. 2020;17(4):223-37.
17. Fiorucci S, Carino A, Baldoni M, Santucci L, Costanzi E, Graziosi L, et al. Bile Acid Signaling in Inflammatory Bowel Diseases. *Dig Dis Sci*. 2021;66(3):674-93.
18. Lee JWJ, Plichta D, Hogstrom L, Borren NZ, Lau H, Gregory SM, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. *Cell Host & Microbe*. 2021;29(8):1294-304.e4.
19. Liu J, Fang H, Hong N, Lv C, Zhu Q, Feng Y, et al. Gut Microbiome and Metabonomic Profile Predict Early Remission to Anti-Integrin Therapy in Patients with Moderate to Severe Ulcerative Colitis. *Microbiol Spectr*. 2023;11(3):e0145723.
20. Plichta DR, Graham DB, Subramanian S, Xavier RJ. Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships. *Cell*. 2019;178(5):1041-56.
21. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. *Lancet Gastroenterol Hepatol*. 2019;4(5):341-53.
22. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, et al. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. *Am J Gastroenterol*. 2018;113(9):1345.
23. Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, et al. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. *Clin Gastroenterol Hepatol*. 2016;14(2):242-50 e1-2.
24. Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. *Clinical Gastroenterology and Hepatology*. 2021;19(10):2031-45.e11.
25. Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. *Frontline Gastroenterol*. 2015;6(3):169-74.
26. Hart AL, Lomer M, Verjee A, Kemp K, Faiz O, Daly A, et al. What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance. *J Crohns Colitis*. 2017;11(2):204-11.
27. Parkes M, Investigators IBDB. IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn's and Colitis. *Gut*. 2019;68(9):1537-40.
28. Ding NS, McDonald JAK, Perdonés-Montero A, Rees DN, Adegbola SO, Misra R, et al. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease. *J Crohns Colitis*. 2020;14(8):1090-102.
29. Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV, et al. The effect of host genetics on the gut microbiome. *Nat Genet*. 2016;48(11):1407-12.
30. Moore CM, Jacobson SA, Fingerlin TE. Power and Sample Size Calculations for Genetic Association Studies in the Presence of Genetic Model Misspecification. *Hum Hered*. 2019;84(6):256-71.
31. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol*. 2013;42(5):1497-501.
32. Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. *Aliment Pharmacol Ther*. 2015;42(10):1200-10.

- 1
- 2
- 3
- 4 33. Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, et al. A retrospective
- 5 analysis: the development of patient reported outcome measures for the assessment of Crohn's
- 6 disease activity. *Aliment Pharmacol Ther.* 2015;41(1):77-86.
- 7
- 8 34. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. *Scand J*
- 9 *Gastroenterol.* 1997;32(9):920-4.
- 10
- 11 35. Bodger K, Ormerod C, Shackcloth D, Harrison M, Collaborative IBDC. Development and
- 12 validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-
- 13 control questionnaire. *Gut.* 2014;63(7):1092-102.
- 14
- 15 36. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported
- 16 Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative
- 17 group during its first two years. *Med Care.* 2007;45(5 Suppl 1):S3-S11.
- 18
- 19 37. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary
- 20 testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res.* 2011;20(10):1727-36.
- 21
- 22 38. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement
- 23 properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country
- 24 study. *Qual Life Res.* 2013;22(7):1717-27.
- 25
- 26 39. Craig CL, Marshall AL, Sjoström M, Bauman AE, Booth ML, Ainsworth BE, et al. International
- 27 physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc.*
- 28 2003;35(8):1381-95.
- 29
- 30 40. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-
- 31 endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis.*
- 32 2009;68(1):18-24.
- 33
- 34 41. Machado PM, Landewe R, Heijde DV, Assessment of SpondyloArthritis international S.
- 35 Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease
- 36 activity states. *Ann Rheum Dis.* 2018;77(10):1539-40.
- 37
- 38 42. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly
- 39 discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. *Ann*
- 40 *Rheum Dis.* 2009;68(12):1811-8.
- 41
- 42 43. Hollis JL, Craig LCA, Whybrow S, Clark H, Kyle JAM, McNeill G. Assessing the relative validity of
- 43 the Scottish Collaborative Group FFQ for measuring dietary intake in adults. *Public Health Nutrition.*
- 44 2017;20(3):449-55.
- 45
- 46 44. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable
- 47 prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. *BMC*
- 48 *Medicine.* 2015;13(1):1.
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1  
2  
3 **WORD COUNT**  
4

5  
6 4,966 words excluding words in figures/tables/boxes, contributorship statement, competing  
7  
8 interests, funding, acknowledgements and references  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## FIGURE LEGENDS

**Figure 1. Schematic illustrating the evolving approach to treatment of inflammatory bowel disease, with the aim of improving treatment outcomes through individualised precision-medicine.** Current treatment selection is stratified and modified based on diagnosis, disease phenotype, imaging (radiological and endoscopic) and limited clinical biomarkers, such as blood and stool markers of inflammation, drug metabolising enzyme activity, drug levels, and anti-drug antibodies. Precision medicine approaches integrating additional complex multi-omic data with information about environmental factors such as dietary intake, smoking and physical activity levels (the exogenous 'exposome'), may enable individualised treatment selection through predictive modelling. Precision medicine may also help to identify of at-risk populations, predict disease course, reduce unnecessary patient risk and health service costs associated with ineffective pharmacological therapies, and guide non-pharmacological interventions such as dietary modification. Figure created with BioRender.com

Figure 1 abbreviations: c-reactive protein (CRP), thiopurine methyltransferase (TPMT)

**Figure 2. Study overview schematic.** 1,325 participants with IBD planned to commence an advanced therapy will be recruited, including a nested sub-cohort of 300 CD patients (CD-metaRESPONSE). All participants will collect two stool sample tubes at each study assessment timepoint (baseline, week 14 and week 54). CD-metaRESPONSE participants will be required to collect a third stool sample tube at baseline and week 14. If a participant attends hospital for a face-to-face appointment within the baseline and/or week 14 study assessment window, blood samples will be collected. If a participant attends hospital for a lower gastrointestinal endoscopy at any time during the study period (pre- or post- treatment), biopsy samples will be collected. Participants will complete several questionnaires at each


1  
2  
3 assessment time point. For CD-metaRESPONSE participants, additional detailed analyses  
4  
5 will be undertaken of metabolic profiles (metabolome) in stool and matched blood plus in-  
6  
7 depth dietary assessment (additional elements highlighted in blue boxes). Data generated will  
8  
9 be used to perform predictive modelling. Any remaining participant samples will form a large  
10  
11 biorepository for use in future research. Figure created with BioRender.com  
12  
13


14  
15  
16 Figure 2 abbreviations: anti-tumour necrosis factor alpha (anti-TNF $\alpha$ ), anti-interleukin (anti-  
17  
18 IL), Bristol stool form scale (BSFS), Crohn's disease (CD), formalin-fixed paraffin embedded  
19  
20 (FFPE), inflammatory bowel disease (IBD), International Physical Activity Questionnaire  
21  
22 (IPAQ), janus kinase inhibitor (JAKi), Joint Pain and Stiffness Score (JPSS), Patient Reported  
23  
24 Outcome-2 (PRO-2), Patient Reported Outcomes Measurement Information System  
25  
26 (PROMIS), sphingosine-1-phosphate receptor (S1PR), ulcerative colitis (UC).  
27  
28  
29

### 30 31 **Figure 3. Flowchart providing overview of study events.**

32  
33  
34 Figure 3 abbreviations: Crohn's disease (CD), inflammatory bowel disease (IBD), Janus  
35  
36 kinase inhibitor (JAKi), Mayo Clinic Score (MCS), multidisciplinary team (MDT), Patient  
37  
38 Reported Outcome-2 (PRO-2), simple endoscopic score for Crohn's disease (SES-CD),  
39  
40 sphingosine-1-phosphate receptor (S1PR), Research Electronic Data Capture (REDCap),  
41  
42 ulcerative colitis (UC).  
43  
44  
45

46  
47 **Supplementary Figure 1.** Power at different sample sizes for detecting associations in the primary  
48  
49 analysis between microbiome variables at baseline and response to treatment at 14 weeks or  
50  
51 remission at week 52, using two different plausible effect sizes ( $d=0.66$  and  $d=0.30$ ). Vertical lines  
52  
53 mark the sample size required to achieve 80% power for the four different scenarios.  
54  
55  
56  
57  
58  
59  
60





### IBD patients




n=1,325

Planned to commence advance therapy for IBD:

**anti-TNF $\alpha$ , anti- $\alpha$ 4 $\beta$ 7, anti-IL12/23, anti-IL23, JAKi, S1PR modulator**


(newly licensed, early access and compassionate use medicines included)



### Predictive modelling



### Biorepository



**Where:** Face-to-face clinics, telephone consultations, endoscopy lists, infusion suites, MDT meetings, virtual biologics clinics, IBD nurse helpline

**Who:** ≥16 years old; symptomatic, active luminal IBD; no minimum disease duration

**Advanced therapy being commenced:** Licensed biologic, JAKi or S1PR modulator (infliximab, adalimumab, vedolizumab, ustekinumab, bfacitinib, filgotinib, upadacitinib, ozanimod) or early access/compassionate use therapy (e.g. risankizumab)

**Screening tips:**

- 5 UC symptoms: increased stool frequency relative to baseline AND at least one episode of recent rectal bleeding within e.g. last 3-5 days
- 6 CD symptoms of active flare: presence of liquid or very soft stools AND/OR presence of abdominal pain
- 7 Active disease confirmed by clinical test in 16 weeks prior to consent: faecal calprotectin, CRP, endoscopy or (CD only) imaging
- 8 Participants do not need to be naïve to advanced therapies e.g. can previously have received a biologic
- 9 Participants switching between advanced therapies do not need a minimum washout period
- 10 Participants can be receiving or about to start concomitant thiopurine or methotrexate alongside planned advanced therapy
- 10 Participants can be receiving or starting steroids at baseline provided likely to have fully weaned by week 14

**Eligibility confirmed**

**Study information and informed consent given**

- 17 Participant Information Sheet (PIS) provided (paper or electronic format)
- 18 Potential participant questions answered by local study team
- 19 REDCap access given to participant to complete informed study consent

**Consent verified**

23 Stool sample collection kit given to/posted to participant once valid consent obtained and verified by local study team

**Baseline assessment**

**Ideal: Week 0**  
 Target: Up to 6 weeks prior to commencing advanced therapy  
 Permitted: Assessment >6 weeks prior to commencing advanced therapy is permitted, e.g. if delayed due to infusion unit capacity

**Participants to complete after consent and before starting advanced therapy:**

- 31 Participant questionnaires completed on REDCap
- 32 Stool sample tubes (n=2) collected and returned using prepaid Royal Mail Safebox™
- 33 If attending hospital for a face-to-face clinical encounter within assessment window, two tubes (total 20mls) blood collected

**CD-metaRESPONSE sub-cohort (in addition to above requirements):**

- 35 Third stool sample tube collected (provided in home stool sample collection kit)
- 37 Prospective 4-day food diary completed

Participants unable or unwilling to complete the PRO-2 questionnaire, not meeting the PRO-2 threshold for clinically active disease, missing stool samples or who do not start treatment with an advanced therapy will be withdrawn from the study

**Eligibility re-confirmed**

41 Baseline 4 day PRO-2 (minimum 2 days data) assessed to confirm inclusion criteria for clinically active disease met

**Biologic, JAKi or S1PR modulator commenced**

**WEEK 0**

**Week 14 assessment**

**Ideal: Week 14**  
 Target: Week 12 - 16  
 Permitted: Week 10 - 20

50 As per baseline assessment (including additional requirements for CD-metaRESPONSE)

**Week 54 assessment**

**Ideal: Week 54**  
 Permitted: Week 48 - 60

**All participants:**


- 56 Participant questionnaires completed on REDCap
- 57 Stool sample tubes (n=2) collected and returned using prepaid Royal Mail Safebox™

If a participant stops treatment, the next planned study assessment should be brought forward and completed as a treatment discontinuation assessment. Where an alternative advanced therapy is then commenced, this discontinuation assessment will serve as the baseline assessment for the next therapy. Further assessments should then be completed at week 14 and 54 after commencing a new advanced therapy as per the study protocol

In addition to the above assessments, if a participant attends hospital for a clinical encounter, the following samples/data will be collected: up to 12 research biopsies, patient-reported 1-day PRO-2 score, endoscopic assessment of disease activity data (SES-CD/MCS endoscopic subscore)



— d=0.66      — Remission  
— d=0.30      - - Response



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

# BMJ Open

## Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: Protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-073639.R2
Article Type:	Protocol
Date Submitted by the Author:	23-Nov-2023
Complete List of Authors:	Wyatt, Nicola; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology Watson, Hannah; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences Anderson, Carl ; Wellcome Sanger Institute, Wellcome Genome Campus Kennedy, Nicholas A; Royal Devon University Healthcare NHS Foundation Trust, Department of Gastroenterology; University of Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group Raine, Tim; Cambridge University Hospitals NHS Foundation Trust Ahmad, T.; Royal Devon University Healthcare NHS Foundation Trust, Department of Gastroenterology; University of Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group Allerton, Dean; Newcastle University, Newcastle Clinical Trials Unit Bardgett, Michelle; Newcastle University, Newcastle Clinical Trials Unit Clark, Emma; Newcastle University, Newcastle Clinical Trials Unit Clewes, Dawn; Newcastle University, Newcastle Clinical Trials Unit Cotobal Martin, Cristina; Wellcome Sanger Institute, Wellcome Genome Campus Doona, Mary; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology Doyle, Jennifer; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences Frith, Katheirne; Newcastle University, Newcastle Clinical Trials Unit Hancock, Helen; Newcastle University, Newcastle Clinical Trials Unit Hart, Ailsa L.; St Mark's Hospital and Academic Institute, Department of Gastroenterology; Imperial College London, Department of Surgery and Cancer Hildreth, Victoria; Newcastle University Irving, Peter; Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology; King's College London, School of Immunology & Microbial Sciences Iqbal, Sameena; Wellcome Sanger Institute, Wellcome Genome Campus Kennedy, Ciara; Newcastle University, Newcastle Clinical Trials Unit King, Andrew; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology Lawrence, Sarah; Newcastle University, Newcastle Clinical Trials Unit

	<p>Lees, Charlie W.; The University of Edinburgh MRC Institute of Genetics and Molecular Medicine; Western General Hospital, Institute of Genetics &amp; Molecular Medicine</p> <p>Lees, Robert; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology</p> <p>Letchford, Laura; Wellcome Sanger Institute, Wellcome Genome Campus</p> <p>Liddle, Trevor; Newcastle Upon Tyne Hospitals NHS Foundation Trust</p> <p>Lindsay, James ; Barts Health NHS Trust, Department of Gastroenterology; Blizard Institute of Cell and Molecular Science, Centre for Immunobiology</p> <p>Maier, Rebecca; Newcastle University, Newcastle Clinical Trials Unit</p> <p>Mansfield, John; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology</p> <p>Marchesi, Julian R.; St Mary's Hospital, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction</p> <p>McGregor, Naomi; Newcastle University, Newcastle Clinical Trials Unit</p> <p>McIntyre, Rebecca ; Wellcome Sanger Institute, Wellcome Genome Campus</p> <p>Ostermayer, Jasmin; Wellcome Sanger Institute, Wellcome Genome Campus</p> <p>Osunnuyi, Tolulope; Wellcome Sanger Institute, Wellcome Genome Campus</p> <p>Powell, Nick; St Mary's Hospital, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction; Imperial College Healthcare NHS Trust, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction</p> <p>Prescott, Natalie; King's College London, Department of Medical and Molecular Genetics, Guy's Hospital</p> <p>Satsangi, J; University of Oxford, Nuffield Department of Medicine</p> <p>Sharma, Shriya; Newcastle University, Newcastle Clinical Trials Unit</p> <p>Shrestha, Tara; Newcastle University, Newcastle Clinical Trials Unit</p> <p>Speight, Ally; Newcastle University Translational and Clinical Research Institute; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology</p> <p>Strickland, Michelle; Wellcome Sanger Institute, Wellcome Genome Campus</p> <p>Wason, James; Newcastle University, Population Health Sciences Institute</p> <p>Whelan, Kevin; King's College London, Department of Nutritional Sciences</p> <p>Wood, Ruth; Newcastle University, Newcastle Clinical Trials Unit</p> <p>Young, Gregory; Newcastle University Faculty of Medical Sciences, Translational and Clinical Research Institute</p> <p>Zhang, Xinyue; Newcastle University, Population Health Sciences Institute</p> <p>Parkes, M; Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology</p> <p>Stewart, Christopher; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences</p> <p>Jostins-Dean, Luke; University of Oxford, Kennedy Institute of Rheumatology</p> <p>Lamb, Christopher; Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology</p>
<p>&lt;b&gt;Primary Subject Heading&lt;/b&gt;:</p>	<p>Gastroenterology and hepatology</p>
<p>Secondary Subject Heading:</p>	<p>Pharmacology and therapeutics, Patient-centred medicine, Immunology (including allergy), Genetics and genomics, Diagnostics</p>

Keywords:	Inflammatory bowel disease < GASTROENTEROLOGY, Gastroenterology < INTERNAL MEDICINE, MICROBIOLOGY, Patient-Centered Care, Patient Reported Outcome Measures

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Defining predictors of responsiveness to advanced therapies in**  
5  
6  
7  
8 **Crohn's disease and ulcerative colitis: Protocol for the IBD-**  
9  
10  
11 **RESPONSE and nested CD-metaRESPONSE prospective,**  
12  
13  
14  
15 **multicentre, observational cohort study in precision medicine**  
16  
17

18 Nicola J. Wyatt<sup>1,2</sup>, Hannah Watson<sup>1</sup>, Carl A. Anderson<sup>3</sup>, Nicholas A. Kennedy<sup>4,5</sup>, Tim Raine<sup>6</sup>,  
19  
20 Tariq Ahmad<sup>4,5</sup>, Dean Allerton<sup>7</sup>, Michelle Bardgett<sup>7</sup>, Emma Clark<sup>7</sup>, Dawn Clewes<sup>7</sup>, Cristina  
21  
22 Cotobal Martin<sup>3</sup>, Mary Doona<sup>2</sup>, Jennifer A. Doyle<sup>1</sup>, Katherine Frith<sup>7</sup>, Helen Hancock<sup>7</sup>, Ailsa  
23  
24 Hart<sup>8,9</sup>, Victoria Hildreth<sup>7</sup>, Peter M. Irving<sup>10,11</sup>, Sameena Iqbal<sup>3</sup>, Ciara Kennedy<sup>7</sup>, Andrew King<sup>2</sup>,  
25  
26 Sarah Lawrence<sup>7</sup>, Charlie W. Lees<sup>12,13</sup>, Robert Lees<sup>2</sup>, Laura Letchford<sup>3</sup>, Trevor Liddle<sup>14</sup>,  
27  
28 James O. Lindsay<sup>15,16</sup>, Rebecca H. Maier<sup>7</sup>, John C. Mansfield<sup>1,2</sup>, Julian R. Marchesi<sup>17</sup>, Naomi  
29  
30 McGregor<sup>7</sup>, Rebecca E. McIntyre<sup>3</sup>, Jasmin Ostermayer<sup>3</sup>, Tolulope Osunnuyi<sup>3</sup>, Nick Powell<sup>17,18</sup>,  
31  
32 Natalie J Prescott<sup>19</sup>, Jack Satsangi<sup>20</sup>, Shriya Sharma<sup>7</sup>, Tara Shrestha<sup>7</sup>, Ally Speight<sup>1,2</sup>, Michelle  
33  
34 Strickland<sup>3</sup>, James M. S. Wason<sup>21</sup>, Kevin Whelan<sup>22</sup>, Ruth Wood<sup>7</sup>, Gregory R. Young<sup>1</sup>, Xinyue  
35  
36 Zhang<sup>21</sup>, Miles Parkes<sup>6</sup>, Christopher J. Stewart<sup>\*1</sup>, Luke Jostins-Dean<sup>\*23</sup>, Christopher A.  
37  
38 Lamb<sup>\*1,2</sup>  
39  
40  
41  
42  
43  
44

45 \*Denotes co-senior authorship  
46  
47  
48  
49  
50

51 **Correspondence:**  
52  
53

54 Dr Christopher Lamb, Translational & Clinical Research Institute, Faculty of Medical Sciences,  
55  
56 Newcastle University, Newcastle upon Tyne, NE2 4HH. United Kingdom  
57  
58

59 christopher.lamb@newcastle.ac.uk  
60

**Affiliations:**

1. Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
2. Department of Gastroenterology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
3. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, United Kingdom
4. Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, United Kingdom
5. Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, United Kingdom
6. Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
7. Newcastle Clinical Trials Unit (NCTU), 1-4 Claremont Terrace, Newcastle University, Newcastle upon Tyne, NE2 4AE, United Kingdom
8. Department of Gastroenterology, St Marks Hospital and Academic Institute, Gastroenterology, London, United Kingdom
9. Department of Surgery and Cancer, Imperial College, London, United Kingdom
10. Department of Gastroenterology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
11. School of Immunology & Microbial Sciences, King's College London, London, United Kingdom

- 1  
2  
3  
4 12. Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, United  
5  
6 Kingdom
- 7  
8 13. Edinburgh IBD Unit, Western General Hospital, NHS Lothian, Edinburgh, United Kingdom
- 9  
10 14. Research informatics team, Clinical Research, The Newcastle upon Tyne Hospitals NHS  
11  
12 Foundation Trust, Newcastle upon Tyne. United Kingdom
- 13  
14 15. Department of Gastroenterology, Barts Health NHS Trust, The Royal London Hospital,  
15  
16 London, United Kingdom
- 17  
18 16. Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine  
19  
20 Queen Mary University of London, London, United Kingdom
- 21  
22 17. Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction,  
23  
24 St Mary's Hospital, Imperial College London, London, United Kingdom
- 25  
26 18. Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, United  
27  
28 Kingdom
- 29  
30 19. Department of Medical and Molecular Genetics, King's College London, Guy's Hospital,  
31  
32 London, United Kingdom
- 33  
34 20. Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, United  
35  
36 Kingdom
- 37  
38 21. Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United  
39  
40 Kingdom
- 41  
42 22. Department of Nutritional Sciences, King's College London, United Kingdom
- 43  
44 23. Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
- 45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

### INTRODUCTION

Characterised by chronic inflammation of the gastrointestinal tract, inflammatory bowel disease (IBD) symptoms including diarrhoea, abdominal pain and fatigue can significantly impact patient quality of life. Therapeutic developments in the last 20 years have revolutionised treatment. Despite these developments, clinical trials and real-world data show primary non-response rates up to 40%. A significant challenge is an inability to predict which treatment will benefit individual patients.

Current understanding of IBD pathogenesis implicates complex interactions between host genetics and the gut microbiome. Most cohorts studying the gut microbiota to date have been underpowered, examined single treatments, and produced heterogeneous results. Lack of cross-treatment comparisons and well-powered independent replication cohorts hampers the ability to infer real-world utility of predictive signatures.

IBD-RESPONSE will use multi-omic data to create a predictive tool for treatment response. Future patient benefit may include development of biomarker-based treatment stratification or manipulation of intestinal microbial targets. IBD-RESPONSE and downstream studies have the potential to improve quality of life, reduce patient risk, and reduce expenditure on ineffective treatments.

### METHODS AND ANALYSIS

This prospective, multicentre, observational study will identify and validate a predictive model for response to advanced IBD therapies, incorporating gut microbiome, metabolome, single-cell transcriptome, human genome and clinical data. 1,325 participants commencing



1  
2  
3 advanced therapies will be recruited from ~40 UK sites. Data will be collected at baseline,  
4  
5 week 14 and week 54. The primary outcome is week 14 clinical response. Secondary  
6  
7  
8 outcomes include clinical remission, loss of response in week 14 responders, corticosteroid-  
9  
10 free response/remission, time to treatment escalation, and change in patient-reported  
11  
12 outcome measures.  
13  
14

## 15 16 **ETHICS AND DISSEMINATION**

17  
18 Ethical approval was obtained from the Wales Research Ethics Committee 5  
19  
20 (ref:21/WA/0228). Recruitment is ongoing. Following study completion, results will be  
21  
22 submitted for publication in peer-reviewed journals and presented at scientific meetings.  
23  
24 Publications will be summarised at [www.ibd-response.co.uk](http://www.ibd-response.co.uk).  
25  
26  
27  
28

## 29 **TRIAL REGISTRATION NUMBER**

30  
31  
32 ISRCTN96296121(pre-results)  
33

## 34 **Keywords:**

35  
36  
37 Inflammatory bowel disease, Crohn disease, gastrointestinal microbiome, multiomics,  
38  
39 precision medicine  
40  
41

## 42 **ORCiDs (alphabetical):**

43  
44  
45 Tariq Ahmad: <https://orcid.org/0000-0002-6058-5528>

46  
47 Dean Allerton: <https://orcid.org/0000-0003-0507-4343>

48  
49 Carl A. Anderson: <https://orcid.org/0000-0003-1719-7009>

50  
51 Michelle Bardgett: <https://orcid.org/0000-0003-1393-2010>

52  
53 Emma Clark: <https://orcid.org/0000-0003-0065-1463>

54  
55 Dawn Clewes: <https://orcid.org/0000-0001-9600-859X>

56  
57 Cristina Cotobal-Martin: <https://orcid.org/0000-0002-5877-2228>

58  
59 Mary Doona: <https://orcid.org/0000-0001-9533-3745>  
60

1  
2  
3 Jennifer A. Doyle: <https://orcid.org/0000-0001-7042-3269>  
4  
5 Katherine Frith: n/a  
6  
7 Helen Hancock: <https://orcid.org/0000-0002-1494-8551>  
8  
9 Ailsa Hart: <https://orcid.org/0000-0002-7141-6076>  
10  
11 Victoria Hildreth: n/a  
12  
13 Peter M. Irving: <https://orcid.org/0000-0003-0972-8148>  
14  
15 Sameena Iqbal: <https://orcid.org/0000-0003-0926-593X>  
16  
17 Luke Jostins-Dean: <https://orcid.org/0000-0002-2475-3969>  
18  
19 Ciara Kennedy: <https://orcid.org/0000-0003-2987-0977>  
20  
21 Nicholas A. Kennedy: <https://orcid.org/0000-0003-4368-1961>  
22  
23 Andrew King: <https://orcid.org/0000-0002-5002-4751>  
24  
25 Christopher A. Lamb: <https://orcid.org/0000-0002-7271-4956>  
26  
27 Sarah Lawrence: n/a  
28  
29 Charlie W. Lees: <https://orcid.org/0000-0002-0732-8215>  
30  
31 Robert Lees: <https://orcid.org/0009-0003-7439-1681>  
32  
33 Laura Letchford: n/a  
34  
35 Trevor Liddle: n/a  
36  
37 James O. Lindsay: <https://orcid.org/0000-0003-3353-9590>  
38  
39 Rebecca H. Maier: <https://orcid.org/0000-0002-7350-3288>  
40  
41 John C. Mansfield: <https://orcid.org/0000-0003-2490-7750>  
42  
43 Julian R. Marchesi: <https://orcid.org/0000-0002-7994-5239>  
44  
45 Naomi McGregor: <https://orcid.org/0000-0002-5961-124X>  
46  
47 Rebecca E. McIntyre: <https://orcid.org/0000-0001-5291-1533>  
48  
49 Jasmin Ostermayer: <https://orcid.org/0000-0001-6461-398X>  
50  
51 Tolulope Osunnuyi: <https://orcid.org/0000-0002-0482-917X>  
52  
53 Miles Parkes: <https://orcid.org/0000-0002-6467-0631>  
54  
55 Nick Powell: <https://orcid.org/0000-0003-3231-6950>  
56  
57 Natalie J. Prescott: <https://orcid.org/0000-0002-5901-7371>  
58  
59 Tim Raine: <https://orcid.org/0000-0002-5855-9873>  
60  
61 Jack Satsangi: <https://orcid.org/0000-0002-6357-9684>  
62  
63 Shriya Sharma: <https://orcid.org/0000-0001-5237-757X>  
64  
65  
66

1  
2  
3 Tara Shrestha: n/a

4  
5 Michelle Strickland: <https://orcid.org/0000-0001-8053-400X>

6  
7 Ally Speight: <https://orcid.org/0000-0003-3184-9181>

8  
9 Christopher J. Stewart: <https://orcid.org/0000-0002-6033-338X>

10  
11 James M. S. Wason: <https://orcid.org/0000-0002-4691-126X>

12  
13 Hannah Watson: <https://orcid.org/0000-0002-7965-938X>

14  
15 Kevin Whelan: <https://orcid.org/0000-0001-5414-2950>

16  
17 Ruth Wood: <https://orcid.org/0000-0002-8296-1774>

18  
19 Nicola J. Wyatt: <https://orcid.org/0000-0001-5050-327X>

20  
21 Gregory R. Young: <https://orcid.org/0000-0001-5342-1421>

22  
23 Xinyue Zhang: <https://orcid.org/0000-0002-5321-4235>

24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Article Summary

### STRENGTHS AND LIMITATIONS OF THIS STUDY

- IBD-RESPONSE is the largest precision medicine study of its kind to date, designed to develop a predictive tool for treatment response – or failure to respond – to IBD treatment, promoting *a priori* selection of the right drug, for the right patient, at the right time.
- IBD-RESPONSE will establish one of the largest biorepositories of longitudinal stool, blood, matched tissue and organoids with detailed linked phenotypic, diet, genetic and treatment outcome data in patients with IBD.
- This study will use a standardised yet pragmatic methodology for sample collection, processing and storage, allowing multicentre participation, improving generalisation and transferability of findings to real-world clinical practice.
- Remote ‘at home’ patient data and stool collection will allow >40 IBD centres to contribute to recruitment, increasing power in this multi-omics study when compared to other studies in the field that generally recruit from one or a small number of centres.
- Whilst recruiting sites are limited to the UK only, identified cross-validation cohorts from the UK and Canada will increase generalisability of our findings.

## INTRODUCTION

Crohn's disease (CD) and ulcerative colitis (UC) are the principal forms of inflammatory bowel disease (IBD).(1) Characterised by symptoms including diarrhoea, rectal bleeding, abdominal pain and extra-intestinal features such as fatigue, IBD can have a substantial negative impact on patient quality of life.(2) Approximately 20% of CD patients and 10% of UC patients are unable to work due to their condition.(3) The global prevalence of IBD is rising. In the United Kingdom (UK), 1 in 125 people are affected, with prevalence expected to reach 1 in 100 by 2028.(4, 5) Outside of Western Europe and North America, the incidence is rising rapidly in many regions including South America, Latin America, Asia and Africa.(6, 7)

The biologics era has revolutionised IBD treatment in the last twenty years. Patients and clinicians have more advanced therapies to choose from than ever before. Several biologic classes are now licensed in the UK, targeting tumour necrosis factor alpha (TNF $\alpha$ ) (including infliximab and adalimumab), interleukin (IL)-12 and/or -23 cytokine pathways (ustekinumab, risankizumab and mirikizumab), or the gut-homing  $\alpha$ 4 $\beta$ 7 integrin (vedolizumab). In addition, recently licensed small molecule therapies for UC include the Janus kinase inhibitors (JAKi) tofacitinib, filgotinib and upadacitinib, and the sphingosine-1-phosphate receptor (S1PR) modulator ozanimod. With several additional therapies in advanced stages of development or having completed phase 3 randomised clinical trials, the number of treatments available to patients is likely to increase.(8)

Current understanding of biological mechanisms driving the pathogenesis and natural history of IBD, implicates complex interactions between host genetics and the gut microbiome (bacteria, viruses, fungi, archaea and phage).(9) Whilst large clinical cohorts for human genetic discovery have led to major advances in understanding disease pathogenesis,(10)

1  
2  
3 cohorts for the study of gut microbiota have mostly been under-powered. Nonetheless,  
4  
5 existing research intriguingly suggests utility of microbiome signatures in predicting response  
6  
7 to therapy. In a small prospective study of 85 patients starting vedolizumab therapy, greater  
8  
9 alpha-diversity and higher abundance of *Roseburia inulinivorans* and a Burkholderiales  
10  
11 species at baseline were associated with therapeutic-induced remission in CD.(11)  
12  
13 Incorporation of microbial taxonomy data alongside clinical data in a predictive model  
14  
15 produced an area under the receiver operating characteristic curve (AUC) of 0.776 (compared  
16  
17 to an AUC of 0.619 using clinical data only). A larger study of 232 patients receiving  
18  
19 ustekinumab implicated *Bacteroides* and *Faecalibacterium* as predictors of treatment  
20  
21 response.(12) Here, a predictive model of response to ustekinumab using clinical metadata  
22  
23 produced an AUC of 0.616, rising to 0.844 when combined with baseline bacterial profile data.  
24  
25  
26  
27  
28  
29

30 Beyond IBD, further proof of concept that the gut microbiome is of prognostic  
31  
32 importance in the context of systemically administered immune-targeted therapies is found  
33  
34 with immune checkpoint inhibitor treatment in cancer, where experimental animal data  
35  
36 demonstrated the beneficial impact of microbial modulation on treatment outcome.(13-15)  
37  
38  
39

40 Metabolites derived from the gut microbiome are important intermediaries in the host-  
41  
42 microbiome dialogue.(16) Specific classes of metabolites, such as bile acids (BA), short-chain  
43  
44 fatty acids (SCFA) and tryptophan metabolites, may play a role in modulating disease activity  
45  
46 and treatment responsiveness in IBD.(17) In a study of 185 (77 UC, 108 CD) patients  
47  
48 commencing anti-cytokine (anti-TNF $\alpha$  or anti-IL12/23) or anti-integrin (vedolizumab) therapy,  
49  
50 metabolomic and proteomic analysis of blood in addition to taxonomic and functional profiling  
51  
52 of stool samples was conducted.(18) Among patients receiving anti-cytokine therapy, 120  
53  
54 enzymes were differentially abundant in baseline samples of remitters versus non-remitters.  
55  
56 Single-species dominance (>50% of enzyme copies in >50% of samples explained by a single  
57  
58  
59  
60

1  
2  
3 species) was observed for 8/120 enzymes. *Eggerthella lenta* was dominant for 5 of these 8  
4  
5 enzymes, 3 of which are involved in secondary BA biosynthesis. Metabolomic analysis of  
6  
7 baseline blood samples revealed significant enrichment of serum secondary BAs in patients  
8  
9 achieving week 14 clinical remission. Paired baseline stool samples revealed a significant  
10  
11 positive correlation with the abundance of 7 $\alpha$ / $\beta$ -dehydroxylation enzymes (responsible for  
12  
13 primary to secondary BA conversion), presence of which was associated with a preferential  
14  
15 response to anti-cytokine therapy. This was replicated by the authors in a small validation  
16  
17 cohort of 46 patients initiating anti-TNF $\alpha$  (infliximab) therapy. In a small study of 29 patients  
18  
19 with moderate-severe UC receiving vedolizumab treatment, untargeted metabolomic analysis  
20  
21 of stool showed significantly higher levels of SCFAs including butyrate in those achieving week  
22  
23 14 remission (defined as total Mayo score  $\leq$ 2, all subscores  $\leq$ 1) versus non-remitters.(19)  
24  
25 Combining metabolite data (SCFA levels for butyrate and isobutyric acid) with microbial profile  
26  
27 data predicted anti-integrin response with an AUC of 0.961.  
28  
29  
30  
31  
32  
33  
34

35 Whilst these previous studies are important first steps to utilising gut microbial  
36  
37 signatures in stratified treatment algorithms, they were mostly underpowered, examined single  
38  
39 treatments, used different sequencing technologies, and produced heterogeneous non-  
40  
41 overlapping results. The lack of cross-treatment comparisons and well-powered independent  
42  
43 replication cohorts hampers the ability to infer real-world utility of these predictive signatures,  
44  
45 and to move from observations of association to causation in IBD.(20)  
46  
47  
48  
49

## 50 METHODS AND ANALYSIS

### 51 Study rationale

52  
53 A significant challenge to effective, personalised use of biologic or small molecule  
54  
55 therapies (collectively termed 'advanced therapies') in IBD is an inability to predict which class  
56  
57  
58  
59  
60

1  
2  
3 of treatment is most likely to benefit an individual patient (see *Figure 1*). Despite increasing  
4  
5 therapeutic options, clinical trial and real-world efficacy data show primary non-response rates  
6  
7 of up to 40% across all therapeutic classes and in those with initial symptomatic benefit, up to  
8  
9 40% lose response by 1 year.(1, 21-23) Consequently, complications of chronic, active  
10  
11 inflammation including strictures, fistulae and malignancy, continue to affect a substantial  
12  
13 number of patients and have a negative impact on patient quality of life.(2) Up to 30% of CD  
14  
15 patients require surgical intervention within 10 years of diagnosis, and around 15% of UC  
16  
17 patients will ultimately require a colectomy.(24) Off-target side effects may also occur,  
18  
19 including infection and malignancy.(1) With average treatment costs of £6,156/year for CD  
20  
21 and £3,084/year for UC, future treatment algorithms must avoid the potential morbidity and  
22  
23 additional cost associated with expensive treatments that do not benefit individual  
24  
25 patients.(25)  
26  
27  
28  
29  
30  
31

32  
33 The absolute importance of precision medicine research to identify biomarkers for  
34  
35 treatment stratification and develop prognostic algorithms was highlighted by two recent  
36  
37 national research prioritisation exercises incorporating responses from almost 3,000 patients,  
38  
39 their families and friends.(1, 26) Validated prognostic models for treatment stratification do not  
40  
41 exist and understanding of mechanisms controlling treatment non-response is limited.  
42  
43 Through a multi-omic, precision medicine approach, the IBD-RESPONSE study seeks to  
44  
45 improve selection of the right drug, for the right patient, at the right time. Other translational  
46  
47 outputs of IBD-RESPONSE could bring into focus potential non-pharmacological approaches  
48  
49 to treating IBD that do not necessarily involve large health economic expenditure. This could  
50  
51 include manipulating the gut microbiome via the microbiota, through refinement of faecal  
52  
53 microbial transplant protocols, use of pre- and probiotics, and dietary interventions.  
54  
55  
56  
57  
58  
59  
60



## Scientific objectives of IBD-RESPONSE

The primary scientific objective of IBD-RESPONSE is to identify and validate a predictive model for clinical response or failure to respond to advanced therapies in IBD after 14 weeks of therapy (the primary clinical outcome, see below). Modelling will incorporate gut microbiome, human genome, blood and intestinal single cell transcriptome data, and detailed clinical data. Through data derived from a nested sub-cohort (CD-metaRESPONSE), predictive modelling will also include detailed dietary information and blood and faecal metabolome data. The co-primary scientific objective of IBD-RESPONSE is to determine the relationship between clinical response and remission at week 14 and baseline gut microbiome.

Secondary scientific objectives of IBD-RESPONSE are to determine if there is a relationship between the microbiome at baseline or changes in the microbiome following advanced therapy with any of the secondary clinical outcomes (*Box 1*). Further exploratory scientific objectives of IBD-RESPONSE are listed in *Box 2*.

- Clinical remission at week 14.
- Clinical response at week 54.
- Clinical remission at week 54.
- Loss of response at week 54 in week 14 responders.
- Durable corticosteroid-free response or remission at week 54 defined as receiving no corticosteroids between week 14 and week 54 assessments inclusive and not meeting criteria for loss of response.
- Time to treatment escalation from baseline, defined as:
  - Advanced therapy switch due to lack of efficacy/those with loss of response (does not include biosimilar switch or switch from IV to SC route).

- Dose intensification of drug due to lack of efficacy (does not include intensification based on therapeutic drug monitoring without flare in responders).
- Resectional intestinal surgery (does not include examination under anaesthesia procedures in patients with perianal CD).
- Induction or dose escalation of corticosteroids.
- Time to treatment escalation as defined above, but disregarding dose intensification.
- Time to treatment escalation as defined above, among week 14 responders.
- Time to discontinuation of index drug (persistence).
- Incidence of and time to potential side effects of treatment during follow up.
- Continuation of drug at week 14 and/or week 54 in those not meeting criteria for response and/or remission.
- Change from baseline SF subscore at week 14 and/or 54 (both CD and UC).
- Change from baseline RB subscore at week 14 and/or 54 (UC only).
- Change from baseline AP subscore at week 14 and/or 54 (CD only).
- Development of anti-drug antibodies by week 14 or 54.
- Change in CRP from baseline at week 14 or 54 (50% reduction or absolute value  $\leq 5\text{mg/L}$  deemed as clinically significant).
- Change in faecal calprotectin from baseline at week 14 or 54 (50% reduction or absolute value  $\leq 100\mu\text{g/g}$  deemed as clinically significant).
- Endoscopic remission during follow up (Mayo endoscopic subscore  $\leq 1$  for UC or SES-CD  $\leq 2$  for CD).

- Change in quality of life, physical activity dietary intake, joint pain and fatigue as measured by study questionnaires.

#### Box 1. IBD-RESPONSE secondary clinical outcome measures

Box 1 abbreviations: abdominal pain (AP), Crohn's disease (CD), c-reactive protein (CRP), intravenous (IV), rectal bleeding (RB), subcutaneous (SC), stool frequency (SF), simple endoscopic score for Crohn's disease (SES-CD), ulcerative colitis (UC)

- Test the association of microbial metabolites (metabolome) in stool or plasma, human genetics and/or single cell transcriptome data from blood or intestinal tissue with the above primary and secondary objectives.
- Determine the influence of diet on the gut microbiome and treatment response in IBD, and the factors associated with dietary intake in IBD.
- Explore host human genetic-gut microbiome-metabolome interactions in IBD pathogenesis and causal pathways to treatment response.
- Ascertain the utility of archived endoscopy collected FFPE biopsies at predicting/imputing the gut microbiome and for inclusion in the predictive model.
- Establish a longitudinal tissue, organoid and stool biobank from this well characterised clinical cohort.

#### Box 2. IBD-RESPONSE exploratory scientific objectives

Box 2 abbreviations: inflammatory bowel disease (IBD), formalin fixed paraffin embedded (FFPE)

## Study design

The design of IBD-RESPONSE and the nested CD-metaRESPONSE studies are summarised in *Figure 2*. This prospective, observational, multi-centre, cohort study will recruit participants with IBD (CD, UC, IBD-unclassified (IBD-U)) who are due to commence either biologic, JAKi or S1PR modulator therapy for symptomatic, clinically active (moderate to severe) luminal disease. Participants do not have to be naïve to advanced therapies and may be recruited when switching within or between class of advance therapy. Participants may be taking or planned to start concurrent thiopurines or methotrexate as combination therapy. Participation in the study will not change standard clinical care received. Detailed longitudinal clinical data will be collected alongside stool, blood and (where possible) biopsy samples, patient reported outcome measures, and dietary intake. Planned recruitment of 1,325 participants will consist of 762 patients with CD and 563 patients with UC (or IBD-U).

Data will be collected at baseline (prior to starting treatment), week 14 (following completion of induction therapy) and week 54. Participants will collect stool samples at each study timepoint. If a participant attends hospital within the baseline and/or week 14 study window, two blood samples (per timepoint) will be collected. Where a participant undergoes endoscopy as part of routine clinical care during the study period, up to 12 research biopsies will be collected.

Of 762 CD participants, 300 will be consented to take part in the nested CD-metaRESPONSE sub-cohort. Inclusion criteria are identical to the main cohort. Clinical data collection will occur at the same time points as in the main cohort. Additional study components will include completion of a 4-day food diary questionnaire, capturing all food and drink consumed at the baseline and week 14 timepoints. This is in addition to the food

1  
2  
3 frequency questionnaire completed by all participants. CD-metaRESPONSE participants will  
4  
5 also be required to provide two additional stool tubes (one at baseline and one at week 14)  
6  
7 for faecal metabolome analysis. Participants will be recruited to CD-metaRESPONSE from a  
8  
9 limited number of the participating sites. These sites will initially preferentially recruit eligible  
10  
11 participants with CD to CD-metaRESPONSE. Once the recruitment target of 300 participants  
12  
13 is achieved, all new participants identified with a diagnosis of CD will be recruited to the main  
14  
15 cohort.  
16  
17  
18  
19

20  
21 All participants recruited to IBD-RESPONSE will be invited to co-recruit to IBD  
22  
23 BioResource (if not already participating). IBD BioResource is a national platform and  
24  
25 recallable biorepository linked to the National Institute for Health and Care Research (NIHR)  
26  
27 BioResource that is designed to expedite IBD research, currently with >36,000  
28  
29 participants.<sup>(27)</sup> Co-recruiting participants to IBD-RESPONSE and the IBD BioResource  
30  
31 platform, will generate a rich dataset and provide a long term means of archiving data from  
32  
33 IBD-RESPONSE to facilitate ongoing research and maximise downstream patient benefit. To  
34  
35 minimise participant burden, the contact for recruitment to IBD BioResource can occur any  
36  
37 time in the 12 months following consent to IBD-RESPONSE. If a participant ultimately decides  
38  
39 not to participate in the IBD BioResource they will not be withdrawn from IBD-RESPONSE.  
40  
41  
42  
43  
44

45  
46 If a participant discontinues treatment prior to week 14 or week 54 follow up, the next  
47  
48 timepoint assessment will be brought forward and completed as a treatment discontinuation  
49  
50 assessment. Where a participant does not respond to the first prescribed advanced therapy  
51  
52 and a second (or third) advanced therapy is subsequently prescribed, this discontinuation  
53  
54 assessment will act as the baseline sample and data collection assessment for the successive  
55  
56 advanced therapy. Follow up samples and data collection will occur at week 14 and week 54  
57  
58 following commencement of each successive agent. The participant may remain in the study  
59  
60

1  
2  
3 up to 54 weeks after commencement of a particular agent or until the end of the study period.

4  
5 We anticipate that up to 40% of patients will not respond to the initial prescribed therapy or  
6  
7  
8 will lose response by 1 year and will move on to a second (or third) advanced therapy. We  
9  
10 therefore anticipate that recruitment of 1,325 participants may capture approximately 1,760  
11  
12 new treatment initiation episodes.  
13  
14

### 15 16 **Study setting**

17  
18 This multi-centre cohort study will be conducted at >40 study centres, based within  
19  
20 National Health Service (NHS) Trusts across the UK. All sites must be able to accommodate  
21  
22 the needs of the IBD-RESPONSE cohort including clinical engagement, research nurse  
23  
24 support and facilities for assessments.  
25  
26  
27

### 28 29 **Eligibility criteria**

30  
31 Individuals will be deemed eligible to enrol in the study if they fulfil all inclusion criteria  
32  
33 and meet none of the exclusion criteria (*Box 3*).  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**INCLUSION CRITERIA**

Individuals must fulfil all the following criteria to be enrolled in the study.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- Aged 16 years and over.
- Diagnosis of IBD: CD, UC or IBD-U.\*
- Already participating or willing to be approached for participation in IBD BioResource.
- Willing and able to provide informed consent.
- Willing to undertake study procedures including:
  - Completion of study questionnaires
  - Collection of home stool specimens
- Provision of blood and (where applicable) biopsy specimens.
- Symptoms of active luminal IBD (see definition of 'Clinically active disease', *Table 1*).
- At least one biochemical, endoscopic or radiological marker of active disease within 16 weeks of study consent (see *Box 4* and *Box 5*)
- Intention of clinical team to commence one of the following licensed advanced therapies for active luminal IBD within 6 weeks of consent:<sup>Δ</sup>
  - Infliximab
  - Adalimumab
  - Vedolizumab
  - Ustekinumab
  - Risankizumab (CD only)
  - Mirikizumab (UC only)
  - Tofacitinib (UC only)
  - Filgotinib (UC only)
  - Upadacitinib
  - Ozanimod (UC only)

\*Individuals with IBD-U will be managed as per the UC relevant protocol.

<sup>Δ</sup>Participants may be advanced therapy-naïve or -exposed. Any new biologic or small molecule drug that becomes licensed for the treatment of IBD during the planned study period will be permitted to allow study inclusion. Drugs used through Early Access to Medicines Schemes, compassionate use or expanded access schemes for unlicensed therapies are also permitted. Patients starting immunosuppressant monotherapy with a thiopurine or methotrexate are not eligible to take part. However, use of these treatments as part of combination therapy with an advanced therapy is not an exclusion to enrolment.



## EXCLUSION CRITERIA

Individuals meeting any of the following criteria will not be eligible to participate in the study.

- Receiving oral corticosteroids for any indication where the dose is unlikely to be weaned by week 14.<sup>^</sup>
- Planned bowel resection surgery within 14 weeks of commencing therapy.
- Advanced therapy being commenced as rescue for ASUC.
- Advanced therapy being commenced as part of a CTIMP.
- Presence of an ileal pouch anal anastomosis.
- Presence of a stoma.
- Perianal CD in the absence of active luminal inflammation.
- Antibiotics or short-term ( $\leq 4$  weeks) use of probiotics within the preceding 2 weeks.<sup>†</sup>
- FMT within the preceding 12 weeks or planned FMT within 14 weeks of commencing advanced therapy for IBD.<sup>‡</sup>

<sup>^</sup>Examples may include long term steroids for IBD where weaning by 14 weeks may not be possible irrespective of response to advanced therapy, or concurrent diagnosis where long term steroids are used e.g. polymyalgia rheumatica.

<sup>†</sup>Use of long-term (>4 weeks), stable doses of probiotics does not exclude individual participation but should be noted in the eCRF.

<sup>‡</sup>Use of antibiotics or prior FMT outside the exclusion period is permitted. Antibiotic use in the preceding 1 year and ever having received FMT will be noted in the eCRF.

### Box 3. Eligibility criteria for IBD-RESPONSE

Box 3 abbreviations: Acute severe ulcerative colitis (ASUC), Clinical Trial of an Investigational Medicinal Product (CTIMP), Crohn's disease (CD), electronic case report form (eCRF), faecal microbial transplantation (FMT), inflammatory bowel disease (IBD), inflammatory bowel disease-unclassified (IBD-U), ulcerative colitis (UC).

Participants must have at least one biochemical, endoscopic or radiological (CD only) marker of clinically active luminal disease within 16 weeks of study consent (see *Box 4* (CD) and *Box 5* (UC)). Endoscopic assessment of disease activity will be judged locally and may

1  
2  
3 be assessed prospectively or retrospectively. Whilst pregnancy may influence advance  
4  
5  
6 therapy selection, pregnancy is not an exclusion criterion.  
7  
8

9 CD patients must also have at least one of the following documented within 16 weeks prior  
10 to consent:

- 11 • Faecal calprotectin  $\geq 250$   $\mu\text{g/g}$ .
- 12 • CRP  $\geq 6$  mg/L.
- 13 • Any endoscopic evidence of active CD, defined as ulceration (with at least one ulcer  
14  $\geq 5\text{mm}$ ) judged locally from available clinical data (as an approximation equivalent to  
15 SES-CD of  $\geq 4$  for ileal disease or  $\geq 6$  for ileocolonic or colonic disease.
- 16 • Active inflammatory disease on imaging (MRI/CT/ultrasound) judged locally from  
17 available clinical data.

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29 **Box 4. IBD-RESPONSE and CD-metaRESPONSE additional inclusion criteria: CD**

30  
31 Box 4 abbreviations: Crohn's disease (CD), C-reactive protein (CRP), Computed tomography (CT), Magnetic resonance  
32 imaging (MRI), Simple Endoscopic Score for Crohn's Disease (SES-CD)  
33  
34  
35

36  
37  
38  
39 UC/IBD-U patients must also have at least one of the following documented within 16 weeks  
40 prior to consent:

- 41 • Faecal calprotectin  $\geq 250$   $\mu\text{g/g}$ .
- 42 • CRP  $\geq 6$  mg/L.
- 43 • Any endoscopic evidence of at least moderately active ulcerative colitis (of any  
44 extent including proctitis), defined as features of MCS endoscopic sub-score  $\geq 2$   
45 (marked erythema, lack of vascular pattern, friability, erosions, spontaneous  
46 bleeding or ulceration).

47  
48  
49  
50  
51  
52  
53  
54  
55 **Box 5. IBD-RESPONSE additional inclusion criteria: UC and IBD-U**  
56  
57  
58  
59  
60

Box 5 abbreviations: C-reactive protein (CRP), inflammatory bowel disease-unclassified (IBD-U), Mayo Clinic Score (MCS), ulcerative colitis (UC)

## Clinical outcome measures

Key definitions related to clinical outcome measures can be found in *Table 1*.

Clinically active disease	<ul style="list-style-type: none"> <li>• CD: Unweighted PRO-2 (CD) of average daily SF subscore <math>\geq 4</math> and/or average daily AP subscore <math>\geq 2</math>.</li> <li>• UC: Total PRO-2 (UC) <math>\geq 3</math> with RB subscore <math>\geq 1</math>.</li> </ul> <p>PRO-2 data will be entered by patients over 4 days (minimum 2 days PRO-2 data is permissible for PRO-2 calculation).</p>
Clinical remission	<p>Patient remains on drug and meets the following criteria:</p> <ul style="list-style-type: none"> <li>• CD: Unweighted PRO-2 (CD) average daily SF subscore <math>\leq 2.8</math> and average daily AP subscore <math>\leq 1</math> (and neither worse than inclusion scores at baseline).</li> <li>• UC: PRO-2 (UC) SF subscore <math>\leq 1</math> with a decrease of <math>\geq 1</math> point(s) in SF subscore from baseline, plus RB subscore = 0.</li> </ul> <p><b>AND</b> an absence of any of the following at time of assessment:</p> <ul style="list-style-type: none"> <li>• Resectional bowel surgery at any time after baseline until time of current assessment.</li> <li>• Current use of oral corticosteroids/failure to wean oral corticosteroids prescribed at baseline.</li> </ul>
Clinical response	<p>Meeting criteria for clinical remission <b>OR</b>:</p> <ul style="list-style-type: none"> <li>• CD: unweighted PRO-2 (CD) <math>\geq 30\%</math> reduction in average daily SF subscore and/or <math>\geq 30\%</math> decrease in average daily AP subscore (and neither worse than inclusion scores at baseline).</li> </ul>

	<ul style="list-style-type: none"> <li>UC: total PRO-2 (UC) decrease <math>\geq 1</math> and <math>\geq 30\%</math> from baseline, and a decrease in RB subscore <math>\geq 1</math> or an absolute RB subscore of <math>\leq 1</math>.</li> </ul> <p><b>AND</b> an absence of any of the following at time of assessment:</p> <ul style="list-style-type: none"> <li>Resectional bowel surgery at any time after baseline until time of current assessment.</li> <li>Current use of oral corticosteroids/failure to wean oral corticosteroids prescribed at baseline.</li> </ul>
Week 14 non-response	<ul style="list-style-type: none"> <li>Not meeting clinical response criteria AND not having stopped drug for any reason other than lack of efficacy.</li> </ul>
Week 54 loss of response	<ul style="list-style-type: none"> <li>Not meeting clinical response criteria at week 54 having met clinical response criteria at week 14 (AND not having stopped drug for any reason other than inefficacy between week 14 and 54 assessments).</li> </ul>
<p><b>Table 1. IBD-RESPONSE key clinical definitions</b></p> <p>Table 1 abbreviations: abdominal pain (AP), Crohn's disease (CD), patient reported outcome (PRO)-2, rectal bleeding (RB), stool frequency (SF), ulcerative colitis (UC).</p>	

### Primary clinical outcome measures

Clinical response at week 14 after commencing therapy.

### Secondary clinical outcome measures

Secondary clinical outcome measures are listed in *Box 1*.

### Sample size calculations

The sample size (n=1,325 cases overall, including n=300 cases for CD-metaRESPONSE sub-cohort) was chosen to ensure sufficient power to answer the co-primary scientific objective (to detect associations between microbiome measures and clinical response or remission) and key exploratory scientific objectives (to detect associations

1  
2  
3 between metabolites and clinical response or remission, and to detect associations between  
4 genetics and microbiome measures). Sample size calculations for predictive models require  
5  
6 extensive assumptions about the number and effect size of associations and the correlation  
7  
8 structure of the data. We noted predictive models built with microbiome and/or metabolite  
9  
10 measures with high in-sample predictive accuracy (including AUC=0.78 with n=84 from  
11  
12 Ananthakrishnan et al.(11), AUC=0.91 with n=76 from Ding et al.(28), and AUC=0.84 with  
13  
14 n=232 from the CERTIFI study(12)), implying that n=300 individuals (from CD-  
15  
16 metaRESPONSE) and n=1,325 individuals (from IBD-RESPONSE), should be sufficient for  
17  
18 high predictive in-sample accuracy.  
19  
20  
21  
22  
23  
24

#### 25 Sample size for analysis of primary objective

26  
27  
28 We took plausible effect sizes for the primary scientific objective analysis from the  
29  
30 effect of *Bacteroides* levels in stool on ustekinumab response (d=0.66, from the CERTIFI  
31  
32 study(12)) and the effect of anti-drug immunogenicity on remission after anti-TNF $\alpha$  treatment  
33  
34 (d=0.30, from the PANTS study(21)). We calculated power for a simple two-sample t-test  
35  
36 (using the R package pwr), assuming the expected non-response rate at 14 weeks (23.8%)  
37  
38 and non-remission rate at 54 weeks (63.1%) from the PANTS study. We assumed a  
39  
40 conservative Bonferroni-corrected significance threshold of 1e-5 (correcting for 5000  
41  
42 microbiome measures). We calculated the minimum sample size required to achieve 80%  
43  
44 power for the two effect sizes and two outcomes (*Supplementary Figure 1*), showing that  
45  
46 relatively low sample sizes are required to have high power to detect the larger plausible effect  
47  
48 size (n=282 for remission and n=361 for response), but that larger sample sizes are required  
49  
50 to have high power to detect the smaller plausible effect size (n=1,331 for remission and  
51  
52 n=1,705 for response). The sample size of n=1,325 chosen for our study gives a power of  
53  
54 close to 100% for the larger *Bacteroides* effect size for both week 14 response and week 54  
55  
56  
57  
58  
59  
60

1  
2  
3 remission, and 57% and 80% for the smaller anti-drug immunogenicity effect size for week 14  
4  
5  
6 response and week 54 remission, respectively.  
7

#### 8 9 Sample size for analysis of secondary and exploratory scientific objectives

10  
11 We took plausible effect sizes for the exploratory metabolite analysis from the effects  
12  
13 of three selected stool lipid and bile acid metabolites on anti-TNF $\alpha$  response from Ding et  
14  
15 al.(28): faecal triglyceride (d=1.00), and two bile acid metabolites; BA1 (d=0.89) and BA3  
16  
17 (d=0.70). We assumed a conservative Bonferroni-corrected significance threshold of 5e-5  
18  
19 (correcting for 1000 metabolites). For n=300, this gives a power of 99.7%, 91% and 74%  
20  
21 for faecal triglyceride, BA1 and BA3 respectively for week 14 response, and 100%, 99.8% and  
22  
23 91% for week 54 remission.  
24  
25  
26  
27

28  
29 We do not anticipate that this study on its own will be well powered to detect new  
30  
31 associations between genotype and microbiome measures in IBD. It is known from studies of  
32  
33 healthy individuals that genetic variants that explain more than 3% of variation ( $R^2=0.03$ ) in  
34  
35 microbial abundance are rare.(29) Assuming a conservative significance threshold of  $< 1e-11$   
36  
37 (correcting for  $1e6$  independent genotypes and 5000 microbiome measures), n=1,325  
38  
39 samples would only have 33% power to detect associations with  $R^2=0.03$  (calculated  
40  
41 using genpwr(30)). We will therefore combine our samples with a further  
42  
43 genotype/microbiome study of IBD (PREdiCCt) to increase sample size to n=2,325. This will  
44  
45 provide us 80% power to detect genetic associations with  $R^2>0.025$ . In the case where such  
46  
47 genotype/microbiome measure associations exist, and are associated with a causal  
48  
49 biomarker for week 54 remission, a Mendelian Randomization analysis would have >80%  
50  
51 power to demonstrate causality of this biomarker when the causal effect odds ratios is larger  
52  
53 than 2 (calculated using mRnd(31)).  
54  
55  
56  
57  
58  
59  
60

## Study procedures and measures

Participants  $\geq 16$  years old may be identified from a variety of settings such as outpatient clinics (face-to-face or virtual), flare assessments, IBD clinical nurse specialist helplines/email contact, endoscopy examinations, infusion suites, multidisciplinary team meetings and virtual biologics clinics (*Figure 2*). Consent will be taken electronically using a REDCap (Research Electronic Data Capture) online database. Full informed e-consent will be supported by an appropriately delegated member of the study team, using a laptop, tablet or mobile device in the patient's own home, or using a hospital tablet, laptop, computer or patient mobile device during a scheduled visit to hospital as part of routine clinical care. Paper copies of the consent form will be made available for those patients unable to access e-consent. If a later decision is made not to commence an advanced therapy for IBD, the participant will not be eligible to continue in the study and must be withdrawn. Data collected up to the point of withdrawal may be used for the study. Any samples collected will be used for research within IBD-RESPONSE or stored for future research.

All research activity will be completed by the participant either remotely or during hospital visits scheduled to deliver routine clinical care (see *Figure 3*). Participants will be asked to complete data collection after consent and before starting treatment (baseline), and at week 14 and week 54 following commencement of advanced therapy in line with routine dosing schedule visits. This will include patient questionnaires, stool samples and, where applicable, blood and biopsy specimens. Participants will be asked to complete questionnaires with data entered directly into the study specific REDCap database. Paper questionnaires will be made available for those participants without access or who express a preference to complete in paper format. Participants will be asked to complete questionnaires related to

1  
2  
3 disease activity, health, physical activity, quality of life and diet at the three assessment  
4  
5  
6 timepoints (see *Box 6*).  
7

## 8 9 **Participant samples**

10  
11 All sample collection and processing will be standardised, with full requirements  
12  
13 detailed in a study Sample Collection Manual.  
14  
15

16  
17 Stool samples will be collected by participants at home using stool collection kits and  
18  
19 returned using a prepaid Royal Mail Safebox™. All participants will collect two stool samples  
20  
21 per study assessment timepoint (DNA Genotek OMNIgene®•GUT tube and universal  
22  
23 polystyrene tube). Participants recruited to the CD-metaRESPONSE sub-cohort will be  
24  
25 required to collect a third stool sample at baseline and week 14 (DNA Genotek  
26  
27 OMNImet®•GUT tube). DNA extraction and metagenomic shotgun sequencing will be  
28  
29 performed on buffered samples. Calprotectin will be measured in unbuffered stool. Remaining  
30  
31 fresh stool and nucleic acids will be cryopreserved for use in future research.  
32  
33  
34

35  
36 Participants who attend a clinical appointment prior to commencing advanced therapy  
37  
38 or within the week 14 visit window (week 10-20; week 12-16 preferred) will be asked to provide  
39  
40 two blood samples (lithium heparin (LiH) tube and ethylenediaminetetra-acetic acid (EDTA)  
41  
42 tube). Blood samples will be utilised for single cell analysis, plasma extraction and  
43  
44 cryopreservation. Any remaining blood samples or derivatives will be stored at Newcastle  
45  
46 Biobank for use in future research. Participants will not be asked to attend hospital specifically  
47  
48 for blood sample collection. If participants are not scheduled to attend hospital face-to-face  
49  
50 within either study assessment window, blood samples will not be taken.  
51  
52  
53

54  
55  
56 If a participant has a lower gastrointestinal endoscopy as part of planned care during  
57  
58 study participation, up to 12 research biopsies (one set of six biopsies to be collected from the  
59  
60



1  
2  
3 colon in all participants and a further set of six biopsies from the ileum in CD participants) will  
4  
5 be taken. Where a participant meets the study eligibility criteria and a disease assessment  
6  
7 endoscopy is planned prior to starting therapy, consent should be received ahead of their  
8  
9 planned endoscopy to enable the collection of research biopsies. Biopsy samples will be  
10  
11 utilised for single cell sequencing and organoid generation. 16S rRNA gene sequencing of  
12  
13 both FFPE and fresh tissue will also be undertaken. Any remaining biopsy samples will be  
14  
15 stored for use in future research.  
16  
17  
18  
19  
20

21 **COMPLETED BY ALL PARTICIPANTS AT BASELINE, WEEK 14 AND WEEK 54**

22  
23  
24 **PRO-2 (CD or UC version depending on diagnosis)**

25  
26 PRO-2 is a validated questionnaire measuring patient reported outcomes including stool  
27  
28 frequency, abdominal pain and rectal bleeding.(32, 33)  
29

30  
31 **Bristol Stool Form Scale (BSFS)**

32  
33 The BSFS is a 7-point scale that helps describe stool shape and consistency and assess  
34  
35 bowel patterns and habits.(34)  
36

37  
38 **IBD-Control**

39  
40 The IBD-Control questionnaire comprises 13 items plus a visual analogue scale (VAS)  
41  
42 ranging from 0–100.(35) The questionnaire measures patient related outcome of their  
43  
44 disease state during the past 2 weeks.  
45

46  
47 **PROMIS-Fatigue 8a Short Form**

48  
49 The Patient Reported Outcomes Measurement Information System (PROMIS), are  
50  
51 validated questionnaires that help evaluate patients' quality of life.(36)  
52

53  
54 **EQ-5D-5L**

55  
56 The EQ-5D-5L is a quality-of-life questionnaire and is a widely used generic PROM  
57  
58 incorporating five domains: 1) mobility, 2) self-care, 3) usual activities, 4) pain/discomfort,  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

5) anxiety/depression.(37, 38) Scores for each domain are combined to describe the patient's state of health.

### **International Physical Activity Questionnaire (IPAQ)**

IPAQ is a commonly used self-reported questionnaire to estimate physical activity and sedentary behaviours for adults across a range of socio-economic settings.(39) The IPAQ measures the type of physical activities people do as part of their everyday lives.(39)

### **IBD-RESPONSE Joint Pain and Stiffness Score (JPSS)**

The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a patient reported questionnaire which quantifies clinical disease activity in Ankylosing Spondylitis (AS) and combines five disease activity variables (four 10-point Likert scale patient symptom responses and a CRP measurement), to produce a single score.(40-42) We believe joint pain to be an under-recognised symptom in active inflammatory bowel disease which may change in response to therapy as inflammation resolves/fails to resolve and so we have modified the ASDAS to assess joint pain, swelling and stiffness in all IBD-RESPONSE patients irrespective of whether they have a rheumatological diagnosis. We have called this modified score the IBD-RESPONSE Joint Pain and Stiffness Score (JPSS).

### **Food frequency questionnaire (FFQ)**

The FFQ will be completed by participants directly into the study specific REDCap database and can also be completed on paper. The FFQ requests information on 175 food items, their typical portion size and frequency of consumption and has been extensively validated for measuring nutrient intakes in adults.(43) Data are converted to nutrient intake using the Composition of Foods Integrated Dataset (COFIDs), as well as diet quality indices and other food components (e.g. polyphenols) and food categorisation (e.g. ultra-processed foods). The FFQ data will initially be analysed at the Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen and other collaborating institutions at the Department of Nutritional Sciences, King's College London.

1  
2  
3  
4 **COMPLETED BY CD-METARESPONSE PARTICIPANTS AT BASELINE AND WEEK 14**  
5 **ONLY**  
6  
7

8 **4-day food diaries**  
9

10 The 4-day food diary measures current food intake. It will comprehensively and  
11 prospectively measure all intake allowing calculation of energy and nutrient intake, dietary  
12 indices (e.g. diet diversity and Mediterranean diet), intake of ultra-processed foods, prebiotic  
13 and emulsifier intake.  
14  
15  
16  
17

18  
19 Box 6. Summary of patient questionnaires completed throughout study period  
20  
21  
22  
23  
24

25 **Statistical analysis**  
26

27  
28 The analysis approach for our primary objective will be to test for the association  
29 between features of the patient microbiome at baseline and primary clinical response to  
30 treatment at 14 weeks. Features will include alpha diversity, abundance of bacterial taxa  
31 (including species, genus and phyla) as well as the abundance of genes within various  
32 microbial pathways (for example using KEGG pathways, MetaCyc metabolic pathways and  
33 gene families). Association testing will be carried out using negative binomial regression,  
34 controlling for total sequence depth and pre-defined technical and clinical confounders, and  
35 significance will be determined using Benjamini-Hochberg multiple testing correction to ensure  
36 a false discovery rate of less than 5%.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 For the predictive modelling aim, we will use a random forest classifier to predict  
51 primary response to treatment at 14 weeks using microbiome, host genetic and clinical  
52 features at baseline. Model parameters will be tuned and accuracy assessed using nested  
53 cross-validation. This full model will be compared to a clinical-variables-only model, with model  
54 performance quantified by area under the receiver operator curve (AUROC), as well as the  
55  
56  
57  
58  
59  
60

1  
2  
3 sensitivity, specificity and positive and negative predictive power. A further model will be fitted  
4  
5 using the same approach including metabolomic and dietary data on the CD-metaRESPONSE  
6  
7 subset. Our primary predictive measure will be reported for a random forest classifier, but a  
8  
9 further sensitivity analysis will be carried out by fitting alternative prediction models to test  
10  
11 whether this has a strong effect on the predictive accuracy, using both simpler models  
12  
13 (including logistic regression with a LASSO penalty) and other more advanced methods (such  
14  
15 as neural networks and support vector machines), The results of the predictive models will be  
16  
17 reported in future publications according to the TRIPOD guidelines.(44)  
18  
19  
20  
21  
22

23 Secondary and exploratory objective analyses will use the same general analysis  
24  
25 approach as described above. For time-dependent events, such as treatment escalation due  
26  
27 to loss of response, a Cox proportional hazards regression will be used to assess the impact  
28  
29 of microbiome features on time to event, with patients censored at 54 weeks, last recorded (if  
30  
31 lost to follow-up) or date of withdrawal (if withdrawn). The dietary data will be analysed to test  
32  
33 the association between primary response and measures of specific nutrients (such as dietary  
34  
35 fibre) and dietary indices will be used to assess adherence to certain recommended diets  
36  
37 (such as achievement of food-based dietary guidelines or a “Mediterranean diet”). Host  
38  
39 genotype data will be used to test for associations between primary response and generate  
40  
41 polygenic risk scores of susceptibility to Crohn’s disease and ulcerative colitis, as well as pre-  
42  
43 specified variants associated with response to therapy (including HLA-DQA1\*05). In all these  
44  
45 individual analyses, Benjamini-Hochberg will be applied used to control the false discovery  
46  
47 rate at 5%.  
48  
49  
50  
51  
52  
53  
54

55 Loss to follow-up and missing data will be handled during the analyses in different  
56  
57 ways depending on the specific question being addressed. For the primary analysis at 14  
58  
59 weeks, individuals who are lost to follow-up or withdraw from the study before 14 weeks will  
60

1  
2  
3  
4 be removed from the analysis, though we will also carry out a robustness analysis where we  
5  
6 include individuals lost to follow-up as non-responders to ensure the results are robust to this  
7  
8 choice. Secondary and exploratory analyses at specific time-points will be treated in the same  
9  
10 fashion. For time-dependent events, analysed using survival models, individuals who are lost  
11  
12 to follow-up or withdraw will be treated as censored at this time point (the point of withdrawal  
13  
14 for withdrawn participants, and the last point of contact for patients lost to follow-up), though  
15  
16 we will also carry out sensitivity analyses where these are instead treated as adverse  
17  
18 outcomes where appropriate (e.g. treating withdrawals as adverse events). For missing data,  
19  
20 standard quality control criteria for microbiome, metabolome and genetic data will be used to  
21  
22 remove variables with excessive missing data (as well as other markers of poor data quality).  
23  
24 Where data is missing for microbiome or other experimental assays for specific individuals  
25  
26 after QC, only participants with non-missing data for this variable will be analysed. When  
27  
28 constructing and validating predictive models, individuals with missing data for the predictive  
29  
30 variables being tested, or that have withdrawn or been lost to follow-up before the assessment  
31  
32 time, will be excluded from model building and testing. Statistical analysis will be carried out  
33  
34 in R.  
35  
36  
37  
38  
39  
40

## 41 42 **Replication**

43  
44  
45       Scaling up microbiome discoveries and providing validation of results is needed to  
46  
47 benefit patients. Whilst IBD-RESPONSE is the largest project of its kind to date, it is a UK-  
48  
49 only programme. Translating findings to maximise patient benefit requires international  
50  
51 collaboration. Standardised data collection and data integration from different countries and  
52  
53 ethnic groups is key to establishing predictors of treatment response that are generalisable  
54  
55 and replicable.  
56  
57  
58  
59  
60

1  
2  
3  
4 We will validate our predictive model using an appropriate, already assembled  
5  
6 microbiome validation cohort. To generate this replication cohort, we will use banked stool  
7  
8 DNA from the Prognostic effect of Environmental factors in Crohn's and Colitis Study  
9  
10 (PREdiCCt; [www.predicct.co.uk](http://www.predicct.co.uk)), led by Professor Charlie Lees. PREdiCCt is a prospective  
11  
12 observational study of IBD participants in clinical remission, designed to identify whether  
13  
14 baseline factors (including genetics, dietary habits and gut microbiota) predict subsequent  
15  
16 disease flare. We will perform metagenomic sequencing of 1,000 stool samples from patients  
17  
18 who experienced a disease flare during the PREdiCCt study. We expect approximately 40%  
19  
20 of PREdiCCt patients to experience a disease flare requiring commencement of biologics. As  
21  
22 these patients all have baseline (clinical remission) stool microbiome samples in storage, they  
23  
24 provide a well matched and cost-efficient set of samples for replicating IBD-RESPONSE  
25  
26 results.  
27  
28  
29  
30  
31

### 32 **Potential future benefit to patients**

33  
34  
35 IBD-RESPONSE will provide timely and important information regarding associations  
36  
37 between the gut microbiome and responsiveness to treatment in IBD. It will likely highlight  
38  
39 potential mechanisms through which the microbiota may drive inflammation. We hope that  
40  
41 findings from IBD-RESPONSE will lead to new personalised avenues for IBD treatment  
42  
43 through discovery and validation of predictive tools that may be incorporated directly into  
44  
45 clinical practice or further tested in stratified clinical trials. This could lead to the development  
46  
47 of experimental techniques to modify gut microbes; for example, donor selection for faecal  
48  
49 microbial transplantation, identification of single or multiple strains of microbes, or use of  
50  
51 antimicrobials, phage or microbial metabolites that may be used to induce a more 'treatment  
52  
53 responsive' microbiome.  
54  
55  
56  
57  
58  
59  
60

## Patient and public involvement statement

IBD-RESPONSE was informed by two national patient research prioritisation exercises in IBD care led by members of our team and involving feedback from 3,000 people living with IBD, their family and friends.(1, 26) These identify aspects of precision medicine, microbiome and diet in IBD as of high importance. The initial IBD-RESPONSE grant proposal to the Medical Research Council (MRC) was reviewed by the NIHR Research Design Service North East and North Cumbria Patient and Public Involvement Panel and was presented and discussed at the 2020 Crohn's & Colitis UK Patient and Public Involvement in Research Day. IBD-RESPONSE has been supported by two patient representatives in the Study Oversight Committee (SOC) since inception. The study team have engaged with lay members of the SOC to ensure all patient facing documents including the participant information sheet (PIS), consent forms, stool collection guidance for patients and study questionnaires have undergone review. Patients will also be involved in dissemination activities relating to outputs from this research.

## ETHICS AND DISSEMINATION

Ethical approval for the study was obtained from the Wales Research Ethics Committee 5 (reference 21/WA/0228). Recruitment to IBD-RESPONSE began in February 2022 and is currently ongoing at sites around the UK.

In line with the Newcastle University and The Newcastle upon Tyne Hospitals NHS Foundation Trust research data policy, datasets will be kept for at least five years after the date they were last accessed. Metadata linked to genomic and metagenomic datasets will include anonymised clinical information. Examples include diagnosis (UC/CD/IBD-U), disease

1  
2  
3 location, disease behaviour, complications, extra-intestinal manifestations, co-morbidities,  
4  
5 family history, smoking history, surgical interventions, and outcomes from prior drug therapies.  
6  
7

8  
9 Raw data files in the original format (e.g. fastq) and the accompanying anonymised  
10  
11 phenotypic data will be uploaded to a public repository e.g. the NCBI database of Genotypes  
12  
13 and Phenotypes (dbGaP) at <https://www.ncbi.nlm.nih.gov/gap/>.  
14  
15

16  
17 As part of CD-metaRESPONSE, microbial sequence and faecal/serum metabolomic  
18  
19 data will be integrated with single-cell RNA sequencing, human genomics and clinical outcome  
20  
21 data; the whole dataset will be made available to other investigators and will be archived long  
22  
23 term within the IBD BioResource to facilitate downstream research.  
24  
25

26  
27 The CI, SMG, Sponsor, Funders and research team members are committed to ensure  
28  
29 that the research findings are shared. Findings will be written up and submitted to a peer-  
30  
31 reviewed scientific journal. Findings will be presented by the study team at national and  
32  
33 international conferences for example the British Society of Gastroenterology (BSG) annual  
34  
35 meeting, the European Crohn's and Colitis (ECCO) meeting and Digestive Diseases Week  
36  
37 (DDW). The study team will prepare a lay summary of the study findings for dissemination to  
38  
39 the study participants and members of the national patient group, Crohn's & Colitis UK.  
40  
41 Following study completion, results will be submitted for publication in peer-reviewed journals  
42  
43 and presented at national and international scientific meetings.  
44  
45  
46  
47

## 48 **REGISTRATION DETAILS**

49  
50  
51 Trial registration number: ISRCTN96296121 (pre-results).  
52  
53

## 54 **FUNDING**

55  
56  
57 The IBD-RESPONSE cohort is supported by a grant from the Medical Research Council  
58  
59 (funder reference MR/T032162/1) and the CD-metaRESPONSE cohort by The Leona M. and  
60



1  
2  
3 Harry B. Helmsley Charitable Trust (funder reference 2002-04255). Single cell RNA  
4  
5 sequencing in IBD-RESPONSE and CD-metaRESPONSE is supported by a grant from the  
6  
7 Helmsley Charitable Trust (funder reference 2304-05972). CJS is supported by a Sir Henry  
8  
9 Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number  
10  
11 221745/Z/20/Z) and the 2021 Lister Institute Prize Fellow Award. NJW is supported by the  
12  
13 NIHR Academic Clinical Fellowship (ACF) programme. LJD is supported by a Sir Henry Dale  
14  
15 Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number  
16  
17 208750/Z/17/Z) and the Kennedy Trust for Rheumatology Research. JMSW is funded by a  
18  
19 NIHR Research Professorship (NIHR301614). XZ is funded by a NIHR Pre-doctoral  
20  
21 Fellowship (NIHR302014).  
22  
23  
24  
25  
26  
27

## 28 **ACKNOWLEDGEMENTS**

29  
30 We are grateful for support from the Newcastle Clinical Trials Unit, the National Phenome  
31  
32 Centre, Imperial College London and the NIHR Biomedical Research Centres from Newcastle,  
33  
34 Imperial and Cambridge. The views expressed are those of the authors and not necessarily  
35  
36 those of our funders, the NIHR or the Department of Health and Social Care.  
37  
38  
39  
40

## 41 **CONTRIBUTORSHIP STATEMENT**

42  
43 All authors contributed to clinical protocol and/or laboratory standard operating procedure  
44  
45 design, development and operationalisation. CAL is the Chief Investigator of the programme.  
46  
47 The grants to fund IBD-RESPONSE and CD-metaRESPONSE were conceptualised and  
48  
49 written by CAL, LJ-D, CJS, MP, CAA, NAK, TR, TA, AH, HH, CWL, JCM, JRM, NP, NJP, AS  
50  
51 and JS. Clinical study design, operationalisation, data acquisition and analytical plans were  
52  
53 further developed by these authors plus DA, MB, EC, DC, MD, KF, VH, AK, CK, PMI, JOL,  
54  
55 RL, SL, TL, NM, RHM, SS, TS, HW, JMSW, KW, NJW, RW, GRY and XZ with critical review  
56  
57  
58  
59  
60

1  
2  
3 from all authors. Laboratory standard operating procedures were developed by CAL, CJS,  
4  
5 HW, REM, LJ-D, CK, NAK, CA, MB, EC, DC, JAD, MD, SI, JOL, LL, CCM, JRM, JO, TO, MP,  
6  
7 MS, NP, NJP, TR, MS, SS and NJW. Manuscript drafting was led by NJW and CAL with  
8  
9 subsequent critical review and revision by all authors.  
10  
11  
12

### 13 **COMPETING INTERESTS**

14  
15  
16 Tariq Ahmad reports personal grants from F. Hoffmann-La Roche AG, Biogen Inc, AbbVie,  
17  
18 Janssen, Celltrion, Galapagos NV, Immunodiagnostik, and Takeda, outside the submitted  
19  
20 work; personal fees for educational development/delivery from Pfizer, payment or honoraria  
21  
22 for lectures, presentations, speakers bureaus, manuscript writing or educational events from  
23  
24 Pfizer, Takeda, and F. Hoffman-La Roche AG; support for attending meetings from Celltrion,  
25  
26 Tillotts, and Pfizer. Carl A. Anderson reports grants from the Wellcome Sanger Institute  
27  
28 Quinquennial Review 2021-2026, Crohn's and Colitis Foundation (USA), the Medical  
29  
30 Research Council, Open Targets UK, and the Helmsley Charitable Trust; consulting fees from  
31  
32 BridgeBio Ltd, Genomics PLC, and Brigham & Women's Hospital Boston; payment or  
33  
34 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
35  
36 events from GlaxoSmithKline; support for attending meetings and/or travel membership from  
37  
38 the Wellcome Sanger Institute Quinquennial Review 2021-2026; (Chair) of the Board of  
39  
40 Trustees for the Sanger Prize; other interests as Director of Anderson Genomics Consultancy  
41  
42 Ltd. Michelle Bardgett reports partial personal salary funding from the Medical Research  
43  
44 Council. Ailsa Hart reports personal consulting fees from AbbVie, BMS, Celltrion, Falk,  
45  
46 Galapagos, Janssen, Pfizer, Takeda, and Roche; payment or honoraria for lectures,  
47  
48 presentations, speakers bureaus, manuscript writing or educational events from BMS,  
49  
50 Celltrion, Falk, Galapagos, Janssen, Pfizer, Takeda, Roche, and AbbVie; support for attending  
51  
52 meetings and/or travel from BMS, Celltrion, Falk, Galapagos, Janssen, Pfizer, Takeda, Roche,  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and AbbVie. Peter M. Irving reports reports personal grants from Celltrion, Galapagos, and  
4  
5  
6 Pfizer, outside the submitted work; personal consulting fees from AbbVie, Takeda, BMS,  
7  
8 Janssen, Arena, Pfizer, Galapagos, Lilly, Boehringer-Ingelheim, and Celgene; payment or  
9  
10 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
11  
12 events from AbbVie, Takeda, Janssen, Lilly, BMS, Pfizer, and Galapagos; support for  
13  
14 attending meetings and/or travel from AbbVie and Tillotts. Luke Jostins-Dean reports grants  
15  
16 from the Wellcome Trust, the Royal Society, the Kennedy Trust for Rheumatology Research,  
17  
18 the Helmsley Charitable Trust, and the Medical Research Council; grants from Novartis  
19  
20 Pharmaceutical, outside the submitted work; consulting fees from Nightingale Health and  
21  
22 Genomics PLC. Ciara Kennedy reports partial salary funding from the Medical Research  
23  
24 Council. Nicholas A. Kennedy reports grants from AbbVie, Biogen, Celltrion, Galapagos, and  
25  
26 Immunodiagnostik; consulting fees from AbbVie, Bristol-Meyer Squibb, and Dr Falk; payment  
27  
28 or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
29  
30 events from AbbVie, Dr Falk, Tillotts, Galapagos, and Takeda; support for attending meetings  
31  
32 and/or travel from Tillotts; participation (Chair) on the Board of the British Society of  
33  
34 Gastroenterology IBD Clinical Research Group. Christopher A. Lamb reports grants from  
35  
36 and/or consultancy for Janssen, Takeda, AbbVie, AstraZeneca, Eli Lilly, Orion, Pfizer, Roche,  
37  
38 Sanofi Aventis, UCB, Biogen, GSK, Bristol Myers Squibb and Genentech Inc; payment or  
39  
40 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
41  
42 events from Ferring, Takeda, Janssen, Nordic Pharma and Dr Falk; participation (Secretary)  
43  
44 on the British Society of Gastroenterology IBD Section; participation on the Steering  
45  
46 Committee of IBD UK. Charlie W. Lees reports grants from UKRI Future Leaders Fellowship;  
47  
48 personal consulting fees from AbbVie, Pfizer, Janssen, Takeda, Galapagos, Fresenius Kabi,  
49  
50 Novartis/Sandoz, BMS, and Celltrion; payment or honoraria for lectures, presentations,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 speakers bureaus, manuscript writing or educational events from AbbVie, Pfizer, Janssen,  
4  
5  
6 Takeda, Galapagos, Fresnius Kabi, Novartis/Sandoz, BMS, Ferring, Dr Falk, and Celltrion.  
7  
8 James O. Lindsay reports grants from AbbVie, and Gilead; personal consulting fees from  
9  
10 Allergan, AbbVie, Bristol Myers Squibb, Celgene, Cornerstones US, Galapagos, Gilead, GSK,  
11  
12 Lilly, MSD UK, Shire UK, Shire International, Ferring UK, Ferring International, Celltrion,  
13  
14 Lilly, MSD UK, Shire UK, Shire International, Ferring UK, Ferring International, Celltrion,  
15  
16 Takeda, Pfizer, and Janssen; payment or honoraria for lectures, presentations, speakers  
17  
18 bureaus, manuscript writing or educational events from AbbVie, Bristol Myers Squibb,  
19  
20 Cornerstones US, Galapagos, Ferring UK, Ferring International, Celltrion, Takeda, Pfizer, and  
21  
22 Janssen; support to attend meetings and/or travel from AbbVie, and Janssen. Rebecca H.  
23  
24 Maier reports that she is an independent membership on the Trial Steering Committee for the  
25  
26 National Institute for Health and Care Research funded ALLEGRO trial. Julian R. Marchesi  
27  
28 reports personal consulting fees from EnteroBiotix Limited and Cultech Limited; patent held  
29  
30 (without financial gain) on *C. Difficile* therapy (WO2019197836A1), participation (Chair) on the  
31  
32 IDMC Board. Naomi McGregor reports partial (10%) salary funding from the Medical  
33  
34 Research Council. Rebecca E. McIntyre reports personal salary funding from the Wellcome  
35  
36 Sanger Institute. Jasmin Ostermayer reports stock held in Novartis AG. Miles Parkes reports  
37  
38 grants from Pfizer and Gilead; personal consulting fees from Galapagos; payment or honoraria  
39  
40 for lectures, presentations, speakers bureaus, manuscript writing or educational events from  
41  
42 Janssen. Nick Powell reports grants from Bristol-Myers Squibb, Takeda, and Pfizer;  
43  
44 consulting fees from AbbVie, Allergan, Astra-Zeneca, Bristol-Myers Squibb, Celgene,  
45  
46 Celltrion, Galapagos, GSK, Takeda, and Vifor; payment or honoraria for lectures,  
47  
48 presentations, speakers bureaus, manuscript writing or educational events from AbbVie,  
49  
50 Bristol-Myers Squibb, Ferring, Galapagos, Janssen, Roche, Pfizer, Takeda, and Tillotts;  
51  
52 support for attending meetings and/or travel from AbbVie, Allergan, Celltrion, Janssen, and  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Takeda; participation on a data safety monitoring board or advisory board for AbbVie,  
5  
6 Allergan, Astra-Zeneca, Bristol-Myers Squibb, Celgene, Celltrion, Galapagos, GSK, Takeda,  
7  
8 and Vifor. Tim Raine reports personal grants from AbbVie; personal consulting fees from  
9  
10 AbbVie, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Ferring,  
11  
12 Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer,  
13  
14 Roche, Sandoz, Takeda, UCB, and XAP therapeutics; participation on the board of UCB,  
15  
16 membership (Chair) of the ECCO Guidelines Committee, membership of the UEG Scientific  
17  
18 Committee. Jack Satsangi reports grants from Crohn's and Colitis UK, the Helmsley  
19  
20 Charitable Trust, ECCO, the European Commission, CCFA, and Action Medical Research;  
21  
22 payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or  
23  
24 educational events from Roche; participation on a Data Safety Monitoring Board or Advisory  
25  
26 Board for the MODULATE trial and the TRIBUTE trial; leadership or fiduciary role as the  
27  
28 Director of the Royal College of Physicians IBD Registry, and Governing Body Fellow at Green  
29  
30 Templeton College. Ally Speight reports personal consulting fees from GSK; payment or  
31  
32 honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational  
33  
34 events from Falk, and AbbVie; payment of conference fees to attend the British Society of  
35  
36 Gastroenterology Annual Conference 2022 from Celltrion; participation on a Data Safety  
37  
38 Monitoring Board or Advisory Board for the IBD-RESPONSE study (unpaid), and Abbvie;  
39  
40 participation on the British Society of Gastroenterology IBD Section Committee. Christopher  
41  
42 J. Stewart reports personal consultancy fees from Astarte Medical; payment or honoraria for  
43  
44 lectures, presentations, speakers bureaus, manuscript writing or educational events from  
45  
46 Nestle Nutrition Institute. James M. S. Wason reports grants from Intercept; consulting fees  
47  
48 from Worg and UCB; payment or honoraria for lectures, presentations, speakers bureaus,  
49  
50 manuscript writing or educational events from Janssen; participation on a Data Safety  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Monitoring Board or Advisory Board for Roche. Kevin Whelan reports grants from the  
4  
5  
6 Helsmsley Charitable Trust, Crohn's and Colitis UK, Almond Board of California, Danone,  
7  
8 International Dried Fruit and Nut Council, Medical Research Council, National Institute for  
9  
10 Health and care Research; royalty or license payments for Volatile organic compounds in the  
11  
12 diagnosis and management of irritable bowel syndrome, and Wiley BDA Advances in Nutrition  
13  
14 & Dietetics book series; personal consulting fees from Danone; payment or honoraria for  
15  
16 lectures, presentations, speakers bureaus, manuscript writing or educational events from  
17  
18 Janssen; support for attending meetings and/or travel from Yakult; participation on a Data  
19  
20 Safety Monitoring Board or Advisory Board for the MODULATE trial (unpaid). The remaining  
21  
22  
23 authors disclose no conflicts of interest.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*. 2019;68(Suppl 3):s1-s106.
2. Floyd DN, Langham S, Severac HC, Levesque BG. The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review. *Dig Dis Sci*. 2015;60(2):299-312.
3. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Risk factors of work disability in patients with inflammatory bowel disease--a Dutch nationwide web-based survey: work disability in inflammatory bowel disease. *J Crohns Colitis*. 2014;8(7):590-7.
4. Jones GR, Lyons M, Plevris N, Jenkinson PW, Bisset C, Burgess C, et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. *Gut*. 2019;68(11):1953-60.
5. Hamilton B, Green H, Heerasing N, Hendy P, Moore L, Chanchlani N, et al. Incidence and prevalence of inflammatory bowel disease in Devon, UK. *Frontline Gastroenterology*. 2021;12(6):461.
6. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol*. 2020;5(1):17-30.
7. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet*. 2017;390(10114):2769-78.
8. Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. *BioDrugs*. 2021;35(5):473-503.
9. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature*. 2012;491(7422):119-24.
10. Luo Y, de Lange KM, Jostins L, Moutsianas L, Randall J, Kennedy NA, et al. Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. *Nat Genet*. 2017;49(2):186-92.
11. Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, et al. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. *Cell Host Microbe*. 2017;21(5):603-10 e3.
12. Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, et al. Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients. *MBio*. 2018;9(2).
13. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science*. 2018;359(6371):91-7.
14. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science*. 2018;359(6371):104-8.
15. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*. 2018;359(6371):97-103.

16. Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. *Nature Reviews Gastroenterology & Hepatology*. 2020;17(4):223-37.
17. Fiorucci S, Carino A, Baldoni M, Santucci L, Costanzi E, Graziosi L, et al. Bile Acid Signaling in Inflammatory Bowel Diseases. *Dig Dis Sci*. 2021;66(3):674-93.
18. Lee JWJ, Plichta D, Hogstrom L, Borren NZ, Lau H, Gregory SM, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. *Cell Host & Microbe*. 2021;29(8):1294-304.e4.
19. Liu J, Fang H, Hong N, Lv C, Zhu Q, Feng Y, et al. Gut Microbiome and Metabonomic Profile Predict Early Remission to Anti-Integrin Therapy in Patients with Moderate to Severe Ulcerative Colitis. *Microbiol Spectr*. 2023;11(3):e0145723.
20. Plichta DR, Graham DB, Subramanian S, Xavier RJ. Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships. *Cell*. 2019;178(5):1041-56.
21. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. *Lancet Gastroenterol Hepatol*. 2019;4(5):341-53.
22. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, et al. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. *Am J Gastroenterol*. 2018;113(9):1345.
23. Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, et al. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. *Clin Gastroenterol Hepatol*. 2016;14(2):242-50 e1-2.
24. Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. *Clinical Gastroenterology and Hepatology*. 2021;19(10):2031-45.e11.
25. Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. *Frontline Gastroenterol*. 2015;6(3):169-74.
26. Hart AL, Lomer M, Verjee A, Kemp K, Faiz O, Daly A, et al. What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance. *J Crohns Colitis*. 2017;11(2):204-11.
27. Parkes M, Investigators IBDB. IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn's and Colitis. *Gut*. 2019;68(9):1537-40.
28. Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, et al. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease. *J Crohns Colitis*. 2020;14(8):1090-102.
29. Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV, et al. The effect of host genetics on the gut microbiome. *Nat Genet*. 2016;48(11):1407-12.
30. Moore CM, Jacobson SA, Fingerlin TE. Power and Sample Size Calculations for Genetic Association Studies in the Presence of Genetic Model Misspecification. *Hum Hered*. 2019;84(6):256-71.
31. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol*. 2013;42(5):1497-501.
32. Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. *Aliment Pharmacol Ther*. 2015;42(10):1200-10.



- 1  
2  
3 33. Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, et al. A retrospective  
4 analysis: the development of patient reported outcome measures for the assessment of Crohn's  
5 disease activity. *Aliment Pharmacol Ther.* 2015;41(1):77-86.  
6  
7 34. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. *Scand J*  
8 *Gastroenterol.* 1997;32(9):920-4.  
9  
10 35. Bodger K, Ormerod C, Shackcloth D, Harrison M, Collaborative IBDC. Development and  
11 validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-  
12 control questionnaire. *Gut.* 2014;63(7):1092-102.  
13  
14 36. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported  
15 Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative  
16 group during its first two years. *Med Care.* 2007;45(5 Suppl 1):S3-S11.  
17  
18 37. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary  
19 testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res.* 2011;20(10):1727-36.  
20  
21 38. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement  
22 properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country  
23 study. *Qual Life Res.* 2013;22(7):1717-27.  
24  
25 39. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International  
26 physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc.*  
27 2003;35(8):1381-95.  
28  
29 40. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-  
30 endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis.*  
31 2009;68(1):18-24.  
32  
33 41. Machado PM, Landewe R, Heijde DV, Assessment of SpondyloArthritis international S.  
34 Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease  
35 activity states. *Ann Rheum Dis.* 2018;77(10):1539-40.  
36  
37 42. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly  
38 discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. *Ann*  
39 *Rheum Dis.* 2009;68(12):1811-8.  
40  
41 43. Hollis JL, Craig LCA, Whybrow S, Clark H, Kyle JAM, McNeill G. Assessing the relative validity of  
42 the Scottish Collaborative Group FFQ for measuring dietary intake in adults. *Public Health Nutrition.*  
43 2017;20(3):449-55.  
44  
45 44. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable  
46 prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. *BMC*  
47 *Medicine.* 2015;13(1):1.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **WORD COUNT**  
4

5  
6 4,972 words excluding words in figures/tables/boxes, contributorship statement, competing  
7  
8 interests, funding, acknowledgements and references  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## FIGURE LEGENDS

**Figure 1. Schematic illustrating the evolving approach to treatment of inflammatory bowel disease, with the aim of improving treatment outcomes through individualised precision-medicine.** Current treatment selection is stratified and modified based on diagnosis, disease phenotype, imaging (radiological and endoscopic) and limited clinical biomarkers, such as blood and stool markers of inflammation, drug metabolising enzyme activity, drug levels, and anti-drug antibodies. Precision medicine approaches integrating additional complex multi-omic data with information about environmental factors such as dietary intake, smoking and physical activity levels (the exogenous 'exposome'), may enable individualised treatment selection through predictive modelling. Precision medicine may also help to identify of at-risk populations, predict disease course, reduce unnecessary patient risk and health service costs associated with ineffective pharmacological therapies, and guide non-pharmacological interventions such as dietary modification. Figure created with BioRender.com

Figure 1 abbreviations: c-reactive protein (CRP), thiopurine methyltransferase (TPMT)

**Figure 2. Study overview schematic.** 1,325 participants with IBD planned to commence an advanced therapy will be recruited, including a nested sub-cohort of 300 CD patients (CD-metaRESPONSE). All participants will collect two stool sample tubes at each study assessment timepoint (baseline, week 14 and week 54). CD-metaRESPONSE participants will be required to collect a third stool sample tube at baseline and week 14. If a participant attends hospital for a face-to-face appointment within the baseline and/or week 14 study assessment window, blood samples will be collected. If a participant attends hospital for a lower gastrointestinal endoscopy at any time during the study period (pre- or post- treatment), biopsy samples will be collected. Participants will complete several questionnaires at each

1  
2  
3 assessment time point. For CD-metaRESPONSE participants, additional detailed analyses  
4  
5 will be undertaken of metabolic profiles (metabolome) in stool and matched blood plus in-  
6  
7 depth dietary assessment (additional elements highlighted in blue boxes). Data generated will  
8  
9 be used to perform predictive modelling. Any remaining participant samples will form a large  
10  
11 biorepository for use in future research. Figure created with BioRender.com  
12  
13


14  
15  
16 Figure 2 abbreviations: anti-tumour necrosis factor alpha (anti-TNF $\alpha$ ), anti-interleukin (anti-  
17  
18 IL), Bristol stool form scale (BSFS), Crohn's disease (CD), formalin-fixed paraffin embedded  
19  
20 (FFPE), inflammatory bowel disease (IBD), International Physical Activity Questionnaire  
21  
22 (IPAQ), janus kinase inhibitor (JAKi), Joint Pain and Stiffness Score (JPSS), Patient Reported  
23  
24 Outcome-2 (PRO-2), Patient Reported Outcomes Measurement Information System  
25  
26 (PROMIS), sphingosine-1-phosphate receptor (S1PR), ulcerative colitis (UC).  
27  
28  
29

### 30 **Figure 3. Flowchart providing overview of study events.**


31  
32  
33 Figure 3 abbreviations: Crohn's disease (CD), inflammatory bowel disease (IBD), Janus  
34  
35 kinase inhibitor (JAKi), Mayo Clinic Score (MCS), multidisciplinary team (MDT), Patient  
36  
37 Reported Outcome-2 (PRO-2), simple endoscopic score for Crohn's disease (SES-CD),  
38  
39 sphingosine-1-phosphate receptor (S1PR), Research Electronic Data Capture (REDCap),  
40  
41 ulcerative colitis (UC).  
42  
43  
44  
45

46 **Supplementary Figure 1.** Power at different sample sizes for detecting associations in the primary  
47  
48 analysis between microbiome variables at baseline and response to treatment at 14 weeks or  
49  
50 remission at week 52, using two different plausible effect sizes ( $d=0.66$  and  $d=0.30$ ). Vertical lines  
51  
52 mark the sample size required to achieve 80% power for the four different scenarios.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38



Pre-treatment Week 14 Week 54



### IBD patients





n=1,325


Planned to commence advanced therapy for IBD:

anti-TNF $\alpha$ , anti- $\alpha$ 4 $\beta$ 7, anti-IL12/23, anti-IL23, JAKi, S1PR modulator


(newly licensed, early access and compassionate use medicines included)




Gut microbiome




Faecal metabolome




Plasma metabolome



Human genome



Blood single cell transcriptome



Intestinal single cell and bulk transcriptome




Food frequency questionnaire

4-day food diary




**Treatment outcomes**  
 PRO-2  
 PROMIS-Fatigue  
 EQ-5D-5L  
 IBD-Control  
 IPAQ  
 BSFS  
 JPSS

### Predictive modelling



### Biorepository



FFPE biopsies  
 Plasma  
 Cryopreserved biopsies  
 Organoids  
 Unbuffered stool  
 Nucleic acids

**Where:** Face-to-face clinics, telephone consultations, endoscopy lists, infusion suites, MDT meetings, virtual biologics clinics, IBD nurse helpline

**Who:** ≥16 years old; symptomatic, active luminal IBD; no minimum disease duration

**Advanced therapy being commenced:** Licensed biologic, JAKi or S1PR modulator (infliximab, adalimumab, vedolizumab, ustekinumab, bfacitinib, filgotinib, upadacitinib, ozanimod) or early access/compassionate use therapy (e.g. risankizumab)

**Screening tips:**

- 5 UC symptoms: increased stool frequency relative to baseline AND at least one episode of recent rectal bleeding within e.g. last 3-5 days
- 6 CD symptoms of active flare: presence of liquid or very soft stools AND/OR presence of abdominal pain
- 7 Active disease confirmed by clinical test in 16 weeks prior to consent: faecal calprotectin, CRP, endoscopy or (CD only) imaging
- 8 Participants do not need to be naïve to advanced therapies e.g. can previously have received a biologic
- 9 Participants switching between advanced therapies do not need a minimum washout period
- 10 Participants can be receiving or about to start concomitant thiopurine or methotrexate alongside planned advanced therapy
- 10 Participants can be receiving or starting steroids at baseline provided likely to have fully weaned by week 14

**Eligibility confirmed**

**Study information and informed consent given**

- 17 Participant Information Sheet (PIS) provided (paper or electronic format)
- 18 Potential participant questions answered by local study team
- 19 REDCap access given to participant to complete informed study consent

**Consent verified**

23 Stool sample collection kit given to/posted to participant once valid consent obtained and verified by local study team

**Baseline assessment**

**Ideal: Week 0**  
Target: Up to 6 weeks prior to commencing advanced therapy  
Permitted: Assessment >6 weeks prior to commencing advanced therapy is permitted, e.g. if delayed due to infusion unit capacity

**Participants to complete after consent and before starting advanced therapy:**

- 31 Participant questionnaires completed on REDCap
- 32 Stool sample tubes (n=2) collected and returned using prepaid Royal Mail Safebox™
- 33 If attending hospital for a face-to-face clinical encounter within assessment window, two tubes (total 20mls) blood collected

**CD-metaRESPONSE sub-cohort (in addition to above requirements):**

- 35 Third stool sample tube collected (provided in home stool sample collection kit)
- 37 Prospective 4-day food diary completed

Participants unable or unwilling to complete the PRO-2 questionnaire, not meeting the PRO-2 threshold for clinically active disease, missing stool samples or who do not start treatment with an advanced therapy will be withdrawn from the study

**Eligibility re-confirmed**

41 Baseline 4 day PRO-2 (minimum 2 days data) assessed to confirm inclusion criteria for clinically active disease met

**Biologic, JAKi or S1PR modulator commenced**

**WEEK 0**

**Week 14 assessment**

**Ideal: Week 14**  
Target: Week 12 - 16  
Permitted: Week 10 - 20

50 As per baseline assessment (including additional requirements for CD-metaRESPONSE)

**Week 54 assessment**

**Ideal: Week 54**  
Permitted: Week 48 - 60

**All participants:**

- 56 Participant questionnaires completed on REDCap
- 57 Stool sample tubes (n=2) collected and returned using prepaid Royal Mail Safebox™

If a participant stops treatment, the next planned study assessment should be brought forward and completed as a treatment discontinuation assessment. Where an alternative advanced therapy is then commenced, this discontinuation assessment will serve as the baseline assessment for the next therapy. Further assessments should then be completed at week 14 and 54 after commencing a new advanced therapy as per the study protocol

In addition to the above assessments, if a participant attends hospital for a clinical encounter, endoscopy at any time during the study period following consent, the following samples/data will be collected: up to 12 research biopsies, patient-reported 1-day PRO-2 score, endoscopic assessment of disease activity data (SES-CD/MCS endoscopic subscore)

